



# **Beta-Amyloid Antibodies for Early Alzheimer’s Disease**

**Draft Evidence Report**

**December 22, 2022**

**Prepared for**



**AUTHORS:**

Grace Lin, MD  
Medical Director for Health Technology Assessment  
Institute for Clinical and Economic Review

Melanie D. Whittington, PhD, MS  
Director of Health Economics  
Institute for Clinical and Economic Review

Abigail Wright, PhD, MSc  
Senior Research Lead, Evidence Synthesis  
Institute for Clinical and Economic Review

Foluso Agboola, MBBS, MPH  
Vice President of Research  
Institute for Clinical and Economic Review

Serina Herron-Smith, BA  
Associate Research Manager  
Institute for Clinical and Economic Review

Steven D. Pearson, MD, MSc  
President, Institute for Clinical and Economic Review

David Rind, MD, MSc  
Chief Medical Officer  
Institute for Clinical and Economic Review

**DATE OF****PUBLICATION:** December 22,2022

**How to cite this document:** Lin GA, Whittington MD, Wright A, Agboola F, Herron-Smith S, Pearson SD, Rind DM. Beta-Amyloid Antibodies for Early Alzheimer’s Disease: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, December 22, 2022.

<https://icer.org/assessment/alzheimers-disease-2022/#timeline>

Grace Lin served as the lead author for the report. Abigail Wright led the systematic review in collaboration with Serina Herron-Smith. Foluso Agboola provided methodologic guidance. Melanie Whittington developed the economic model. David M. Rind and Steven D. Pearson provided methodologic guidance on the clinical and economic evaluations. We would also like to thank Noemi Fluetsch, Monica Frederick, Kelsey Gosselin and Yasmine Kayali for their contributions to this report. Additionally, we would like to thank UsAgainstAlzheimer’s for connecting us with individuals living with Alzheimer’s disease and caregivers to help us better understand their lived experiences.

## About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at <https://icer.org/>.

The funding for this report comes from government grants and non-profit foundations, with the largest single funder being the Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers, or life science companies. ICER receives approximately 24% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. No life science companies relevant to this review currently participate in this program. For a complete list of funders and for more information on ICER's support, please visit <https://icer.org/who-we-are/independent-funding/>.

For drug topics, in addition to receiving recommendations [from the public](#), ICER scans publicly available information and also benefits from a collaboration with [IPD Analytics](#), an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

## About CTAF

The California Technology Assessment Forum (CTAF) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. CTAF seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The CTAF Panel is an independent committee of medical evidence experts from across California, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Panel members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about CTAF is available at <https://icer.org/who-we-are/people/independent-appraisal-committees/ctaf>.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost-effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings.

*In the development of this report, ICER’s researchers consulted with several clinical experts, patients, manufacturers, and other stakeholders. The following experts provided input that helped guide the ICER team as we shaped our scope and report. It is possible that expert reviewers may not have had the opportunity to review all portions of this draft report. None of these individuals is responsible for the final contents of this report, nor should it be assumed that they support any part of it. The report should be viewed as attributable solely to the ICER team and its affiliated researchers.*

*For a complete list of stakeholders from whom we requested input, please visit: <https://icer.org/assessment/alzheimers-disease-2022/#overview>*

## **Expert Reviewers**

**VICTOR HENDERSON, MD, MS**

**Professor**

**Stanford University**

*No relevant conflicts of interest to disclose, defined as more than \$10,000 in healthcare company stock or more than \$5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers. Dr. Henderson has previously received honorarium for serving as an external reviewer on an ICER review in 2021.*

**JASON KARLAWISH, MD**

**Professor**

**University of Pennsylvania**

*Dr. Karlawish has served as a site investigator for clinical trials sponsored by Biogen, Eisai Co., Ltd and Eli Lilly & Co.*

***We also received comments from consultants of a patient organization but have not named them at their request. Those comments did result in some changes to the Report.***

# Table of Contents

Executive Summary .....	ES1
1. Background .....	1
2. Patient and Caregiver Perspectives .....	4
3. Comparative Clinical Effectiveness .....	8
3.1. Methods Overview .....	8
Scope of Review .....	8
Evidence Base.....	8
3.2. Results .....	11
Clinical Benefits .....	11
Harms.....	15
Subgroup Analyses and Heterogeneity.....	18
Uncertainty and Controversies.....	20
3.3. Summary and Comment.....	23
4. Long-Term Cost Effectiveness .....	26
4.1. Methods Overview .....	26
4.2. Key Model Assumptions and Inputs .....	28
4.3. Results.....	30
Base-Case Results.....	30
Sensitivity Analyses .....	32
Scenario Analyses.....	34
Threshold Analyses.....	35
Model Validation .....	36
Uncertainty and Controversies.....	37
4.4 Summary and Comment.....	38
5. Contextual Considerations and Potential Other Benefits .....	39
6. Health Benefit Price Benchmarks .....	41
7. Potential Budget Impact.....	42
7.1. Overview of Key Assumptions .....	42
7.2. Results.....	42

References .....	46
A. Background: Supplemental Information .....	A1
A1. Definitions.....	A1
A2. Potential Cost-Saving Measures in Alzheimer’s Disease.....	A6
B. Patient Perspectives: Supplemental Information .....	B1
B1. Methods.....	B1
C. Clinical Guidelines .....	B1
American Academy of Neurology <sup>5</sup> .....	C1
National Institute for Health and Care Excellence (NICE) <sup>6</sup> .....	C1
American Psychiatric Association <sup>75</sup> .....	C1
D. Comparative Clinical Effectiveness: Supplemental Information.....	D1
D1. Detailed Methods .....	D1
PICOTS.....	D1
Data Sources and Searches.....	D6
Study Selection.....	D8
Data Extraction and Quality Assessment.....	D9
Assessment of Level of Certainty in Evidence.....	D11
Assessment of Bias .....	D11
Data Synthesis and Statistical Analyses .....	D11
D2. Additional Clinical Evidence .....	D12
Lecanemab.....	D12
Donanemab.....	D23
D3. Evidence Tables.....	D29
D4. Ongoing Studies .....	D82
D5. Previous Systematic Reviews and Technology Assessments .....	86
NICE.....	D86
Pang, M. et al. (2022). “Effect of Reduction in Brain Amyloid Levels on Change in Cognitive and Functional Decline in Randomized Clinical Trials: An Instrumental Variable Meta-Analysis” <sup>107</sup> .....	D86

Villain, N. et al. (2022). “High-clearance Anti-amyloid Immunotherapies in Alzheimer’s Disease. Part 1: Meta-analysis and Review of Efficacy and Safety Data, and Medico-economical Aspects” <sup>109,110</sup> .....	D87
E. Long-Term Cost-Effectiveness: Supplemental Information .....	E1
E1. Detailed Methods .....	E1
Target Population .....	E2
Treatment Strategies .....	E2
E2. Model Inputs and Assumptions .....	E3
Model Inputs .....	E5
E3. Results .....	E15
Description of evLY Calculations .....	E15
E4. Sensitivity Analyses .....	E16
E5. Scenario Analyses .....	E17
Scenario Analysis 1: Treatment Stop at Severe AD .....	E17
Scenario Analysis 2: Continuous Treatment Strategy for Donanemab .....	E18
Scenario Analysis 3: Updated Caregiver Disutility Estimates .....	E19
E6. Model Validation .....	E19
Prior Economic Models .....	E20

## List of Acronyms and Abbreviations Used in this Report

AD	Alzheimer’s disease
ADAS-Cog 13	Alzheimer’s Disease Assessment Scale – Cognitive Subscale
ADSC-ADL	Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory
AE	Adverse event
AHRQ	Agency for Healthcare Research and Quality
APOE ε4	Apolipoprotein ε4
ARIA[-E,H]	Amyloid-related imaging abnormalities[-edema/effusion, hemorrhage or superficial siderosis]
CDR-SB	Clinical Dementia Rating Scale – Sum of Boxes
CI	Confidence interval
CSF	Cerebrospinal fluid
evLYG	Equal value of life years gained
FDA	Food and Drug Administration
HBPB	Health benefit price benchmark
HR	Hazard ratio
HRQoL	Health-related quality of life
ICER	Institute for Clinical and Economic Review
ITT	Intention-to-treat
IV	Intravenous kg Kilogram
LTC	Long-term care
LY	Life year
MCI	Mild cognitive impairment
mg	Milligram
MMSE	Mini-Mental State Exam
MRI	Magnetic resonance imaging
N	Total number
n	Number
NICE	National Institute for Health and Care Excellence
NPI-10	Neuropsychiatric Inventory 10
NR	Not reported
PET	Positron emission tomography
PICOTS	Population, Intervention, Comparators, Outcomes, Timing, Settings
PV4	Protocol Version 4
QALY	Quality-adjusted life year
SD	Standard deviation
SE	Standard error
SUVR	Standardized uptake value ratio
US	United States
WAC	Wholesale acquisition cost

# Executive Summary

---

Alzheimer's disease (AD) is a fatal neurodegenerative brain disease characterized by the progressive accumulation of beta-amyloid protein plaques and neurofibrillary tangles; these are hypothesized to damage neurons and lead to the loss of cognition and physical functioning.<sup>1</sup> AD affects more than six million people in the United States (US), with more women than men affected and Black Americans at a higher risk of developing the disease.<sup>2</sup> Symptoms of AD include impairment of memory, language, executive function, and visuospatial function that affects one's ability to care for themselves. People living with Alzheimer's disease require a substantial amount of caregiving, and eventually may require around-the-clock in-home or institutional care. Caregivers, most often unpaid family members and friends, can suffer significant negative physical, financial, and emotional outcomes from the strain of caregiving.<sup>3,4</sup>

Current treatment of AD is focused on supportive care, which may include treatment of dementia symptoms with medications that do not alter the course of the disease.<sup>5,6</sup> Because of the devastating burden of AD, there is a great need for disease-modifying treatments (DMT) that slow or stop progression of the disease. Although aducanumab was approved for the treatment of AD in June 2021, there remain substantial uncertainties about its benefits and harms. In this report, we focus on lecanemab and donanemab, two late-stage anti-amyloid monoclonal antibodies being considered for approval by the FDA under the accelerated pathway.

Lecanemab was evaluated in a Phase III randomized clinical trial, CLARITY AD. The trial randomized 1,795 participants with early AD (i.e., mild cognitive impairment [MCI] or mild dementia due to AD) to a biweekly 10 mg/kg intravenous infusion or placebo. The primary clinical outcome was change in mean score on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB). At 18 months, the lecanemab-treated group showed a statistically significant 27% slowing of cognitive decline compared with placebo, representing an average difference of about one-half point on the 18-point CDR-SB scale. Analyses of secondary endpoints, including other cognitive measures and patient and caregiver quality of life consistently favored the lecanemab-treated group. Among participants treated with lecanemab, 21.5% experienced amyloid related imaging abnormalities with edema/effusion (ARIA-E), ARIA-hemorrhage or superficial siderosis (ARIA-H), or both, and 3.5% of patients experienced symptomatic ARIA-E or -H.

Donanemab was studied in the Phase II TRAILBLAZER-ALZ trial of 257 participants diagnosed with MCI or mild AD. Participants were randomized to donanemab 1400 mg monthly (after titration) or placebo, and the primary outcome was the change in the Integrated Alzheimer's Disease Rating Scale (iADRS; scored from 0-144), with measurement of CDR-SB as a key secondary outcome. At 76 weeks, donanemab was associated with a statistically significant smaller decline (difference of 3.20, 95% CI 0.12 to 6.27) in iADRS compared with placebo. Changes in CDR-SB, while favoring donanemab, were not statistically significant. Most of the other cognitive measures also did not

show statistically significant differences. However, 67.8% of participants in the donanemab group had amyloid clearance by PET scan (<24.1 centiloids) at 76 weeks, compared with 7.8% in the placebo group. More than 45% of participants in the trial experienced some type of ARIA, with 6.1% of participants experiencing symptomatic ARIA. There were high treatment discontinuation rates in the trial (37.4% in the donanemab group and 27.2% in the placebo group), mainly due to adverse events. Only about three-quarters of participants completed the trial (71.8% in the donanemab group and 74.4% in the placebo group).

We remain uncertain that amyloid removal is an appropriate surrogate outcome for clinical benefit and instead look to the clinical outcomes found in randomized trials. However, there is disagreement among experts about the clinical meaningfulness of the magnitude of change in CDR-SB in the lecanemab trial, <sup>7</sup> and we await clinical outcome data from the donanemab Phase III trial. We remain concerned that real world ARIA occurrences and consequences may be more severe if, as expected, monitoring MRIs are not as frequent as in the clinical trial, the patient population treated differs from the trial population, and clinicians are less expert than those who participated in the randomized trial.

In aggregate, the net health benefits of **lecanemab** in patients with early AD may be small or even substantial, but there remains a possibility of net harm from ARIA. We rate treatment with lecanemab in MCI due to AD or mild AD as “Promising but Inconclusive” (P/I).

We await the results of the Phase III trial to help clarify **donanemab’s** net health effects. Currently, we have low certainty in such net health benefits and rate the evidence as “Insufficient” (I).

**Table ES2. Evidence Ratings**

Treatment	Comparator	Evidence Rating
<b>Patients with Early Alzheimer’s Disease</b>		
Lecanemab	Supportive care only	P/I
Donanemab	Supportive care only	I

We estimated the lifetime cost effectiveness of lecanemab and donanemab in addition to supportive care as compared to supportive care alone (Table ES3). We report results from two perspectives: a health care sector perspective (i.e., focusing on the direct medical care costs and health outcomes of the patient) and a modified societal perspective (i.e., including patient productivity impacts, caregiver time spent caregiving, caregiver quality of life, and caregiver direct medical costs). In the base-case, lecanemab was discontinued according to disease severity (at moderate AD), whereas, donanemab was discontinued due to complete amyloid clearance or according to disease severity (at moderate AD). A number of optimistic assumptions were required to estimate the cost-effectiveness of donanemab, including 1) modeling the same treatment effectiveness as lecanemab, 2) stopping treatment at complete amyloid clearance, 3) maintaining the treatment benefit for those who stopped treatment due to complete amyloid clearance, and 4)

using adverse-event related discontinuation from Phase II evidence. Given the “I” rating, we do not expect to be able to suggest a HBPB for donanemab in the next version of this Report.

**Table ES3. Base-Case Incremental Cost-Effectiveness Ratios**

<b>Lecanemab* vs. Supportive Care</b>			
<b>Perspective</b>	<b>Cost per Life Year Gained</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Health Care Sector</b>	\$279,000	\$258,000	\$208,000
<b>Societal</b>	\$268,000	\$241,000	\$187,000
<b>Donanemab*† vs. Supportive Care</b>			
<b>Perspective</b>	<b>Cost per Life Year Gained</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Health Care Sector</b>	\$150,000	\$139,000	\$112,000
<b>Societal</b>	\$139,000	\$125,000	\$97,000

evLY: equal-value life year, QALY: quality-adjusted life year

\*Assuming a placeholder price of \$26,100.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through mild AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

# 1. Background

---

ICER reviewed aducanumab for early Alzheimer’s disease in 2021 ([Aducanumab for Alzheimer’s Disease: Effectiveness and Value](#)). Much of the background information in this evidence report is updated from that report with additional contextual information about lecanemab and donanemab.

Alzheimer’s disease (AD) is a fatal degenerative brain disease characterized by progressive loss of cognitive skills such as memory, language, navigation, and problem-solving, and physical function. It is the most common cause of dementia in the United States (US), accounting for up to 60-80% of all dementia diagnoses and is the sixth leading cause of death.<sup>2</sup> Direct and indirect costs of health care related to AD are estimated to be around \$500 billion annually.<sup>3</sup> However, the economic burden of the disease may be underestimated, as many non-medical costs such as home safety modifications, adult day care services, and adverse effects on caregiver health and productivity may not be included in cost estimates.<sup>2</sup>

AD affects an estimated 6.5 million Americans, or around 10% of the population aged 65 year or older, and around one-third of people aged 85 and older.<sup>2</sup> Early-onset AD, defined as the onset of AD prior to age 65, accounts for around 5% of cases and is associated with a larger genetic predisposition and differences in clinical and pathologic presentation.<sup>8</sup> Two-thirds of those diagnosed with AD are women,<sup>2</sup> and there is evidence that symptoms of the disease may manifest differently in women and men, particularly with respect to neuropsychiatric symptoms.<sup>9,10</sup> There are racial and ethnic differences in the incidence and prevalence of AD, with higher rates noted in the African American and Hispanic populations compared with non-Hispanic White and Asian populations.<sup>2,11</sup>

The hallmark of AD is the progressive accumulation of beta-amyloid protein plaques and neurofibrillary tangles of hyperphosphorylated tau protein in the brain;<sup>1</sup> these are hypothesized to lead to damage and eventual death of neurons over decades. Single-gene mutations that impact beta-amyloid formation (e.g., amyloid precursor protein and presenilin) are associated with early-onset AD. Genetic variants such as the apolipoprotein E (ApoE)  $\epsilon$ 4 allele increase one’s risk of developing late-onset AD; having one copy of the gene is associated with a two to threefold increase in developing AD, while two copies of the gene may increase risk of AD by as much as 15 times.<sup>12</sup> Additionally, there are different forms of amyloid such as plaques, oligomers, and monomers, and the roles of these different forms and how specifically they are pathophysiologically associated with AD is not well understood; however, the neuronal damage from accumulation of amyloid is thought to trigger a cascade leading to impairment in cognitive domains such as memory, language, executive function, and visuospatial function, which results in the loss of ability to perform instrumental and basic activities of daily living (e.g., paying bills, bathing, dressing, etc.).<sup>13</sup>

The course of AD can be described in three phases: preclinical disease, mild cognitive impairment (MCI) due to AD, and dementia due to AD. People living with AD begin to accumulate beta-amyloid in the brain in the preclinical phase up to 15 years prior to the onset of symptoms.<sup>14</sup> Additionally, changes in certain biomarkers in the cerebrospinal fluid (CSF) (e.g., decreased beta-amyloid and increased CSF tau protein levels) and on imaging (e.g., amyloid on positron emission tomography [PET] scans) may occur; such CSF and imaging biomarkers can be used to identify AD pathology, although other forms of dementia may be present as well.<sup>15</sup> Difficulty remembering recent conversations, names or events is often an early symptom, along with decreased awareness of financial scams<sup>16</sup>; depression and apathy may also be seen at this stage. The diagnosis of MCI is marked by a reduction in cognitive function; however, at this point, the patient can still live and function independently, although they typically show impairment in instrumental activities of daily living. Individuals are diagnosed with Alzheimer’s dementia when there is impairment of two cognitive domains and these deficits significantly interfere with the ability of the patient to function independently at work or at home. At this stage, a person typically needs a caregiver.

As the disease progresses, people living with AD become less and less independent and the need for caregiving increases. Symptoms can include difficulty with communication, disorientation to time and place, confusion, poor judgment, and behavioral changes. At late stages, people living with AD may have difficulty speaking, swallowing and walking. Eventually, many people living with AD require around-the-clock in-home or institutional care. More than 11 million family members and other caregivers and other persons provided an estimated 16 billion hours of unpaid care to people with AD or other dementias, putting these caregivers at risk for negative mental, physical, and emotional outcomes.<sup>2</sup> The average life expectancy for people with AD depends on multiple factors including age, functional status at diagnosis, and comorbidities. Estimates range from 4 to 8 years, but some people with AD live as many as 20 years after diagnosis.<sup>2</sup>

Treatment of AD remains largely supportive, including creation and implementation of individualized care plans (e.g., treatment of dementia symptoms, medication and home safety assessments, advance care planning), caregiver education and support, care navigation, care coordination, and referral to community-based organizations for services and supports (e.g., adult day care, caregiver training, etc.).<sup>17</sup> Non-pharmacologic treatments include physical activity, which some studies have suggested may prevent or mitigate AD<sup>18,19</sup> as well as behavioral and environmental strategies to ameliorate neuropsychiatric symptoms (e.g., agitation, delusions, disinhibition), and problem behaviors (e.g., resistance to care, hoarding, obsessive-compulsive behaviors).<sup>20</sup>

Pharmacological therapy of AD has until recently focused mainly on symptom management. The most commonly prescribed drugs are the cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, and memantine, a drug that affects glutamine transmission. Cholinesterase inhibitors are indicated in mild, moderate, and severe AD, while memantine is

approved for moderate-to-severe AD. These drugs, either alone or in combination, are often used to treat the cognitive and functional symptoms of the disease, despite limited evidence of efficacy and significant side effects.<sup>21,22</sup>

Given the large and growing population of people with AD and the economic and human burden of AD, there is a tremendous need for disease-modifying drugs (i.e., drugs that slow or stop progression of AD). To date, more than 20 drugs targeting purported molecular pathways of AD (e.g., beta-amyloid or tau proteins) have either failed in clinical trials or are still in development. Aducanumab (Aduhelm™, Biogen), a human monoclonal antibody, was the first putative disease-modifying drug to obtain accelerated approval from the FDA in June 2021, based on PET-documented removal of amyloid from the brain. Since then, two additional anti-amyloid monoclonal antibodies have submitted applications for accelerated approval for the treatment of AD: lecanemab (Eisai Co., Ltd) and donanemab (Eli Lilly & Co.), and those two drugs are the focus of this review. Lecanemab has an expected PDUFA decision date of January 6, 2023; there has been no announcement of an expected PDUFA date for donanemab.

**Table 1.1. Interventions of Interest**

<b>Intervention Brand Name (Generic Name)</b>	<b>Mechanism of Action</b>	<b>Delivery Route</b>	<b>Prescribing Information</b>
Lecanemab	Monoclonal antibody that binds to beta-amyloid protofibrils	Intravenous	10 mg/kg biweekly
Donanemab	Monoclonal antibody that binds to beta-amyloid proteins in aggregated plaques	Intravenous	1400 mg every 4 weeks

mg: milligram, kg: kilogram

## 2. Patient and Caregiver Perspectives

---

ICER engaged with people living with Alzheimer’s disease (AD) and caregivers, representatives from advocacy organizations, and clinical experts to understand the specific challenges associated with caring for persons with AD. In informal interviews, we spoke with a total of 13 people with AD from across the US and across the disease spectrum (mild to severe), and in various living arrangements. We also spoke with 5 caregivers from across the US with varied caregiving experiences (from early to late-stage AD). Demographics of the sample are described further in the [Supplement](#). We also drew on conversations from our 2021 Alzheimer’s disease review.<sup>23</sup>

Individuals we spoke with emphasized the following issues, which are discussed in detail below: challenges with diagnosis, experience of coping with the diagnosis and a new way of living, impact on caregiver quality of life, treatment concerns and goals, and financial impacts and disparities.

### Challenges with Diagnosis

Initial symptoms of AD may start many years prior to receiving a diagnosis starting with gradual cognitive decline<sup>24</sup> including difficulties with memory and executive function (a term that describes abilities of planning, flexible thinking, and focusing attention).<sup>25,26</sup> People with AD described forgetting meetings or names, getting lost, and feeling that something was “wrong”; sometimes they also received feedback from others who had noticed changes in behaviors. Caregivers also described that they began noticing subtle changes in their loved one’s thinking and behavior, although sometimes identifying those changes was challenging if they did not live with the person with AD. Although an estimated 10% of people over the age of 65 are living with dementia due to AD, diagnosis is often missed or delayed. People with AD described the diagnosis process as long and, for some, complicated by confusion over whether their symptoms were due to AD or another medical condition. When receiving the diagnosis, some people with AD reported having a negative experience with their physician, such as being told to “get their affairs in order” or that they would decline rapidly. On the other hand, one person with AD reported that their physician told them to focus on living life fully which allowed them to continue to focus on activities they enjoyed (e.g., dancing and exercise).

After the diagnosis, lack of education about how to navigate the disease was described by both people with AD and caregivers. One person noted that “there needs to be more support when diagnosed. It is a complex process, especially when having other medical conditions to deal with.” People living with AD reported wanting more information on such things as the disease and its course, clinical trials, and information on how the diagnosis can impact caregivers. Comprehensive care planning (e.g., functional assessment, review of current medications for high-risk medications, evaluation of home safety, caregiver needs, etc.), linkage to social services, management of comorbidities, and information on end-of-life care was also lacking in many cases. Finally,

caregivers also reported on the lack of resources for them and having to educate themselves on AD to understand the best care for their loved one.

### **Experience of Coping with the Diagnosis and a New Way of Living**

People living with AD described significant life changes after receiving the diagnosis. One person stated that their diagnosis “changed everything”. Adjustments to daily life described to us included accepting more direction, using their phone to help with reminders, wearing headphones in noisy environments, moving to be closer to their family, and online grocery shopping. People with AD reported experiences of loss after the diagnosis, such as giving up certain activities, leaving their jobs, rehoming their animals, and confronting fears about the future loss of their independence. One person described that their “life has gone from a big platform to a small one.” Coping mechanisms for the new changes in their lives included trying to maintain a positive attitude and staying busy, active, and social. AD also had an impact on relationships. People with AD described a loss of ability to be the type of relative they wished to be, such as wanting to look after their grandchildren, remembering special dates or birthdays, or developing new relationships.

Having AD is financially challenging, both because people with AD may have to stop working and because of challenges with navigating the system when applying for Social Security Disability Insurance (SSDI) or moving onto Medicare. Caregivers described taking control of their loved one’s finances early and the challenges of getting access to services. Some caregivers reported that they were unable to gain access to all services and had to use their own funds to provide support for later stages (e.g., 24-hour in-home support to allow caregivers to continue to work, medications, clothes, or hobbies), which could also cause changes their financial circumstances.

### **Impact on Caregiver Quality of Life**

The impact of AD on caregivers is substantial. Nearly half of all caregivers who provide care to older adults do so for someone with dementia – often without training. Women are not only more likely to be caregivers but also to spend more time providing care than men. Surveys of caregivers show that they spend 40 to 60 hours per week directly caring for the patient; hours vary with severity of disease and care setting.<sup>4</sup> Caregivers described that their caregiving responsibilities evolved over time and with stage of disease, and ranged from paying the bills and driving, and as the disease progresses to moderate-to-severe dementia and the patient loses function, assisting with activities of daily living such as bathing and dressing. Some caregivers were able to obtain support from other family members and elder services programs to help keep their loved ones living at home; others transitioned their loved ones to assisted living or nursing homes.

Caregivers described the emotional toll of caregiving, reporting that it was difficult to witness changes in how their loved one interacts with and experiences the world. One caregiver reported that it “took a while to realize that although part of her is still “mom”, not everything that comes

out of her mouth is really her... Those who aren't in the caregiving situation find it hard to understand where their heads are. [We may] come across as too pragmatic that we seem cold, but we all need to function, and this takes an incredible toll." Surveys have quantified the toll on caregivers - as individuals moved from mild to severe AD, the financial, physical, psychosocial, social, and personal strain as measured by the Modified Caregiver Strain Index increased from an average score of 9.0 to 17.5 (out of a maximum of 26), indicating a substantial increase in caregiver impact.<sup>4</sup> As a result, caregivers often suffer physical and mental health consequences including increased chronic health conditions, depression and isolation, and increased use of the health care system. Several caregivers reported that there is not enough support available for their emotional and mental health needs and that there is variation in the degree of support available across the US for both patients and their caregivers.

When asked about their broader experience of caregiving, some caregivers describe the impact on their own life plans. Caregivers described that because of their caregiving responsibilities, they have had less time for their own family, such as fewer vacations or leisure activities. Some caregivers reported resigning from their jobs to be a caregiver, as they were unable to manage both caregiving and job responsibilities. Another caregiver reported that they had to spend time away from their family to care for their loved one with AD which caused strain on their relationship at home. One caregiver described that "I feel like I haven't had the chance to live my life" and another caregiver told us that "[Person with AD] has often asked me if I am going to have kids... that is the only thing that may have stopped."

### **Treatment Concerns and Hopes**

People with AD and caregivers would like more options for treatments. The main goal of treatment is not to cure, but to slow or halt the progression of the disease and maintain their current level of functioning (e.g., independence, hobbies, personal care) as long as possible. One patient described that "more time doesn't do it for me. I would say more quality time".

In terms of anti-amyloid therapies, both people living with AD and caregivers were interested in any treatment that would help slow disease progression. However, both groups described concerns about the side effect of brain swelling and questioned whether the gains in quality of life that might be seen with treatment outweighed that risk. There were also logistical concerns about a treatment with regular infusions, particularly for those persons who do not drive, and concerns about an increased burden on caregivers. Caregivers also reported treatment accessibility issues due to the location of medical centers, the limited number of physicians and health systems offering treatment and concerns about insurance coverage [in the context of aducanumab], and concern over their loved one experiencing pain or anxiety from the infusion.

## **Disparities in Clinical Care and Research**

Both people with AD and caregivers raised concerns surrounding disparities in clinical care and research. Both people with AD and caregivers also raised concerns about the limited or culturally misaligned information provided to communities of color about AD or how to provide care for loved ones with AD, and believed that more resource sharing and more support group leaders who are people of color could raise awareness in the community. Broader access to effective therapies could also help address disparities in treatment. Furthermore, people living with AD noted that “everyone should have the right to participate in clinical trials” but that people of color are less likely to be able to participate due to having other medical comorbidities, location of the clinical trials, or not having a care partner, and would like more opportunities for them.

## 3. Comparative Clinical Effectiveness

---

### 3.1. Methods Overview

#### Scope of Review

We reviewed the clinical effectiveness of lecanemab and donanemab, in addition to supportive care, versus supportive care alone for the treatment of individuals with early Alzheimer’s Disease (AD) (i.e., MCI due to AD and mild dementia due to AD) with evidence of AD pathology. We sought and reviewed evidence, where available, on patient-important outcomes, including change in the ability to maintain independence and cognitive function and perform activities of daily living, as well as delaying entry into institutional care, quality of life, caregiver impact, and behavioral change. We also reviewed evidence on changes in biomarkers (e.g., level of beta-amyloid, level of tau and phosphorylated tau [p-tau], and brain volume). We also aimed to evaluate updated evidence for aducanumab that was not covered in the previous August 2021 review.<sup>27</sup> We found no new clinical evidence for aducanumab that would have affected our assessment and thus it is not reviewed in this report. The full scope and procedures for the systematic literature review are detailed in the [supplement](#).

#### Evidence Base

##### Lecanemab

Evidence informing our review of lecanemab was derived from one Phase III randomized controlled trial (RCT): CLARITY AD. We also reviewed the lecanemab Phase II trial (G000-201), but because there were differences in the trial objectives, dosing, and design, it was not a primary focus of our review. G000-201 is described in [Section D of the Supplement](#).

CLARITY AD was a Phase III placebo-controlled RCT that evaluated the efficacy of 10 mg/kg of intravenous lecanemab administered every two weeks versus placebo for 18 months, with an open-label extension phase with all participants receiving lecanemab for an additional 27 months.<sup>28</sup> The primary outcome was change from baseline in CDR-SB at 18 months. The open-label extension phase examined treatment-emergent adverse events and change in CDR-SB. Participants were included if they were aged between 50 and 90 years and had a mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia, objective impairment in episodic memory, amyloid positivity as determined by PET or CSF (A $\beta$ 1–42), objective impairment in episodic memory, had a Mini-Mental State Exam (MMSE) score of 22–30, BMI 17–35, and, if they were receiving any treatment for AD symptoms, were on a stable dose for 12 weeks prior to baseline. Full inclusion and exclusion criteria are described in [Table D3.1. in the Supplement](#). Baseline characteristics and cognitive scores for CLARITY AD are outlined in Table 3.1.

ARIA was assessed by MRI at baseline and five additional time points across the study and could lead to the study drug being held or discontinued

## **Donanemab**

Evidence informing our review of donanemab was derived from one Phase II RCT: TRAILBLAZER-ALZ and one Phase III RCT: TRAILBLAZER-ALZ 4. TRAILBLAZER-ALZ was a Phase II, multicenter RCT that evaluated the efficacy of intravenous donanemab administered every four weeks (700 mg monthly for the first three doses and 1400 mg monthly after that) versus placebo for 72 weeks.<sup>29</sup> The primary outcome was change in baseline Integrated Alzheimer's Disease Rating Scale (iADRS) score at 76 weeks. Participants were aged 60-85 years with mild cognitive impairment due to AD or mild AD with dementia, had an MMSE score of 20-28 or had a recent Flortaucipir PET scan with adequate tau deposition or had topographic deposition pattern consistent with Alzheimer's Disease, and met florbetapir PET criteria (amyloid SUVR  $\geq 1.17$  or 37 centiloids). Full exclusion criteria are described in [Supplement Table D3.1](#). Baseline characteristics and cognitive scores are outlined in Table 3.1. Additionally, during the trial, if participants reached a pre-specified level of amyloid (<24.10 centiloids), they were considered to have full amyloid clearance and switched to placebo.

ARIA was assessed by MRI at baseline and seven additional time points across the study and could lead to the study drug being held or discontinued.

TRAILBLAZER-ALZ 4 is an ongoing Phase III, open-label, parallel-group RCT that evaluated the efficacy of 1400 mg of intravenous donanemab every four weeks (same titration as TRAILBLAZER-ALZ) versus aducanumab (1 mg/kg monthly for first two doses, 3 mg/kg for next two doses, 6 mg/kg for next two doses and 10 mg/kg for subsequent doses) for up to 18 months.<sup>30</sup> The primary outcome was percentage reaching complete amyloid clearance on donanemab versus aducanumab at six months (presented in this report). Participants were aged 50-85 years, had gradual change in memory function for six months or more, met florbetapir F18 PET scan criteria, and had cognitive difficulties as measured by CDR-Global Score of 0.5 or 1 and MMSE of 20-30. Full exclusion criteria and baseline characteristics of this trial are described in [Supplement Table D3.1 & D3.2](#). In TRAILBLAZER-ALZ 4, in contrast to TRAILBLAZER-ALZ, monitoring for ARIA included fewer (5) MRI scans.

**Table. 3.1. Baseline Characteristics and Cognitive Measures**

<b>Baseline Characteristics and Cognitive Scores</b>	<b>Donanemab</b> TRAILBLAZER-ALZ <sup>29</sup> N=257* (donanemab, N=131 and placebo, N=126)	<b>Lecanemab</b> CLARITY AD <sup>28</sup> N=1795 (lecanemab, N=859, placebo, N=875*)
Age in years, mean (SD)	75.2 (SD=5.5)	71.2 (7.9)
Sex, Female %	51.8%	52.3%
Race/Ethnicity	94.6% White, 3.1% Black, 1.2% Asian, 1.2% Other, 3.1% Hispanic	76.9% White, 2.5% Black, 17% Asian, 3.7% Other, 12.4% Hispanic
Concomitant AD medication	59.1% AChEI and 23% memantine	52.8% AChEI or memantine
ApoE ε4 carrier	73.4%	68.8%
ApoE ε4 heterozygote	51.0%	53.3%
ApoE ε4 homozygote	20.9%	15.5%
Stage of disease	NR	61.9% MCI due to AD and 38.1% Mild AD
iADRS, mean (SD) (range)	106.1 (SD=13.1) (60-139)	106.6 <sup>†</sup>
MMSE, mean (SD) (range)	23.7 (SD=3.0) (14-29)	25.6 (2.2) (22-30)
CDR-SB, mean (SD) (range)	3.5 (SD=1.9) (0.5-11.0)	3.2 (1.34) (0.5-8.5)
ADAS-Cog13 / 14 <sup>‡</sup> , mean (SD) (range)	27.6 (SD=7.7) (5-51)	24.4 (7.32) (4.7-60.7)
ADCS-iADL, mean (SD) (range)	48.7 (SD=7.6) (21-59)	NR
ADCS-MCI-ADL, mean (SD) (range)	NR	41.1 (6.75) (12-53)
ADCOMS, mean (SD) (range)	NR	0.399 (0.147) (0.07-0.94)
Baseline beta-amyloid, mean centiloids (SD)	104.4 (SD=34.7)	76.48 (43.3) <sup>§</sup>

AChEI: acetylcholinesterase inhibitor, AD: Alzheimer's disease, ADAS-Cog 13: Alzheimer's Disease Assessment Scale–Cognitive Subscale 13-item, ADAS-Cog 14: Alzheimer's Disease Assessment Scale–Cognitive Subscale 14-item, ADCOMS: AD composite score, ADCS-iADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory, ADCS MCI-ADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), ApoE: apolipoprotein E, CDR-SB: Clinical Dementia Rating scale Sum of Boxes, iADRS: Integrated Alzheimer's Disease (AD) Rating Scale, MMSE: Mini-Mental State Examination, NR: not reported, SD: standard deviation

\*mITT population

<sup>†</sup>Calculated based using the following calculation: [-1(ADAS-Cog14) +90] + ADCS MCI-ADL. Neither SD nor range were available.

<sup>‡</sup>TRAILBLAZER-ALZ included ADAS-Cog13 and CLARITY AD included ADAS-Cog14

<sup>§</sup>Included only participants enrolled in the PET substudy (N=354 lecanemab and N=344 placebo)

## 3.2. Results

### Clinical Benefits

In this report, we describe the change in cognitive function, health-related quality of life, beta-amyloid, and other biomarkers (tau, p-tau, and brain volume) from baseline to 12-18 months after treatment initiation for lecanemab and donanemab. A variety of cognitive measures were used across the trials. Table 3.2. provides the minimal clinically importance difference (MCID) associated with cognitive outcomes used across the trials. In [Supplement Table A.1.](#), we provide definitions of each of the cognitive outcomes. While MCID applies to changes for a specific patient, when averaged in aggregate it can provide context for the magnitude of changes overall. It is important to remember, though, that if patient responses are normally distributed, half of patients will have outcomes better than the average and half worse than the average.

**Table 3.2. Minimal Clinically Importance Differences for Cognitive Outcomes**

Cognitive Outcome	Minimal Clinically Important Difference (MCID)
Clinical Dementia Rating – Sum of Boxes (CDR-SB)	Change of 1-2 points. <sup>31-33</sup>
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog), including ADAS-Cog-13 and ADAS-Cog14.	Change of 2 points for MCI due to AD <sup>33</sup> and ≥3 points for mild AD. <sup>34,35</sup>
Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (ADCS-ADL), including ADCS-iADL and ADCS-MCI-ADL	There are no data on MCID.
The Integrated Alzheimer’s Disease (AD) Rating Scale (iADRS)	Change of 5 points for MCI due to AD and 9 points for AD with mild dementia <sup>36</sup>
Mini-Mental State Examination (MMSE)	Change of 1-3 points. <sup>31</sup>
AD Composite Score (ADCOMS)	There are no data on MCID.

AD: Alzheimer’s Disease, MCI: Mild cognitive impairment, ADCS-MCI-ADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), ADCS-iADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory – Instrumental items

### Lecanemab

#### *Cognitive outcomes*

The primary outcome in CLARITY AD trial was the change from baseline in CDR-SB score at 18 months. Participants treated with lecanemab had 27% less decline in CDR-SB compared to placebo at 18 months, with a mean difference of -0.45 (95% CI: -0.67 to -0.23;  $p < 0.001$ )<sup>28</sup> (Table 3.3). This mean difference in CDR-SB was less than what some consider as MCID for the scale.<sup>31,32</sup> Changes in CDR-SB remained fairly consistent across the sensitivity analyses that imputed data, included all

randomized participants, or censored assessments after ARIA-E had occurred ([Supplement Table D.27](#)).<sup>28</sup>

Other measures of cognition assessed in the trial also showed statistically significant differences favoring the lecanemab treated group. Participants treated with lecanemab had less decline in ADAS-Cog14 compared to placebo at 18 months, with a mean difference of -1.44; 95% CI: -2.27 to -0.61;  $p < 0.001$ .<sup>28</sup> The mean difference did not meet MCID for ADAS-Cog.<sup>34,35</sup> Those treated with lecanemab also had less decline in ADCS-MCI-ADL compared to placebo, with a mean difference of 2.0; 95% CI: 1.2 to 2.8;  $p < 0.001$ .<sup>28</sup> and less decline in ADCOMS compared to placebo, with a mean difference of -0.05; 95% CI: -0.074 to -0.027;  $p < 0.001$ .<sup>28</sup> This mean difference for ADCOMS was the same as that reported in the Phase II G000-201 trial. Additionally, using data from the ADAS-Cog14 and ADCS-MCI-ADL, we calculated an iADRS score for both groups. Those treated with lecanemab also had less decline in iADRS compared to placebo, with a calculated mean difference of 3.2, which is below MCID values for both the MCI and mild AD groups.<sup>36</sup>

### ***Health-Related Quality of Life***

Definitions of health-related quality of life scales are provided in [Section A of the supplement](#). Changes in health-related quality of life measures were available for around 85% of participants at 18 months. For participant-reported outcomes, participants in the lecanemab group had 49% less decline on European Quality of Life – 5 dimensions (5 level version) (EQ-5D-5L) at 18 months compared to placebo ( $p < 0.01$ ). There was also 56% less decline on the Quality of Life in Alzheimer’s Disease (QOL-AD) in the lecanemab group compared to the placebo group ( $p < 0.01$ ).<sup>37</sup> For caregiver-reported outcomes, caregivers of participants in the lecanemab group reported 38% less decline on Zarit Burden Interview at 18 months compared to placebo ( $p < 0.001$ ) and 23% less decline on the QOL-AD (subject by proxy) compared to placebo ( $p < 0.05$ ).<sup>37</sup> See [Supplement Table D3.4](#).

### ***Beta-Amyloid Levels***

Changes in beta-amyloid, as measured in centiloids using Florbetapir PET, were assessed in a substudy including 698 participants ( $n = 354$  in lecanemab and  $n = 344$  in placebo). At 18 months, participants in the lecanemab group had a larger amount of beta-amyloid removed compared with the placebo group (mean difference -59.12; 95% CI: -62.64 to -55.60;  $p < 0.001$ ),<sup>28</sup> corresponding to a calculated mean percentage difference versus placebo of -76.0%. Additionally, at 18 months, 32.4% of those in the lecanemab group were amyloid negative (defined as having less than 30 centiloids on PET scan) compared to 7.8% in the placebo group.<sup>38</sup> CSF and plasma markers of A $\beta$ 42/40 were also consistent with amyloid removal in the lecanemab group. Descriptions of assessment and findings for Plasma and CSF measures of amyloid are in provided in [Section D of the Supplement](#).

### ***Other Biomarker Outcomes***

There were statistically significant reductions in several tau biomarkers in the lecanemab treated group (CSF t-tau and CSF and plasma p-tau) in the lecanemab group, compared with the placebo group at 18 months<sup>28</sup> ([Supplement Table D3.4](#)) In terms of brain volume, there was greater decrease in whole brain volume and a greater increase in ventricular volume in the lecanemab group compared to the placebo group at month 18. There was less atrophy in hippocampal volume in lecanemab as compared to placebo.<sup>38</sup> At the time of this draft report, the investigators note that tau PET and volumetric MRI results have not been fully analyzed<sup>28</sup> and thus interpretation of these outcomes are limited. Detailed descriptions of these assessments and results of other biomarkers are in provided in [Section D of the Supplement](#).

### **Donanemab**

#### ***Cognitive Outcomes***

The primary outcome in TRAILBLAZER was the change from baseline in iADRS score at 76 weeks. Participants treated with donanemab had less decline in iADRS compared to placebo at week 76, with a mean difference of 3.2; 95% CI: 0.12 to 6.27; p=0.04, but this difference did not meet MCID when examining the difference between groups.<sup>36</sup> See Table 3.3. In a sensitivity analysis, the investigators noted that the occurrence of ARIA-E had no impact of the efficacy of donanemab on the change from baseline in iADRS.<sup>29</sup>

Change from baseline in CDR-SB was a key secondary outcome, and at week 76, the change in CDR-SB in the donanemab group was not statistically different from placebo (-0.36, 95% CI: -0.83 to 0.12). Similarly, treatment with donanemab did not have a statistically significant effect on ADCS-iADL (mean difference from placebo: 1.21; 95% CI: -0.77 to 3.20), or on the MMSE (mean difference from placebo of 0.64; 95% CI: -0.40 to 1.67); the effect on ADAS-Cog13 (mean difference -1.86; 95% CI: -3.63 to -0.09) appears nominally significant but is not statistically significant given hierarchical assessment of outcomes. See Table 3.3 and [Supplement Table D3.3](#) for details about the secondary outcomes.

#### ***Health-Related Quality of Life Outcomes***

Quality of life was not examined as an outcome in the TRAILBLAZER-ALZ trial.

#### ***Beta-Amyloid Levels***

Donanemab decreased beta-amyloid, as measured by centiloids using Florbetapir PET, by almost 80% compared with placebo (mean difference from placebo: -85.06; 95% CI: -92.68 to -77.43). At week 28, 56, and 76, a total of 27.4%, 54.7%, 67.8% participants (respectively) in donanemab group had complete clearance of beta-amyloid, defined as beta amyloid plaque levels <24.10 centiloids.<sup>29</sup> Participants who had complete amyloid clearance at week 24 were significantly older and had lower

baseline levels of amyloid plaque compared to participants who had partial amyloid clearance<sup>39</sup>, and there was no difference between those two groups in baseline cognitive scores or the proportion of participants who were ApoE ε4 carriers (see [Supplement Table D3.18.](#)). Rate of re-accumulation of amyloid plaque was 0.02 centiloids (SD=7.75) per year, with a predictive model reporting time to re-accumulate to amyloid positive status at a median of 3.9 years (IQR: 1.9 to 8.3).<sup>39</sup>

Changes in beta-amyloid were also assessed in the TRAILBLAZER-ALZ 4 trial directly comparing donanemab with aducanumab (N=140). The percentage of participants meeting amyloid clearance, defined as <24.1 centiloids, was significantly greater in the donanemab group compared to the aducanumab group (37.9% vs 1.6% at six months, p<0.001), and was greater than in the TRAILBLAZER-ALZ trial. Percentage and absolute change in beta-amyloid were also significantly greater in the donanemab group compared to the aducanumab group at six months, p<0.001.<sup>40</sup>

### ***Other Biomarker Outcomes***

Tau biomarkers were measured in several ways in the TRAILBLAZER-ALZ trials. There was no substantial difference in overall t-tau measured between those who received donanemab versus placebo.<sup>29</sup> However, statistically significant changes in tau were present in specific brain areas in the donanemab group versus placebo.<sup>39</sup> Additionally, there was a significant reduction in plasma p-tau (p-tau 217) in the donanemab group compared with placebo (p<0.001).<sup>41</sup> In the TRAILBLAZER-ALZ 4 trial, there was also a decline in p-tau in the donanemab group.<sup>40</sup> Finally, there was a greater decrease in whole brain volume and a greater increase in ventricular volume in the donanemab group in TRAILBLAZER-ALZ compared to the placebo group at week 76.<sup>29</sup> More detail and biomarker results are provided in [Section D of the Supplement.](#)

**Table 3.3. Key Trial Results**

Measure		Donanemab (TRAILBLAZER-ALZ)		Lecanemab (CLARITY AD)	
		Intervention	Placebo	Intervention	Placebo
CDR-SB	Baseline (SD) (range)	3.6 (2.1) (0.5-11.0)	3.4 (1.7) (0.5-8.0)	3.17 (1.34) (0.5-8.0)	3.22 (1.34) (0.5-8.5)
	N	93	90	714	757
	Timepoint	76 weeks		18 months	
	Mean change	1.22	1.58	1.21	1.66
	Difference in mean change (95% CI)	-0.36 (-0.83 to 0.12)	REF	-0.45 (-0.67 to -0.23)	REF
iADRS	Baseline (SD) (range)	106.2 (13.0) (60-130)	105.9 (13.2) (67-139)	106.75*	106.53*
	N	93	91	703	738
	Timepoint	76 weeks		18 months	
	Mean change	-6.86	-10.06	-24.39*	-27.61*
	Difference in mean change (95% CI)	3.2 (0.12 to 6.27)	REF	3.22*	REF

ADCOMS: AD composite score, CDR-SB: Clinical Dementia Rating scale Sum of Boxes, CI: confidence interval, iADRS: Integrated Alzheimer's Disease (AD) Rating Scale, MMSE: Mini-Mental State Examination, SD: standard deviation.

\*iADRS was calculated based upon on ADAS-Cog14 and ADCS MCI-ADL using the following calculation from the CLARITY AD protocol:  $[-1(\text{ADAS-Cog14}) + 90] + \text{ADCS MCI-ADL}$ . Neither SD nor range were available.

## Harms

### Lecanemab

Total adverse events and serious adverse events were slightly higher in the lecanemab versus placebo group (Table 3.4) in the CLARITY AD trial. There were 6 deaths in lecanemab treated group and 7 deaths in placebo group, with myocardial infarction, cerebral macrohemorrhage, cerebrovascular accident, respiratory failure, and COVID-19 listed among the causes of death in both groups.<sup>28</sup> There were no deaths directly attributed to ARIA in either group. Discontinuation in CLARITY AD was lower than the Phase II (G000-201) and TRAILBLAZER-ALZ trials, and fairly similar across groups (lecanemab: 18.8% versus placebo: 15.6%). The most common reasons for discontinuation were adverse events, withdrawing consent, and choosing to discontinue from treatment regime. Discontinuation of treatment due to adverse events were higher in lecanemab (6.9% vs. 2.9%) as were discontinuation of trial due to adverse events (5.7% vs. 3.1%) (Table 3.4). Participants in the lecanemab group also reported more infusion-related reactions compared to the placebo group (26.4% vs 7.4%).<sup>28</sup>

ARIA due to edema or effusion (ARIA-E) or brain microhemorrhage or localized superficial siderosis reflecting prior hemorrhage (ARIA-H) were of interest to the review. A total of 21.5% participants in the lecanemab group experienced either ARIA-E or ARIA-H, compared to 9.5% in the placebo group

(Table 3.4, [Supplement Table D3.11](#)). As expected, ARIA-E occurred more often in the lecanemab group compared with placebo (12.6% vs 1.7%), and 2.8% of participants in the lecanemab group experienced symptomatic ARIA-E (e.g., headache, visual disturbance, or confusion or severe radiographic changes on MRI). ARIA-E occurred more frequently in ApoE  $\epsilon$ 4 carriers compared to non-carriers in the lecanemab treated group (3.4% vs 1.4%), and also occurred more in ApoE  $\epsilon$ 4 homozygotes compared to heterozygotes (9.2% vs 1.7%).<sup>28</sup>

ARIA-E generally occurred in the first three months of treatment (71%), was mostly mild-moderate in severity, and the investigators reported that 81% of ARIA-E resolved within four months.<sup>42</sup> Seven participants (0.8%) in the lecanemab group had a significant adverse event (SAE) associated with ARIA-E. Recurrent ARIA-E occurred more often in the lecanemab group compared with the placebo group (3.1% vs 0.1%, [Supplement Table D3.11](#)).

ARIA-H, which was mainly due to cerebral microhemorrhage, occurred more frequently in the in the lecanemab group compared with placebo (17.3% vs 9.0%); very few cases of ARIA-H were symptomatic (0.7% in lecanemab and 0.2% in placebo). ARIA-H was more likely to co-occur with ARIA-E in the lecanemab group (8.2%) compared to placebo (1.0%).<sup>28</sup> Like ARIA-E, ARIA-H occurred more frequently in ApoE  $\epsilon$ 4 carriers compared with non-carriers (19.7% vs 11.9% in the lecanemab treated group) and was more frequent in ApoE  $\epsilon$ 4 homozygotes compared to heterozygotes (39% vs 14%).<sup>28</sup> Unlike ARIA-E, which occurred early in the study period, ARIA-H occurred randomly across the study period.<sup>42</sup> There was one reported case of cerebral macrohemorrhage that occurred 30 days after stopping the study drug and thus its relationship to lecanemab treatment is uncertain. Full data are not available from the OLE phase of CLARITY AD; however, at the time of posting this draft report, it was reported that there were two deaths in the lecanemab group due to cerebral macrohemorrhage (0.1%); one participant was reportedly on the anticoagulant apixaban, and the other was given tissue plasminogen activator (tPA) while being treated for an acute stroke.<sup>42</sup>

## **Donanemab**

Total adverse events, serious events, and deaths were similar across donanemab and placebo groups in the TRAILBLAZER-ALZ trial (Table 3.4). Aside from ARIA, infusion-related reactions (7.6% donanemab vs 0% placebo), superficial siderosis of the central nervous system, and nausea were significantly more likely to occur in the donanemab group compared with placebo.<sup>29</sup> More details can be found in [Table D3.11 in the Supplement](#).

More than 45% of participants in the TRAILBLAZER-ALZ trial experienced either ARIA-E or ARIA-H, with significantly more cases in the donanemab group compared with placebo (38.9% vs 8.0%) (Table 3.4). Symptomatic ARIA-E, which was assessed by central review of MRI studies and self-reported symptoms by the participant, occurred in more participants in the donanemab group compared to placebo (3.8% vs 0.8%). From data shared by the manufacturer, most ARIA-E cases occurred within the first 12 weeks of treatment and were associated with a median time to

complete resolution of 9.6 weeks for ARIA-E and 18 weeks for serious ARIA-E. Two participants in the donanemab group had symptomatic ARIA-E leading to hospitalization. ARIA-E was more common in ApoE  $\epsilon$ 4 heterozygotes (30.9% in donanemab and none in placebo) and ApoE  $\epsilon$ 4 homozygotes (44.0% in donanemab and 3.6% in placebo). ARIA-H occurred in more participants in the donanemab group compared to placebo (30.5% vs 7.2%). All cases of ARIA-H were due to microhemorrhage or superficial siderosis; no cases of cerebral macrohemorrhage were reported during the trial.

There was a large amount of discontinuation in the TRAILBLAZER-ALZ trial, with 37.4% of participants in the donanemab group and 27.2% of participants in the placebo group discontinuing from the treatment (Table 3.4). Discontinuation from donanemab occurred due to a variety of reasons, but mostly due to adverse events (30.5%) including symptomatic ARIA (3.8%). Only 94 participants (71.8%) in the donanemab group and 93 participants (74.4%) in the placebo group completed the trial. Of those in the donanemab group, the main reason for discontinuing the trial was adverse events (15%).

In the TRAILBLAZER-ALZ 4 trial, total adverse events and serious events were similar across the donanemab group and aducanumab group at six months, and there were no deaths reported (Table 3.4). Discontinuation of treatment due to adverse events was low in both groups. ARIA-E, symptomatic ARIA-E, and ARIA-H all occurred less frequently in the treated group in TRAILBLAZER-ALZ 4 compared to TRAILBLAZER-ALZ. Infusion-related reactions were similar across the two trials.

**Table 3.4. Adverse Events**

Harms	Donanemab				Lecanemab	
	TRAILBLAZER-ALZ <sup>29</sup>		TRAILBLAZER-ALZ 4 <sup>40</sup>		CLARITY AD <sup>28</sup>	
	Donanemab	Placebo	Donanemab	Aducanumab	Lecanemab	Placebo
<b>Any Adverse Event, n/N (%)</b>	119/131 (90.8%)	113/125* (90.4%)	44/71 (62%)	46/69 (66.7%)	798/898 (88.9%)	735/897 (81.9%)
<b>Serious Adverse Event, n/N (%)</b>	23/131 (17.6%)	22/125 (17.6%)	6/71 (8.5%)	6/69 (8.7%)	126/898 (14.0%)	101/897 (11.3%)
<b>Discontinuation Due to Adverse Event, n/N (%)</b>	40/141 (30.5%)†	9/125 (7.2%)†	2/71 (2.8%)	1/69 (1.4%)	62/898 (6.9%)‡	26/897 (2.9%)‡
<b>Any ARIA-H, n/N (%)</b>	40/131 (30.5%)	9/125 (7.2%)	14/71 (19.7%)	12/69 (17.4%)	155/898 (17.3%)	81/897 (9.0%)
<b>Any ARIA-E, n/N (%)</b>	36/131 (27.5%)	1/125 (0.8%)	15/71 (21.1%)	16/69 (23.2%)	113/898 (12.6%)	15/897 (1.7%)
<b>Symptomatic ARIA-E, n/N (%)</b>	5/131 (3.8%)§	1/125 (0.8%)	2/71 (2.8%)	3/69 (4.3%)	25/898 (2.8%)	0/897 (0%)

ARIA-E: amyloid-related imaging abnormalities due to edema/effusion, ARIA-H: amyloid-related imaging abnormalities due to hemorrhage or superficial siderosis, N: total participants, n: number of participants

\*There was one fewer participant in the placebo group as one participant was not included in the modified intention-to-treat population.

†Per the protocol, discontinuation of treatment was due to: subject decision; hepatic event or liver test abnormality; second incidence of ARIA-E; any increase in ARIA-H accompanied by clinically significant symptoms; >4 new microhemorrhages, >1 new area of superficial siderosis or significant worsening of pre-existing superficial siderosis; ARIA-E reported as a SAE; prolonged acute infusion reaction; AE/MRI/Lab finding of such severity that continuing treatment is not in patient’s best interest; non-compliance that is a safety concern; patient requires treatment with an excluded agent.

‡Per the protocol, primary reasons for discontinuation from the study are; AE, lost to follow-up, subject choice, withdrawal of consent, pregnancy, study terminated by sponsor, and other.


§Mintun et al.<sup>29</sup> reported that 8 participants experienced symptomatic ARIA-E. However, the manufacturers reported that 3 participants in the donanemab group had been inaccurately classified as experiencing “symptomatic” ARIA and these participants were later determined to have asymptomatic ARIA.

## Subgroup Analyses and Heterogeneity

CLARITY AD trial included a more diverse sample than the Phase II (G000-201) and TRAILBLAZER-ALZ trial, with adequate representation of Asian participants compared with the prevalence of AD in the Asian population.<sup>43</sup> Hispanic participants were fairly well represented, although not quite reflective of the prevalence of AD in the Hispanic population overall.<sup>43</sup> In addition, over half the sample had two or more comorbidities (e.g., diabetes, hypertension etc.) and 4.5% were on anticoagulants, more closely representing participants who may seek this therapy in real-world clinical settings. Prespecified subgroup analyses were conducted on the cognitive outcomes across various subgroups of interest. There were four subgroup analyses that appeared to have consistent results across the cognitive measures. The effect of lecanemab on cognitive outcomes appeared to vary across ApoE ε4 carrier status, with lecanemab showing a larger effect in ApoE ε4 noncarriers

compared to carriers and having the least effect in ApoE ε4 homozygote participants, particularly on the CDR-SB and ADCOMS measures. When disease state was examined, there was similar relative change in CDR-SB in MCI compared with mild AD (28% vs 27% change, respectively). There was a trend towards greater slowing of decline in older participants (≥75 years) compared to younger participants (<65 years) in 3 of the 4 cognitive outcomes. Finally, male participants showed a greater slowing of decline compared to female participants.<sup>44</sup> See Figure 1. For CDR-SB specifically, the treatment effect remained consistent across participants with comorbidities, such as hypertension, diabetes, heart disease ([Supplement Table D3.22](#)).<sup>37</sup> Detailed results on subgroups are presented in [Supplement Tables D3.23-26](#) and additional subgroups are described in [Supplement D2](#). Caution must be taken in the interpretation of these subgroup effects as they were likely underpowered and did not correct for multiplicity.

**Figure 3.1. Forest Plot of Subgroup Analyses for CDR-SB at 18 Months (Age, ApoE ε4 Genotype, and Sex)**



TRAILBLAZER-ALZ trial included mostly White participants (94.6%), underrepresenting Black, Asian, and Hispanic participants. Few subgroup analyses were conducted on cognitive outcomes. A disease progression model-based analysis demonstrated that, for ApoE  $\epsilon$ 4 carriers, donanemab slowed the rate of decline in iADRS by 42% ( $p < 0.001$ ) but, for non-carriers, there was no significant treatment effect.<sup>45</sup>

## Uncertainty and Controversies

If the amyloid hypothesis is correct, it would be expected that removal of amyloid should be associated with treatment effect. For both lecanemab and donanemab we do not yet have adequate data showing such correlations (see Table D3.29) or data showing differences in outcomes by achieving or not achieving amyloid negativity.

MCID refers to changes within a specific patient. Aggregate measures, such as mean change in an outcome, will potentially obscure changes in individual patients that are above or below the MCID. It would be helpful in assessing magnitude of benefit relative to clinical benefit if manufacturers provide analyses of the percentage of patients who experience decreases in an outcome measure beyond a prespecified endpoint (percentage clinically important decline, for instance) in the placebo and treatment groups. However, with or without such an analysis, unless changes in the assessed outcome measure are very non-normally distributed, comparison to MCID will be helpful to those assessing the data in understanding the magnitude of benefits for patients.

There have been concerns among experts that improvements seen in trials of anti-amyloid therapies may reflect “functional unblinding”. This could occur on subjective scales when patients, caregivers, and providers recognize that a patient who develops ARIA is very likely receiving an active treatment rather than placebo. As noted in our prior report, the best approach to this would be to ensure that there are equal numbers of patients managed as if they had developed ARIA in the placebo arm so as to maintain blinding. As this was not done, ICER reviewed data across trials (data not shown) to see if frequency of ARIA correlated with benefit. We did not find such a correlation and so continue to consider it relatively unlikely that the results seen in trials of anti-amyloid therapies are due to functional unblinding.

### **Lecanemab**

The FDA accepted a statistically significant change in CDR-SB in the aducanumab trials as sufficient evidence of benefit to proceed with approval; however, experts disagree on this point.<sup>7,46</sup> Some experts have suggested that the minimal clinically important difference (MCID) for CDR-SB is on the order of 1 or 2 points.<sup>31</sup> Others suggest that MCID only reflects mean group differences and does not capture patient-level change and thus may not accurately reflect benefit to individual patients.<sup>47</sup> Thus, the absolute difference in CDR-SB of 0.45 points between groups, while statistically significant, may or may not result in a change in status that is meaningful to individual

patients and caregivers. However, assessments of patient and caregiver quality of life in CLARITY-AD suggest measurable differences due to treatment with lecanemab.

Even in people with cognitive abnormalities and imaging showing amyloid, some individuals likely have other causes of dementia. A treatment that removes amyloid would have been anticipated to be most effective in patients least likely to have other forms of dementia. Patients who are older and male are at higher risk for vascular dementia, and APOE  $\epsilon$ 4 is a known risk factor for AD. As such, older male participants without APOE  $\epsilon$ 4 would be more likely to form a group in CLARITY-AD that has more vascular dementia (and possibly other non-Alzheimer's-type dementia). However, the actual subgroup analyses in CLARITY-AD show just the opposite (see Figure 1). This is in contrast to the EMERGE trial for aducanumab, where similar changes in CDR-SB were seen overall, but where APOE  $\epsilon$ 4 carriers had greater improvement than non-carriers.

While a substantial percentage of participants treated with lecanemab reached amyloid negativity by PET scan, it should also be noted that 7.8% of participants in the placebo group were also amyloid negative at the end of the trial. This points to the complexity of the pathophysiology of AD and underscores that we do not fully understand the role of amyloid in AD and what factors (e.g., degree or rate of amyloid removal, a threshold of amyloid removal, or removal of certain amyloid subspecies) may impact clinical outcomes.

The effectiveness of lecanemab in people with moderate or severe AD is unknown, as the drug was not studied in these groups. It is uncertain whether treatment should be continued indefinitely or discontinued either when a certain degree of amyloid clearance is attained or at a specific point in the course of the disease.

ARIA is the major adverse effect seen with anti-amyloid therapies. Risks of ARIA in real world use may be greater than was seen in clinical trials given issues including that participants in clinical trials typically do better than randomly selected patients, clinical expertise is likely to be less in real world use, and labeling is unlikely to require the intensity of MRI monitoring that was done in CLARITY-AD. Furthermore, concerns about an increased risk of cerebral hemorrhage with concomitant use of anticoagulants have heightened with the report of two deaths in the lecanemab open label extension study in participants receiving anticoagulation.

The average age of participants in CLARITY-AD was 71.2 years and included participants with some comorbidities. However, since two-thirds of individuals in the US with AD are 75 years old or older, who are also more likely to have significant comorbidities, the trial results may not be generalizable to the broader Alzheimer's population.

## ***Donanemab***

The concerns about effectiveness in moderate or severe AD, risks with ARIA, and the age of participants studied also apply to donanemab. Additionally, information on the degree of comorbidities of participants in the trial has not been reported, so it is unknown how similar the donanemab population was to the broader population of people with AD.

A very high percentage of participants did not complete the TRAILBLAZER-ALZ trial. This leads to substantial uncertainties when interpreting the results.

We do not yet have results from a Phase III trial of donanemab. Given the diversity of results seen in trials of anti-amyloid therapies, assuming a class effect would be inappropriate.


It currently appears likely that donanemab labeling will suggest discontinuation once participants reach amyloid negativity. In the absence of longer-term trials, it is impossible to know whether continued administration is required to maintain any clinical benefits seen with treatment.

Racial diversity was lacking in TRAILBLAZER-ALZ, where 95% of participants were White. CLARITY-AD showed that Hispanic and non-Hispanic participants had similar treatment effects with lecanemab, and it may be reasonable to extrapolate this to donanemab. CLARITY-AD did not suggest treatment effects differing by race with lecanemab, but the confidence intervals were wide enough that extrapolating to another anti-amyloid therapy seems less reasonable.

### 3.3. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.2) is provided in the [Supplement](#).

Figure 3.2. ICER Evidence Rating Matrix



#### Comparative Net Health Benefit

- A = "Superior" - High certainty of a substantial (moderate-large) net health benefit
- B = "Incremental" - High certainty of a small net health benefit
- C = "Comparable" - High certainty of a comparable net health benefit
- D = "Negative" - High certainty of an inferior net health benefit
- B+= "Incremental or Better" - Moderate certainty of a small or substantial net health benefit, with high certainty of at least a small net health benefit
- C+ = "Comparable or Incremental" - Moderate certainty of a comparable or small net health benefit, with high certainty of at least a comparable net health benefit
- C- = "Comparable or Inferior" - Moderate certainty that the net health benefit is either comparable or inferior with high certainty of at best a comparable net health benefit
- C++ = "Comparable or Better" - Moderate certainty of a comparable, small, or substantial net health benefit, with high certainty of at least a comparable net health benefit
- P/I = "Promising but Inconclusive" - Moderate certainty of a small or substantial net health benefit, small (but nonzero) likelihood of a negative net health benefit
- I = "Insufficient" - Any situation in which the level of certainty in the evidence is low

The FDA approval of aducanumab, the first disease-modifying therapy for AD in June of 2021, based on biomarker evidence of beta-amyloid removal but with inconsistent clinical benefit from identically designed trials, brought forth several controversies, including how extensively amyloid is involved in the pathogenesis of AD and whether removal could result in meaningful clinical benefit, how to interpret outcomes from trials with protocol changes and that were stopped early for futility, and how great the risk of ARIA and its potentially severe consequences may be with use in the real world with less monitoring than clinical trials. Many prior anti-amyloid drugs have not

demonstrated clinical benefits, and results reported subsequent to the approval of aducanumab were also negative for crenezumab and gantenerumab. Although it is possible to interpret these results as showing that inadequate amyloid was removed by those two therapies to achieve benefit, it is also possible that there is something specific to lecanemab's mechanism of action that resulted in cognitive benefits, alone or in combination with amyloid removal. We do not feel that evidence is adequate at this point to assume that clearance of amyloid will necessarily improve cognitive outcomes. Patient-level evidence across trials and agents showing that degree of amyloid removal correlates with clinical benefit would be an important step in establishing amyloid removal as an important surrogate outcome.

Since removal of amyloid remains unproven as a surrogate outcome, it remains important to look to clinical outcomes directly. Any cognitive benefits seen with an anti-amyloid therapy must be weighed against harms, and particularly the risk of ARIA.

### **Lecanemab**

CLARITY AD, a Phase III trial testing the efficacy of lecanemab, is the first clinical trial of an anti-amyloid antibody to clearly demonstrate that amyloid clearance is associated with a slowing of cognitive decline in participants with early AD. The 27% relative change in CDR-SB is similar to the change seen in EMERGE, the positive aducanumab trial. The CLARITY AD trial also showed positive results on other cognitive, MRI, and biomarker outcomes and on patient and caregiver quality of life, consistent with the primary outcome. However, whether the absolute change in CDR-SB, the primary outcome in the trial, is clinically relevant remains less certain. As a comparison, one RCT of donepezil 10 mg showed a statistically significant change in CDR-SB compared with placebo over 24 weeks of treatment (-0.60,  $p=0.0007$ ).<sup>48</sup> Additionally, as discussed above (see Figure 3.1 showing subgroup forest plots), we have some concerns that cognitive benefits were greatest in the subgroup of participants most likely to have included participants with other etiologies of dementia. As such, we have some concerns that lecanemab's mechanism of action may not be fully understood. Given all this, and the many prior negative trials of anti-amyloid therapies, we have some remaining uncertainties even about clinical benefits when looking at a single randomized trial.

Rates of ARIA were less than seen in the aducanumab and donanemab trials. Although there was no significant difference in the rate of death during the core clinical trial, there were two recently reported deaths in the open label extension trial, and thus we remain concerned that real world ARIA occurrences and consequences may be more severe if, as expected, monitoring MRIs are not as frequent as in the clinical trial, the patient population treated differs from the trial population, and clinicians are less expert than those who participated in the randomized trial.

In aggregate, the net health benefits of lecanemab in participants with early AD may be small or even substantial, but there remains a possibility of net harm from ARIA. We rate treatment with lecanemab in MCI due to AD or mild AD as "Promising but Inconclusive" (P/I).

## Donanemab

We have concerns about interpreting results from a Phase II study in which one quarter of participants discontinued the trial to be inadequate to have certainty about outcomes. Additionally, while the trial showed a statistically significant change in the primary outcome of the iADRS scale, this was not necessarily statistically significant, and the change in the secondary outcome of CDR-SB was not statistically significant. We await the results of the Phase III trial to help clarify donanemab’s net health effects. Currently, we have low certainty in such net health benefits and rate the evidence as “Insufficient” (I).

**Table 3.5. Evidence Ratings**

Treatment	Comparator	Evidence Rating
<b>Patients with Early Alzheimer’s Disease</b>		
Lecanemab	Supportive care	P/I
Donanemab	Supportive care	I

## 4. Long-Term Cost Effectiveness


---

### 4.1. Methods Overview

The primary aim of this analysis was to estimate the lifetime cost effectiveness of lecanemab and donanemab in addition to supportive care as compared to supportive care alone. Supportive care could include non-pharmacologic and pharmacologic, but not disease-modifying, interventions. We report results from two perspectives: a health care sector perspective (i.e., focusing on the direct medical care costs and health outcomes of the patient) and a modified societal perspective (i.e., including patient productivity impacts, caregiver time spent caregiving, caregiver quality of life, and caregiver direct medical costs). In alignment with our approach from our prior AD review, these perspectives are presented as co-base-case analyses given the enormity of the societal costs in AD.

We adapted our AD decision analytic model developed for our prior AD assessment that included aducanumab.<sup>27</sup> The model consisted of five health states that tracked the severity of disease, including mild cognitive impairment (MCI) due to AD, mild AD, moderate AD, severe AD, and death. Figure 4.1 on the following page displays each of these health states and the possible transitions between them. Patients in the MCI due to AD health state could progress to the mild AD health state or stay in the MCI due to AD health state. Individuals in the mild AD health state could either stay in the mild AD health state, progress to either the moderate AD or severe AD health states or revert back to the MCI due to AD health state. Individuals in the moderate AD health state could either stay in the moderate AD health state, progress to the severe AD health state, or revert to the mild AD health state. Individuals in the severe AD health state could either stay in the severe AD health state or revert to the moderate AD health state. All health states could transition to the death health state due to all-cause or disease-specific mortality. Model cycle length was one year as has been used in prior published economic models and in clinical evidence.<sup>49-52</sup> Specific to each health state, the model also tracked the setting of care (e.g., community or long-term care). Patients could transition from community to long-term care; however, once in long-term care, they remained there over the lifetime time horizon. The model was developed in Microsoft Excel.

**Figure 4.1. Model Structure**



AD: Alzheimer’s disease, MCI: mild cognitive impairment

The model included a hypothetical cohort of patients with MCI due to AD or mild AD entering the model and receiving either the intervention or comparator treatments. Baseline population characteristics can be found in the [Supplement](#). Consistent with population estimates, slightly more than half (55%) of the cohort started in the MCI due to AD health state, with the remaining cohort (45%) starting in the mild AD health state. Patients could progress to more severe AD health states over the model time horizon. The majority of the cohort (92%) started the model in a community setting of care. Model outcomes included quality-adjusted life years (QALYs), equal-value life years (evLYs), life years (LYs), years living outside of long-term care, and costs over a lifetime time horizon. All future costs and outcomes were discounted at 3% per year.

## 4.2. Key Model Assumptions and Inputs

Table 4.1 reports model assumptions along with their rationale that are important to consider when interpreting the findings. A full list of model assumptions can be found in the [Supplement](#).

**Table 4.1. Key Model Assumptions**

Assumption	Rationale
The treatments were effective at slowing the progression of disease while a patient had MCI due to AD or mild AD. The treatments were no longer effective once a patient reached moderate AD.	The evidence on clinical outcomes that exists for these treatments is in early AD. Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts suggested there is likely no effect with these treatments at reducing disease progression once a patient has reached moderate AD. This assumption was tested in scenario analyses.
Donanemab’s effectiveness on slowing the progression of disease was equivalent to lecanemab’s effectiveness on slowing the progression of disease.	There is no evidence for donanemab on how donanemab influences the progression to the next stage of dementia. Evidence for lecanemab suggests a hazard ratio of 0.69 for the progression to the next stage of dementia. The hazard ratio for lecanemab is similar to the relative change in the primary endpoint for donanemab; therefore, we made an optimistic assumption that donanemab’s effectiveness on slowing progression to the next stage of dementia was the same as lecanemab. Further research must be conducted to determine donanemab’s effectiveness on slowing progression of disease before a health benefit price benchmark can be established for donanemab.
Patients stopped receiving lecanemab treatment once they reached moderate AD.	Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts suggested there is likely no effect with these treatments at reducing disease progression once a patient has reached moderate AD, and therefore in our model, treatment stopped once a patient reached moderate AD. In a scenario analysis, we modeled patients stopping treatment once they reached severe AD. Robust evidence is lacking on a treatment’s effect on clinical outcomes after a patient has stopped the treatment, and thus no additional clinical benefit was assumed after a patient stopped treatment.
Patients stopped receiving donanemab treatment once they reached complete amyloid clearance or moderate AD, whichever happened first.	The mechanism of action for donanemab suggests that stopping treatment at the point of amyloid clearance could be a reasonable strategy. From currently available evidence on complete amyloid clearance following treatment with donanemab, we modeled 60% of patients treated with donanemab stopped treatment within the first model cycle/year and 68% stopped treatment within the second model cycle/year. <sup>29</sup> Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts

	suggested there is likely no effect with these treatments at reducing disease progression once a patient reached moderate AD, and therefore in our model, treatment stopped once a patient reached moderate AD. Alternative treatment stopping scenarios for donanemab were explored in scenario analyses.
Donanemab’s effectiveness on slowing progression of disease was applied throughout MCI due to AD and mild AD for those who stopped treatment due to achieving complete amyloid clearance.	If donanemab’s effectiveness is driven by its ability to achieve amyloid clearance, then the benefit may persist even while off treatment so long as amyloid remains cleared. Modeling a continued treatment benefit even while off treatment but during complete amyloid clearance is an optimistic assumption. Further research must be conducted to determine donanemab’s effectiveness for those that stop treatment due to complete amyloid clearance before a health benefit price benchmark can be established for donanemab.
Patients who stopped receiving treatment with donanemab due to complete amyloid clearance restarted donanemab once amyloid was detected again if they had not reached moderate AD. The second course of donanemab was modeled as a fixed duration of 6 months.	The mechanism of action for donanemab suggests a patient would start donanemab again once they had detectable amounts of amyloid again. Modeling projections suggested that it would take approximately four years for a patient treated with donanemab to the point of amyloid clearance to reach detectable amounts of amyloid again. <sup>39</sup> The second course of donanemab was modeled as a fixed duration of 6 months given the lower levels of amyloid at the restart period as compared to baseline.
Donanemab’s adverse-event related discontinuation was from the available Phase II evidence.	Early evidence for TRAILBLAZER-ALZ 4 suggests much lower adverse-event related discontinuation than what was observed in the Phase II evidence; however, the early evidence for TRAILBLAZER-ALZ 4 on adverse-event related discontinuation could not be used because there were no clinical outcomes presented and it was only for six months. A lower discontinuation rate for donanemab would result in less favorable cost-effectiveness estimates for donanemab because it would increase the treatment costs over the time horizon. Updated discontinuation evidence from the Phase III trial is needed for donanemab before a health benefit price benchmark can be established.

AD: Alzheimer’s disease, CDR-SB: Clinical Dementia Rating-Sum of Boxes, MCI: mild cognitive impairment

Model inputs were identified from best-available evidence and stakeholder engagement. The primary clinical inputs included the transition probabilities among alive health states, mortality, progressions to long-term care, treatment efficacy, the occurrence of adverse events, and discontinuation. Utility estimates were retrieved for both the patient and caregiver. The primary cost inputs included intervention acquisition costs, administration costs, monitoring costs, adverse event costs, long-term care costs, and other patient medical and pharmacy costs. Costs to inform

the societal perspective included patient productivity, caregiver productivity, and caregiver health care costs. Table 4.2 reports key model inputs, but an exhaustive description of all model inputs and their sources can be found in the [Supplement](#).

**Table 4.2. Key Model Inputs**

<b>Treatment Effectiveness* on Slowing Disease Progression:</b>	<b>Lecanemab</b>	<b>Donanemab</b>
<b>MCI due to AD</b>	0.69	0.69
<b>Mild AD</b>	0.69	0.69
<b>Moderate AD</b>	1.00	1.00
<b>Severe AD</b>	1.00	1.00
<b>ARIA:</b>	<b>Lecanemab</b>	<b>Donanemab</b>
<b>Probability of Any ARIA</b>	21.5%	36.4%
<b>Probability of Symptomatic ARIA</b>	3.5%	5.2%
<b>Probability of AE-Related Discontinuation</b>	6.9%	30.5%
<b>Patient Disutilities:</b>	<b>Community</b>	<b>Long-Term Care</b>
<b>MCI due to AD</b>	-0.17	-0.17
<b>Mild AD</b>	-0.22	-0.19
<b>Moderate AD</b>	-0.36	-0.42
<b>Severe AD</b>	-0.53	-0.59
<b>Caregiver Disutilities:</b>	<b>Community</b>	<b>Long-Term Care</b>
<b>MCI due to AD</b>	-0.03	-0.03
<b>Mild AD</b>	-0.05	-0.05
<b>Moderate AD</b>	-0.08	-0.08
<b>Severe AD</b>	-0.10	-0.10
<b>Cost Inputs:</b>	<b>Lecanemab</b>	<b>Donanemab</b>
<b>Placeholder Annual Acquisition Cost</b>	\$26,100	\$26,100
<b>MRI Unit Cost</b>	\$261	
<b>PET Scan Unit Cost</b>	\$4,467	
<b>Annual Cost of Long-term Care</b>	\$88,728	

AD: Alzheimer’s disease, AE: adverse event, ARIA: amyloid-related imaging abnormalities, MCI: mild cognitive impairment, MRI: magnetic resonance imaging, PET: positron emission tomography

\*Only applied to health state progressions (i.e., transitions to more severe health states).

## 4.3. Results

### Base-Case Results

Table 4.3 reports the model outcomes for each intervention and comparator from the health care sector perspective and Table 4.4 reports the model outcomes for each intervention and comparator from the societal perspective. Each intervention is associated with more costs than the comparator, but also increases in life years, QALYs, evLYs, and years in the community. The clinical outcomes are the same for lecanemab and donanemab due to the optimistic assumption we made that donanemab’s treatment effectiveness was equivalent to lecanemab’s.

**Table 4.3. Model Outcomes for the Health Care Sector Perspective**

Treatment	Intervention Cost*	Total Cost	Life Years	QALYs	evLYs	Years in the Community
<b>Lecanemab</b>	\$104,000	\$461,000	5.96	3.71	3.82	4.10
<b>Donanemab†</b>	\$39,000	\$405,000	5.96	3.71	3.82	4.10
<b>Supportive Care</b>	\$0	\$339,000	5.53	3.23	3.23	3.61

evLYs: equal-value life years, QALYs: quality-adjusted life years

\*Assuming a placeholder price of \$26,100; intervention cost doesn't include provider administered mark-up (modeled as 6%), monitoring costs, or administration costs.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through mild AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

The absolute QALYs and evLYs are lower in the societal perspective (Table 4.4) for each intervention and comparator due to the additional disutility added in this perspective to capture the reduction in quality of life for the caregiver.

**Table 4.4. Model Outcomes for the Modified Societal Perspective**

Treatment	Intervention Cost*	Total Cost	Life Years	QALYs	evLYs	Years in the Community
<b>Lecanemab</b>	\$104,000	\$746,000	5.96	3.38	3.52	4.10
<b>Donanemab†</b>	\$39,000	\$690,000	5.96	3.71	3.82	4.10
<b>Supportive Care</b>	\$0	\$629,000	5.53	2.89	2.89	3.61

evLYs: equal-value life years, QALYs: quality-adjusted life years

\*Assuming a placeholder price of \$26,100; intervention cost doesn't include provider administered mark-up (modeled as 6%), monitoring costs, or administration costs.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through mild AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

Table 4.5 reports the incremental cost-effectiveness ratios for the base-case from the health care sector perspective and from the modified societal perspective. The modified societal perspective incremental cost-effectiveness ratios are slightly more favorable than those from the health care sector perspective.

**Table 4.5. Base-Case Incremental Cost-Effectiveness Ratios\***

<b>Lecanemab vs. Supportive Care</b>			
<b>Perspective</b>	<b>Cost per Life Year Gained</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Health Care Sector</b>	\$279,000	\$258,000	\$208,000
<b>Societal</b>	\$268,000	\$241,000	\$187,000
<b>Donanemab† vs. Supportive Care</b>			
<b>Perspective</b>	<b>Cost per Life Year Gained</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Health Care Sector</b>	\$150,000	\$139,000	\$112,000
<b>Societal</b>	\$139,000	\$125,000	\$97,000

evLY: equal-value life year, QALY: quality-adjusted life year


\*Assuming a placeholder price of \$26,100.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through mild AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

## Sensitivity Analyses

Figure 4.2 displays the tornado diagram from the one-way sensitivity analysis comparing lecanemab in addition to supportive care as compared to supportive care alone. The vertical axis is the incremental cost per QALY gained from the health care sector perspective. The blue coloring represents the range in incremental cost-effectiveness ratios from the base-case estimate to the incremental cost-effectiveness ratio corresponding to the lower bound of that model input. The green coloring represents the range in incremental cost-effectiveness ratios from the base-case estimate to the incremental cost-effectiveness ratio corresponding to the upper bound of that model input. As depicted in the figure, cost-effectiveness is primarily dependent on the effectiveness of the treatment in slowing progression of disease. Table 4.6 reports the lower and upper input, along with their associated incremental cost-effectiveness ratios, for the ten most influential model inputs from the one-way sensitivity analysis. Findings from the one-way sensitivity analysis comparing donanemab to supportive care can be found in the [Supplement](#), Figure E1 and Table E18.

**Figure 4.2. One-Way Sensitivity Analysis Results: Lecanemab versus Supportive Care Alone, Health Care Sector Perspective**



AD: Alzheimer’s disease, MCI: mild cognitive impairment

**Table 4.6. Tornado Diagram Inputs: Lecanemab versus Supportive Care Alone, Health Care Sector Perspective**

Model Input	Low Input ICER	Upper Input ICER	Lower Input	Upper Input
Hazard ratio on Slowing Progression of Disease*	\$165,000	\$974,000	0.49	0.92
Percent of MCI Alive Patients Moving to Mild	\$276,000	\$245,000	0.19	0.28
Patient Disutility Severe AD, Long-term Care Setting	\$245,000	\$273,000	-0.71	-0.47
Percent of Mild Alive Patients Moving to Moderate	\$274,000	\$247,000	0.28	0.42
Patient Disutility MCI, Community Care Setting	\$267,000	\$249,000	-0.20	-0.14
Relative Risk of Death from MCI	\$251,000	\$266,000	1.48	2.19
Patient Disutility Moderate AD, Community Care Setting	\$252,000	\$264,000	-0.43	-0.29
Patient Disutility Mild AD, Community Care Setting	\$264,000	\$252,000	-0.26	-0.18
Annual Medical Cost Multiplier for MCI	\$252,000	\$264,000	0.91	1.35
Annual Medical Cost Multiplier for Mild	\$253,000	\$263,000	1.27	1.88

AD: Alzheimer’s disease, MCI: mild cognitive impairment

\*Standard error was estimated based on the 95% confidence interval for the primary endpoint of the pivotal trial.

Table 4.7 reports results from the probabilistic sensitivity analysis for lecanemab versus standard of care from the health care sector perspective and the modified societal perspective. Other findings from the probabilistic sensitivity analyses, including credible intervals for lecanemab versus supportive care and probabilistic findings comparing donanemab to supportive care, can be found in [Supplement Tables E19-E21](#).

**Table 4.7. Probabilistic Sensitivity Analysis Results: Lecanemab versus Supportive Care**

	Cost Effective at \$50,000	Cost Effective at \$100,000	Cost Effective at \$150,000	Cost Effective at \$200,000
Per QALY Gained	0%	0%	0%	20%
Per evLY Gained	0%	0%	10%	46%
<b>Modified Societal Perspective</b>	Cost Effective at \$50,000	Cost Effective at \$100,000	Cost Effective at \$150,000	Cost Effective at \$200,000
Per QALY Gained	0%	0%	3%	29%
Per evLY Gained	0%	0%	24%	60%

evLY: equal-value life year, QALY: quality-adjusted life year

## Scenario Analyses

We conducted numerous scenario analyses to test the structural assumptions that were made. Details on the methods and results of each scenario analysis can be found in the [Supplement](#). In Table 4.8, we highlight the findings from the scenario that assumed treatment stopped once a

patient reached severe AD with the same assumed treatment effectiveness for moderate AD as what was modeled in MCI due to AD and mild AD. In this scenario, the incremental clinical outcomes are greater than they were in the base-case because the treatment benefit was assumed to persist through moderate AD, but the treatment costs and non-intervention costs are also greater in this scenario than they were in the base-case.

**Table 4.8. Incremental Cost-Effectiveness Ratios Assuming Treatment Continues until Severe AD\***

<b>Lecanemab vs. Supportive Care</b>			
<b>Perspective</b>	<b>Cost per Life Year Gained</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Health Care Sector</b>	\$295,000	\$289,000	\$230,000
<b>Societal</b>	\$292,000	\$283,000	\$215,000
<b>Donanemab<sup>†</sup> vs. Supportive Care</b>			
<b>Perspective</b>	<b>Cost per Life Year Gained</b>	<b>Cost per QALY Gained</b>	<b>Cost per evLY Gained</b>
<b>Health Care Sector</b>	\$159,000	\$156,000	\$124,000
<b>Societal</b>	\$156,000	\$151,000	\$115,000

evLY: equal-value life year, QALY: quality-adjusted life year

\*Assuming a placeholder price of \$26,100.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through moderate AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

## Threshold Analyses

Table 4.9 reports the annual threshold prices for lecanemab from both the health care sector perspective and the modified societal perspective.

**Table 4.9. Threshold Analysis\* Results for Lecanemab**

<b>Health Care Sector Perspective</b>	<b>Annual Price to Achieve \$50,000 Threshold</b>	<b>Annual Price to Achieve \$100,000 Threshold</b>	<b>Annual Price to Achieve \$150,000 Threshold</b>	<b>Annual Price to Achieve \$200,000 Threshold</b>
<b>Per QALY Gained</b>	\$2,900	\$8,500	\$14,100	\$19,600
<b>Per evLY Gained</b>	\$4,300	\$11,200	\$18,100	\$25,000
<b>Modified Societal Perspective</b>	<b>Annual Price to Achieve \$50,000 Threshold</b>	<b>Annual Price to Achieve \$100,000 Threshold</b>	<b>Annual Price to Achieve \$150,000 Threshold</b>	<b>Annual Price to Achieve \$200,000 Threshold</b>
<b>Per QALY Gained</b>	\$4,300	\$10,000	\$15,700	\$21,400
<b>Per evLY Gained</b>	\$5,900	\$13,300	\$20,600	\$28,000

evLY: equal-value life year, QALY: quality-adjusted life year

\*These threshold prices do not include the provider-administered markup, which was modeled as 6%.

Table 4.10 reports the annual threshold prices for donanemab from both the health care sector perspective and the modified societal perspective. Importantly, numerous optimistic assumptions were made for donanemab, including assuming the same treatment effectiveness as lecanemab, modeling discontinuation upon complete amyloid clearance while the benefit persisted throughout

mild AD, and modeling a high adverse-event discontinuation that was observed in Phase II evidence, all of which benefit the treatment by reducing the treatment costs. These are optimistic assumptions that maximize the threshold prices calculated.

**Table 4.10. Threshold Analysis\* Results for Donanemab†**

Health Care Sector Perspective	Annual Price to Achieve \$50,000 Threshold	Annual Price to Achieve \$100,000 Threshold	Annual Price to Achieve \$150,000 Threshold	Annual Price to Achieve \$200,000 Threshold
Per QALY Gained	NR	\$14,500	\$29,400	\$44,300
Per evLY Gained	\$3,100	\$21,600	\$40,100	\$58,600
Modified Societal Perspective	Annual Price to Achieve \$50,000 Threshold	Annual Price to Achieve \$100,000 Threshold	Annual Price to Achieve \$150,000 Threshold	Annual Price to Achieve \$200,000 Threshold
Per QALY Gained	\$3,100	\$18,400	\$33,700	\$49,000
Per evLY Gained	\$7,500	\$27,200	\$46,900	\$66,600

evLY: equal-value life year, NR: not reported, QALY: quality-adjusted life year

\*These threshold prices do not include the provider-administered markup, which was modeled as 6%.

†These threshold prices are not expected to become health benefit price benchmarks without further evidence to reduce the insufficiency of evidence available at this time.

For donanemab, the annual price to achieve the \$50,000 threshold using QALY as an outcome is not reported because it is less than zero. Under this scenario where treatment stops at complete amyloid clearance, there are additional monitoring costs (e.g., PET scans) that are separate from the treatment acquisition cost that is used to calculate the threshold price. At a threshold of \$50,000 per QALY, the added monitoring costs in addition to the other health state costs are greater than \$50,000 per QALY.

## Model Validation

We used several approaches to validate the model. First, we provided the preliminary model structure, methods and assumptions to manufacturers, patient groups, and clinical experts. Based on feedback from these groups, we refined data inputs used in the model, as needed. Second, we varied model input parameters to evaluate face validity of changes in results. We performed model verification for model calculations using internal reviewers. As part of ICER’s efforts in acknowledging modeling transparency, we will also share the model with the relevant manufacturers for external verification around the time of publishing this draft report. Finally, we compared results to other cost-effectiveness models in this clinical area.

## Uncertainty and Controversies

There are important evidence uncertainties relevant to generating model outcomes, most of which relate to the effectiveness of each intervention and the assumed treatment strategy (e.g., continuous dosing versus fixed duration). For lecanemab, a hazard ratio on the progression to the next stage of dementia was available, but a confidence interval was not available to fully understand and capture the uncertainty in this estimate. For donanemab, no evidence on the treatment's effect on health state transitions was available, and thus we had to make the optimistic assumption that donanemab would have the same effectiveness as lecanemab. Further, due to the mechanism of action and potential treatment strategy for donanemab, we modeled treatment with donanemab stopping at the point of complete amyloid clearance (in addition to treatment stopping based on severity of disease). This reduced the treatment costs associated with donanemab but maintained the treatment benefit, thus improving the cost-effectiveness. Finally, adverse-event related discontinuation was used from the Phase II trial evidence for donanemab, while discontinuation will likely be lower in the Phase III evidence as what was observed between Phase II and Phase III trials for lecanemab. Discontinuation influences the model for those who are assigned treatment costs, so assuming a higher discontinuation rate results in more favorable cost-effectiveness estimates given fewer people receive a treatment cost.

In addition to uncertainty in the effect of each treatment on the progression of disease, there are other inputs in the model that have uncertainty. For example, the utilities for the patient and caregiver are from cross-sectional studies. Limitations of these studies include representing cross-sectional utility weights to estimate impacts of an individual's health state changes over time and using instruments that might not be sensitive enough to detect AD-specific effects and/or second order effects for the caregivers. We have conducted extensive sensitivity and scenario analyses, although there may be uncertainty outside of what was modeled.

We presented the modified societal perspective as a co-base-case analysis in this report due to the large impact of AD on caregivers, represented in the model by a disutility for caregivers and a large loss of caregiver productivity outside of the health care system. However, the cost effectiveness in the modified societal perspective did not greatly differ from analyses performed using the health care system perspective. This result may seem counterintuitive, but is largely the result of these treatments slowing the progression of AD, not stopping the progression or curing the AD. In addition, keeping a patient in earlier AD states longer, which delays the transition to long-term care, can increase productivity losses for the caregiver. These countervailing factors reduce the spread between the cost-effectiveness results using the health care system and modified societal perspectives. This highlights the complexities of capturing caregiver perspectives in the modified societal perspective in that caregivers may prefer to keep loved ones at home, rather than in a long-term care facility, although doing so may increase the negative financial impact on the caregiver.

We do not include aducanumab as an intervention in this cost-effectiveness analysis given the lack of new clinical evidence and the numerous assumptions we included in our prior review. The assumptions we make in the base-case of this review align most closely with the optimistic treatment benefit scenario conducted in our prior AD review, namely the same treatment effect for transitions out of MCI due to AD and mild AD and a treatment stop at moderate AD.

Finally, some commentators have suggested that thresholds should be adjusted for disease severity.<sup>53</sup> Their work suggests a threshold higher than \$100,000 to \$150,000 per QALY gained for severe conditions (like AD). However, thresholds much lower than \$100,000 to \$150,000 per QALY gained are suggested for less severe conditions. Specific methods by which to assign lower thresholds to some conditions and higher thresholds to others have not gained consensus in health economics, in part because they require a view of a single societal value for severity, and also because any divergence in thresholds creates “winners and losers,” with equal health gains for some patients viewed as worth “less” than those of others. We present results at multiple cost-effectiveness thresholds but continue to provide an emphasis on results between \$100,000-\$150,000 per evLYG and QALY gained.

#### **4.4 Summary and Comment**

The cost-effectiveness findings are primarily driven by the effectiveness of each treatment at slowing the progression of disease and the treatment strategy (e.g., continuous dosing, fixed duration). The uncertainty in treatment effectiveness results in a wide range of potential cost-effectiveness estimates, with cost-effectiveness estimates ranging from near commonly-cited thresholds to far exceeding commonly-cited thresholds at a placeholder price of \$26,100.

A number of optimistic assumptions were required to estimate the cost-effectiveness of donanemab, including 1) modeling the same treatment effectiveness as lecanemab, 2) stopping treatment at complete amyloid clearance, 3) maintaining the treatment benefit for those who stopped treatment due to complete amyloid clearance, and 4) using adverse-event related discontinuation from Phase II evidence. Uncertainty in these assumptions need to be reduced before a ceiling price can be established for donanemab.

## 5. Contextual Considerations and Potential

### Other Benefits

Our reviews seek to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that was not available in the evidence base nor could be adequately estimated within the cost-effectiveness model. These elements are listed in the table below, with related information gathered from patients and other stakeholders. Following the public deliberation on this report the appraisal committee will vote on the degree to which each of these factors should affect overall judgments of long-term value for money of the intervention(s) in this review.

**Table 6.1. Contextual Considerations**

<b>Contextual Consideration</b>	<b>Relevant Information</b>
Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability	The acuity of need is high, as AD is a progressive neurodegenerative disease that places a high burden on patients with the disease, caregivers, and society. Currently there is only one FDA-approved disease-modifying therapy.
Magnitude of the lifetime impact on individual patients of the condition being treated	AD has a moderate lifetime impact on patients with the disease. Delaying or stopping progression of AD would improve the quality and, potentially, the length of life of patients. However, late-onset AD affects individuals over the age of 65 and early-onset AD affects only a minority of individuals with the disease. Thus, unlike diseases that impact the patient's entire lifespan, AD has a large effect on a portion of an individual's lifespan, leading to our assessment of moderate impact.

**Table 6.2. Potential Other Benefits or Disadvantages**

<b>Potential Other Benefit or Disadvantage</b>	<b>Relevant Information</b>
Patients' ability to achieve major life goals related to education, work, or family life	AD has a substantial impact on patient independence for activities of daily living such as driving, shopping, financial tasks, etc. While most patients develop AD later in life after they have completed their education and may have left the workforce, delaying progression of the disease may have a significant impact on family life, particularly in patients with early-onset AD.

<p>Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life</p>	<p>Delaying progression of AD with anti-amyloid therapy could potentially decrease caregiver impact and stress, increasing caregiver ability to achieve major life goals. Caregivers tend to be younger than patients with AD, and thus the magnitude of benefit to caregivers may be larger over the lifetime than for patients.</p>
<p>Patients' ability to manage and sustain treatment given the complexity of regimen</p>	<p>Current anti-amyloid therapies require monthly or biweekly intravenous infusions, as well as MRIs for monitoring for side effects. This may place a significant burden on patients and caregivers, particularly for those who have difficulty accessing this level of care (e.g., living in a rural area, lack of transportation, caregivers who aren't able to take time off work, etc.), and as the disease progresses.</p>
<p>Health inequities</p>	<p>The impact of anti-amyloid antibodies on health inequities is unclear. Underrepresented minority groups such as Black and Hispanic populations have a higher prevalence of disease and are diagnosed at later stages, thus an effective treatment could potentially decrease disparities. Additionally, an effective disease-modifying drug could raise awareness of the disease and increase early-stage diagnosis of the disease. However, such groups are less well represented in clinical trials, and the drugs were not tested in people with moderate or severe AD, thus whether the drug has a differential impact in such populations is not known.</p> <p>In highlighting inequalities in the Alzheimer's disease space, ICER calculated the Health Improvement Distribution Index, looking at the relative proportion of any health gains from treatment of AD for the following groups who have a higher prevalence than the general US population. For more information on how we calculate the Health Improvement Distribution Index, refer to the <a href="#">Supplement</a>.</p> <ul style="list-style-type: none"> <li>• African American = 1.6</li> </ul>

## 6. Health Benefit Price Benchmarks

---

ICER does not provide health benefit price benchmarks (HBPBs) as part of draft reports because results may change with revision following receipt of public comments. We therefore caution readers against assuming that the values provided in the Threshold Prices section of this draft report will match the health benefit price benchmarks that will be presented in the next version of this Report.

We do not anticipate providing HBPBs for donanemab even in later versions of this report. As discussed above, we used very optimistic assumptions to calculate threshold prices, but given the rating of “Insufficient” for the evidence and the availability of an anti-amyloid therapy with Phase III data, we do not believe providing HBPBs for donanemab would be policy relevant.

## 7. Potential Budget Impact

---

### 7.1. Overview of Key Assumptions

We used results from the cost-effectiveness model to estimate the potential total budgetary impact of donanemab and lecanemab for people with MCI due to AD or mild AD. We used the assumed placeholder prices and the three threshold prices from the health system perspective (at \$50,000, \$100,000, and \$150,000 per QALY) in our estimates of budget impact. The aim of the potential budgetary impact analysis was to document the percentage of patients who could be treated at selected prices without crossing a potential budget impact threshold that is aligned with overall growth in the US economy. For 2022-2023, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately \$777 million per year for new drugs.

Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapies for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs will be undiscounted and estimated over a five-year time horizon.

The budget impact analysis included the estimated number of patients with MCI due to AD or mild AD in the US who would be eligible for treatment with one of these interventions. Using our prior AD report and other analyses, we estimated there are 1.4 million patients in the US eligible for AD treatment that targets beta-amyloid. We assumed that 20% of these 1.4 million patients would initiate treatment in each of the five years, or approximately 280,000 people with AD per year. We split these patients evenly between the two interventions, so approximately 140,000 patients per year per treatment.

We assumed that donanemab and lecanemab would be added on to standard of care for these individuals and that no current treatments would be displaced by use of the new treatments within the eligible population.

### 7.2. Results

Figure 7.1 illustrates the health care sector perspective cumulative per-patient budget impact calculations for lecanemab compared to supportive care, based on the annualized placeholder price of \$26,100 per year of treatment. The average potential budgetary impact for lecanemab was approximately \$26,000 per patient in year one, with the cumulative net cost increasing in years two through five as treatment continues, reaching approximately \$102,000 by the end of the five-year horizon. The annual net cost slowly declined each year given various factors including treatment discontinuation and cost offsets.

**Figure 7.1. Cumulative Per-Patient Budget Impact of Lecanemab**




Figure 7.2 illustrates the health care sector perspective potential budget impact of lecanemab treatment, based on the annualized placeholder price (\$26,100 per year of treatment), and the prices to reach \$50,000, \$100,000, and \$150,000 per QALY. Approximately 10% of the roughly 140,000 patients could be treated each year without crossing the ICER potential budget impact threshold of \$777 million per year over five years at the annualized placeholder price of \$26,100 per year. Approximately 19% of patients could be treated each year without crossing the budget impact threshold at the \$150,000 per QALY threshold price, increasing to approximately 33% of the population at the \$100,000 per QALY threshold price. All patients with MCI and mild AD could be treated at the \$50,000 per QALY threshold price.

**Figure 7.2. Potential Budgetary Impact of Lecanemab Treatment**




Figure 7.3 illustrates the health care sector perspective cumulative per-patient budget impact calculations for donanemab compared to supportive care, based on the annualized placeholder price of \$26,100 per year of treatment. The average potential budgetary impact for donanemab was approximately \$24,000 per patient in year one, with the cumulative net cost increasing in years two through five as treatment continues, reaching approximately \$67,000 by the end of the five-year horizon. The annual net cost declined each year given various factors including treatment discontinuation and cost offsets.

**Figure 7.3. Cumulative Per-Patient Budget Impact of Donanemab**





Figure 7.4 illustrates the health care sector perspective potential budget impact of lecanemab treatment, based on the annualized placeholder price (\$26,100 per year of treatment), and the prices to reach \$50,000, \$100,000, and \$150,000 per QALY. Approximately 17% of the roughly 140,000 people with AD could be treated each year without crossing the ICER potential budget impact threshold of \$777 million per year over five years at the annualized placeholder price of \$26,100 per year. Approximately 16% of people with AD could be treated each year without crossing the budget impact threshold at the \$150,000 per QALY threshold price, increasing to approximately 27% of the population at the \$100,000 per QALY threshold price. Nearly all individuals with MCI and mild AD could be treated at the \$50,000 per QALY threshold price.

**Figure 7.4. Potential Budgetary Impact of Donanemab Treatment**



# References

---

1. Rajmohan R, Reddy PH. Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. *J Alzheimers Dis.* 2017;57(4):975-999.
2. Alzheimer's Association. 2022 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2022;18(4):700-789.
3. Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing alzheimer's disease and related dementias in the United States. *Expert Rev Pharmacoecon Outcomes Res.* 2017;17(2):189-202.
4. UsAgainstAlzheimer's. *AD PACE* usagainstalzheimers.org: UsAgainstAlzheimer's; 7/29/2020 2020.
5. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment. *Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.* 2018;90(3):126-135.
6. National Institute for Health and Care Excellence. *Dementia: assessment, management, and support for people living with dementia and their carers - Interventions to promote cognition, independence, and wellbeing (NICE Guide NG97).* 2019.
7. Prillaman M. Alzheimer's drug slows mental decline in trial - but is it a breakthrough? *Nature.* 2022;610(7930):15-16.
8. Mendez MF. Early-onset Alzheimer Disease and Its Variants. *Continuum (Minneap Minn).* 2019;25(1):34-51.
9. Xing Y, Tang Y, Jia J. Sex Differences in Neuropsychiatric Symptoms of Alzheimer's Disease: The Modifying Effect of Apolipoprotein E epsilon4 Status. *Behav Neurol.* 2015;2015:275256.
10. Kim S, Kim MJ, Kim S, et al. Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer's disease: A CREDOS study. *Compr Psychiatry.* 2015;62:114-122.
11. Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. *Alzheimers Dement.* 2016;12(3):216-224.
12. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA.* 1997;278(16):1349-1356.
13. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. *Ann Neurol.* 1990;27(5):457-464.
14. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med.* 2012;367(9):795-804.
15. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology.* 2007;69(24):2197-2204.
16. Boyle PA, Yu L, Schneider JA, Wilson RS, Bennett DA. Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment: A Prospective Cohort Study. *Ann Intern Med.* 2019;170(10):702-709.
17. Reuben DB, Tan ZS, Romero T, Wenger NS, Keeler E, Jennings LA. Patient and Caregiver Benefit From a Comprehensive Dementia Care Program: 1-Year Results From the UCLA Alzheimer's and Dementia Care Program. *J Am Geriatr Soc.* 2019;67(11):2267-2273.
18. Gronek P, Balko S, Gronek J, et al. Physical Activity and Alzheimer's Disease: A Narrative Review. *Aging Dis.* 2019;10(6):1282-1292.

19. Du Z, Li Y, Li J, Zhou C, Li F, Yang X. Physical activity can improve cognition in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. *Clin Interv Aging*. 2018;13:1593-1603.
20. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. *JAMA*. 2012;308(19):2020-2029.
21. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. *BMJ*. 2005;331(7512):321-327.
22. Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. *Int J Neuropsychopharmacol*. 2014;18(5).
23. Lin GA WM, Synnott PG, McKenna A, Campbell J, Pearson, SD RD. Aducanumab for Alzheimer's Disease: Effectiveness and Value; Evidence Report. *Institute for Clinical and Economic Review*. 2021.
24. Sperling RA, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., ... & Phelps, C. H. . Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. . *Alzheimer's & dementia*. 2011;7(3):280-292.
25. Storandt M. Cognitive deficits in the early stages of Alzheimer's disease. *Current Directions in Psychological Science*. 2008;17(3):198-202.
26. Howieson DB, Carlson, N. E., Moore, M. M., Wasserman, D., Abendroth, C. D., Payne-Murphy, J., & Kaye, J. A. . Trajectory of mild cognitive impairment onset. *Journal of the International Neuropsychological Society*. 2008;14(2):192-198.
27. Lin GA WM, Synnott PG, McKenna A, Campbell J, Pearson, SD RD. Aducanumab for Alzheimer's Disease: Effectiveness and Value. Final Evidence Report and Meeting Summary. *Institute for Clinical and Economic Review*. 2021.
28. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*. 2022.
29. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. *New England Journal of Medicine*. 2021;384(18):1691-1704.
30. Clinicaltrials.gov. A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4). Published 2021. Accessed December 21, 2022.
31. Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. *Alzheimers Dement (N Y)*. 2019;5:354-363.
32. Liu KY, Schneider LS, R. H. The need to show minimum clinically important differences in Alzheimer's disease trials. *The Lancet Psychiatry*. 2021;8(11):1013-1016.
33. Lansdall CJ MF, Butler LM, Delmar P, Pross N, Qin S, McLeod L, Zhou X, Kerchner GA, Doody RS. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease. *The Journal of Prevention of Alzheimer's Disease*. 2022.
34. Schrag A, Schott JM, Alzheimer's Disease Neuroimaging I. What is the clinically relevant change on the ADAS-Cog? *J Neurol Neurosurg Psychiatry*. 2012;83(2):171-173.
35. Rockwood K, Fay S, M G. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. *International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences*. 2010;25(2):191-201.

36. Wessels AM, Rentz DM, Case M, Lauzon S, JR. S. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2022;8(1).
37. Cohen S. Context of Clarity AD Results. Paper presented at: Clinical Trials on Alzheimer's Disease2022; San Francisco.
38. Bateman R. Imaging, Plasma, and CSF Biomarkers Assessments from Clarity AD. Paper presented at: Clinical Trials on Alzheimer's Disease2022; San Francisco.
39. Shcherbinin S, Evans CD, Lu M, et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA Neurology*. 2022;79(10):1015-1024.
40. Salloway S. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimers disease. Paper presented at: Clinical Trials on Alzheimer's Disease2022; San Francisco.
41. Pontecorvo MJ, Lu M, Burnham SC, et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA Neurology*. 2022.
42. Sabbagh M. Safety Profile of Lecanemab in Early Alzheimers Disease. Paper presented at: Clinical Trials on Alzheimer's Disease2022; San Francisco.
43. Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥ 65 years. *Alzheimer's & Dementia*. 2019;15(1):17-24.
44. van Dyck C. Lecanemab for the Treatment of Early Alzheimers Disease: Topline Efficacy Results from Clarity AD. Paper presented at: Clinical Trials on Alzheimer's Disease2022; San Francisco.
45. Gueorguieva I, Chua L, Chow KH, et al. Donanemab exposure-efficacy relationship in patients with early symptomatic Alzheimer's disease. Paper presented at: Alzheimer's Association International Conference2022; San Diego, USA.
46. Alexander GC, Karlawish J. The Problem of Aducanumab for the Treatment of Alzheimer Disease. *Ann Intern Med*. 2021;174(9):1303-1304.
47. Administration USFD. Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. In. *Patient-Focused Drug Development Guidance Workshop*2022.
48. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. *Neurology*. 1998;50(1):136-145.
49. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. *Neurology*. 2001;57(6):964-971.
50. Green C, Handels R, Gustavsson A, et al. Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework. *Alzheimers Dement*. 2019;15(10):1309-1321.
51. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. *Neurology*. 1999;52(6):1138-1145.
52. Nguyen KH, Comans TA, Green C. Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment. *International psychogeriatrics*. 2018;30(11):1593-1605.
53. Lakdawalla DN, Phelps CE. Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach. *Value in Health*. 2021;24(2):244-249.

54. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):263-269.
55. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):270-279.
56. Food and Drug Administration. Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document. 2020.
57. National Organization for Rare Disorders I. Superficial Siderosis. Rare Disease Database Web site. Published 2020. Accessed December 12, 2022.
58. Gharbi-Meliani A, Dugravot A, Sabia S, et al. The association of APOE  $\epsilon$ 4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study. *Alzheimer's research & therapy*. 2021;13(1):1-1.
59. Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. *Alzheimers Dement*. 2009;5(5):406-418.
60. Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacologica Sinica*. 2017;38(9):1205-1235.
61. Medeiros R, Baglietto-Vargas D, FM. L. The role of tau in Alzheimer's disease and related disorders. *CNS neuroscience & therapeutics*. 2011;17(5):514-524.
62. Tanner JA, GD. R. Relationship between tau and cognition in the evolution of Alzheimer's disease: New insights from tau PET. *Journal of Nuclear Medicine*. 2021;62(5):612-613.
63. Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *The lancet neurology*. 2013;12(2).
64. Drummond E, Pires G, MacMurray C, et al. Phosphorylated tau interactome in the human Alzheimer's disease brain. *Brain*. 2020;143(9):2803-2817.
65. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3):199-208.
66. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of Life-Alzheimer's Disease Scale (QOL-AD). In: *PsychTests A*, ed1999.
67. Zarit SH, Reever KE, Back-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. *The Gerontologist*. 1980;20:649-655.
68. Kueper JK, Speechley M, M. M-O. The Alzheimer's disease assessment scale—cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. a narrative review. *Journal of Alzheimer's disease*. 2018;63(2):423-444.
69. Kahle-Wroblewski K, Coley N, Lepage B, Cantet C, Vellas B, S. A. Understanding the complexities of functional ability in Alzheimer's disease: more than just basic and instrumental factors. *Current Alzheimer Research*. 2014;11(4):357-366.
70. Pedrosa H, De Sa A, Guerreiro M, et al. Functional evaluation distinguishes MCI patients from healthy elderly people—the ADCS/MCI/ADL scale. *The journal of nutrition, health & aging*. 2010;14(8):703-709.
71. Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016;87(9):993-999.

72. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). *Alzheimers Dement.* 2021;17(12):1966-1975.
73. DiBenedetti DB, Slota C, Wronski SL, et al. Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. *Alzheimers Res Ther.* 2020;12(1):90.
74. UsAgainstAlzheimer's. *AD PACE.* [usagainstalzheimers.org](http://usagainstalzheimers.org): UsAgainstAlzheimer's; 7/29/2020 2020.
75. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. *American Journal of Psychiatry.* 2016;173(5):543-546.
76. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14(4):535-562.
77. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate Use Recommendations. *The Journal of Prevention of Alzheimer's Disease.* 2021;8(4):398-410.
78. Food and Drug Administration. Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry. <https://www.fda.gov/media/110903/download>. Published 2018. Accessed November 13, 2020.
79. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med.* 1997;126(5):376-380.
80. Higgins J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, Welch, VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). <https://training.cochrane.org/handbook/current>. Published 2020. Accessed.
81. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine.* 2009;6(7):e1000097.
82. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019;366.
83. Higgins J, Savović J, Page M, Sterne J. *Revised Cochrane risk-of-bias tool for randomized trials (RoB 2).* 2019.
84. Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. *Med Care.* 2010;48(6 Suppl):S145-152.
85. Ollendorf D, Pearson, SD. ICER Evidence Rating Matrix: A User's Guide. <https://icer-review.org/methodology/icers-methods/icer-evidence-ratingmatrix/>. . Published 2020. Updated January 31, 2020. Accessed.
86. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A $\beta$  protofibril antibody. *Alzheimer's research & therapy.* 2021;13(1):1-4.
87. Satlin A, Wang J, Logovinsky V, et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2016;2(1):1-12.
88. Dhadda S, Kanekiyo M, Li D, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease. *Alzheimer's Research & Therapy.* 2022;14(1):1-9.

89. Yagi T, Swanson C, Nakagawa M, et al. The Phase 2 study of BAN2401 (anti-amyloid beta protofibril antibody) in early Alzheimer's disease. Paper presented at: 61st Annual Meeting of the Japanese Society of Neurology 2020.
90. Swanson CJ, Dhadda S, Irizarry M, et al. Clinical, Biomarker, and Safety Update from the Lecanemab Phase 2 Study. Lecanemab: An Assessment of the Clinical Effects, the Correlation of Plasma A $\beta$ 42/40 Ratio With Changes in Brain Amyloid PET SUVR, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer's Disease. Paper presented at: CTAD Annual Meeting 2021; Boston, MA, USA.
91. Swanson CJ, Zhang Y, Dhadda S, et al. Treatment of early AD subjects with BAN2401, an anti-Ab protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline. *Alzheimers & Dementia*. 2018;14(7):1668.
92. Molinuevo JL, Koyama A, Dhadda S, et al. BAN2401 in early Alzheimer's disease: Neurodegeneration biomarker analysis from a randomized Phase 2 study. Paper presented at: Alzheimer's Association International Conference 2019; Los Angeles, CA.
93. Landry I, Kanekiyo M, Aluri J, et al. Lecanemab (BAN2401) infusion reactions and immunogenicity: results from randomized Phase 2 study and an open-label extension. Paper presented at: Alzheimer's Association International Conference (AAIC) Annual Meeting. 2022; San Diego, CA.
94. Swanson C, Dhadda S, Hodgkinson M, et al. Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The Open-Label Extension Of The Phase 2b Study BAN2401-G000-201 In Subjects With Early Alzheimer's Disease. *Neurology*. 2021;96.
95. Rawal S, Doung A, Landry I, et al. Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects. Paper presented at: Alzheimer's Association International Conference 2022; San Diego, CA.
96. Amft M, Ortner M, Eichenlaub U, et al. The cerebrospinal fluid biomarker ratio A $\beta$ 42/40 identifies amyloid positron emission tomography positivity better than A $\beta$ 42 alone in a heterogeneous memory clinic cohort. *Alzheimer's Research & Therapy*. 2022;14(1):1-9.
97. Shcherbinin S, Lu M, Morris A, et al. Flortaucipir in the TRAILBLAZER-ALZ trial. CTAD; 2021.
98. Devous MD, Joshi AD, Navitsky M, et al. Test-retest reproducibility for the tau PET imaging agent Flortaucipir F 18. *Journal of Nuclear Medicine*. 2018;59(6):937-943.
99. Kotari V, Southeikal S, Kennedy IA, Morris A, MJ P. Extent - A Global Spatial Distribution Measure to Estimate Progression and Demonstrate Treatment Effect in Flortaucipir Scans. Paper presented at: Alzheimer's Association International Conference 2022; San Diego, USA.
100. Ott BR, Cohen RA, Gongvatana A, et al. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. *Journal of Alzheimer's disease*. 2010;20(2):647-657.
101. Fjell AM, KB. W. Structural brain changes in aging: courses, causes and cognitive consequences. *Reviews in the Neurosciences*. 2010;21(3):187-222.
102. Irizarry M. Clarity AD: Clinical Trial Background and Study Design Overview. Paper presented at: Clinical Trials on Alzheimer's Disease 2022; San Francisco.
103. DA B. Consistency of Efficacy Assessments Across Various Statistical Methods from the Lecanemab Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects with Early Alzheimer's Disease. CTAD; 2022.
104. Chonghwee L. Association of Regional Amyloid Burden and Brain Volume with Cognitive Performances Among Individuals with Subjective Cognitive Decline. *Clinical Trials of Alzheimers Disease (CTAD)*; 2022.

105. Swanson CJ, Zhang Y, Dhadda S, et al. Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer's Disease (1330). *Neurology*. 2020;94(15 Supplement):1330.
106. M S. Safety Profile of Lecanemab in Early Alzheimers Disease. CTAD; 2022.
107. Pang M, Zhu L, Gabelle A, et al. Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis. *Alzheimer's & dementia*. 2022.
108. Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. *BMJ*. 2021;372:n156.
109. Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. *Rev Neurol (Paris)*. 2022.
110. N V, Planche V. Meta-Analysis of High Clearance Anti-Amyloid Immunotherapies Trials in Early Alzheimer's Disease: a Significant CLinical Effect but a High Risk/Benefit Ratio. CTAD; 2022.
111. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. 2016;316(10):1093-1103.
112. Potashman M, Benea L, Gillis C, Gianinazzi M, Ikram MA, Maserejian N. Estimating the prevalence of A $\beta$  confirmed Alzheimer's disease using a funnel based approach. International Society of Pharmacoeconomics and Outcomes Research Europe 2020; 2020; Virtual.
113. Johnson RW. What is the lifetime risk of needing and receiving long-term services and supports? <https://aspe.hhs.gov/basic-report/what-lifetime-risk-needing-and-receiving-long-term-services-and-supports>. Published 2019. Accessed January 4, 2021.
114. Potashman M, Buessing M, Levitchi Benea M, et al. Estimating progression rates across the spectrum of Alzheimer's disease for amyloid positive individuals using National Alzheimer's Coordinating Center data. CTAD 2020; 2020.
115. Andersen K, Lolk A, Martinussen T, Kragh-Sørensen P. Very mild to severe dementia and mortality: A 14-year follow-up - The Odense study. *Dement Geriatr Cogn Disord*. 2010;29(1):61-67.
116. Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. *Med Care*. 1999;37(1):27-32.
117. Landeiro F, Mughal S, Walsh K, et al. Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. *Alzheimers Res Ther*. 2020;12(1):154.
118. Xu R, Insinga RP, Golden W, Hu XH. EuroQoL (EQ-5D) health utility scores for patients with migraine. *Quality of Life Research*. 2011;20(4):601-608.
119. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer's disease. *Curr Alzheimer Res*. 2010;7(4):358-367.
120. IBM Micromedex. Redbook. [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Published 2021. Accessed.
121. Centers for Medicare & Medicaid Services. Physician Fee Schedule. 2022.
122. Boustani M, Doty EG, Garrison LP, Jr., et al. Assessing the Cost-effectiveness of a Hypothetical Disease-Modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease. *Clin Ther*. 2022.
123. Leibson CL, Long KH, Ransom JE, et al. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. *Alzheimers Dement*. 2015;11(8):917-932.

124. Barthold D, Joyce G, Ferido P, et al. Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities. *J Alzheimers Dis.* 2020;76(2):579-589.
125. Administration on Aging. Costs of Care. <https://longtermcare.acl.gov/costs-how-to-pay/costs-of-care.html#:~:text=Below%20are%20some%20national%20average,room%20in%20a%20nursing%20home>. Published 2020. Accessed December 23, 2020.
126. Bureau of Economic Analysis. Price Indexes for Personal Consumption Expenditures by Major Type of Product. In:2020.
127. Robinson RL, Rentz DM, Andrews JS, et al. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1. *J Alzheimers Dis.* 2020;75(2):437-450.
128. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. 2020.
129. Haro JM, Kahle-Wroblewski K, Bruno G, et al. Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. *J Nutr Health Aging.* 2014;18(7):677-684.
130. Hauber B, DiBenedetti, D. A Quantitative Approach to Understanding What Matters Most to People With and at Risk for Alzheimer's Disease and to Care Partners. *RTI Health Solutions.* 2020.
131. Pickard AS, Law EH, Jiang R, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.* 2019;22(8):931-941.
132. Belger M, Dell'Agnello G, Enstone A, Wyn R, Tockhorn-Heidenreich A. PCR24 The Impact of Informal Caregiving in Alzheimer's Disease Dementia: A Health Utility Study in the UK. *Value in Health.* 2022;25(7):S545.
133. Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling. *Neurol Ther.* 2022;11(3):1285-1307.

## Supplemental Materials

# A. Background: Supplemental Information

---

## A1. Definitions

### *General definitions*

**Alzheimer’s disease (AD):** A neurodegenerative brain disease with presenting symptoms including impairment in cognition (memory, language, executive function (e.g., problem-solving and completing tasks), and visuospatial function, all of which result in the loss of ability to perform activities of daily living (e.g., paying bills, bathing, dressing, etc.).<sup>54,55</sup> Changes in mood and personality, along with decreased or poor judgment and sleep disturbances, also occur. The main pathologies of AD are the accumulation of two abnormal protein deposits: protein tau tangles inside neurons and beta-amyloid plaques outside of the neurons in the brain. Stages of AD include a preclinical phase, MCI due to AD, and dementia due to AD.<sup>2</sup>

**Amyloid-related imaging abnormalities (ARIA):** Abnormalities on MRI that can present as either edema/effusion (ARIA-E) or hemorrhage or superficial siderosis (ARIA-H), and is commonly associated with anti-amyloid therapies. ARIA may be asymptomatic (observed only on neuroimaging) or can cause symptoms such as headache, nausea, confusion, and gait abnormalities. ARIA is most commonly seen early on in a treatment period and is more frequently observed in ApoE  $\epsilon$ 4 carriers as compared to non-carriers. Management of ARIA may include MRI monitoring, dose suspension or termination, treatment titration, etc.<sup>56</sup>

- Hemorrhage: Bleeding from a damaged blood vessel.
- Superficial siderosis: A degenerative disorder affecting the brain and spinal cord. It is the result of persistent long-term bleeding into the subarachnoid space in the brain resulting in a build-up of hemosiderin on the brain surface and pia matter from cerebrospinal fluid.<sup>57</sup> Symptoms include hearing loss, movement abnormalities, and motor difficulties.

**Apolipoprotein  $\epsilon$ 4 (ApoE  $\epsilon$ 4):** An allele that increases the risk of an individual developing AD. Up to 25% of Caucasian individuals are heterozygous (carry one copy) of the  $\epsilon$ 4 allele, which increases the risk of developing AD by 3-fold.<sup>58</sup> 2% of the population are homozygous (carry two copies) of the  $\epsilon$ 4 allele, and have a 15-fold risk of developing AD compared with the general population. More research is recommended by the Alzheimer’s Association to better understand the correlation between ApoE  $\epsilon$ 4 carriers and the onset of AD.<sup>2</sup>

**Disease-modifying therapy:** Treatments or interventions that affect the underlying pathophysiology of a disease and have a beneficial outcome on the course of AD.<sup>59</sup>

## **Biomarkers**

**Amyloid plaque:** Extracellular deposits of the amyloid beta protein mainly in the grey matter of the brain.

**Beta-amyloid:** Beta-amyloid ( $A\beta$ ) plays a key role in the pathogenesis of Alzheimer's disease and can be imaged in vivo using F-florbetapir PET. Beta-amyloid is formed from the breakdown of an amyloid precursor protein. Beta-amyloid refers to peptides of 36-43 amino acids that are the main component of amyloid plaques.  $A\beta$  monomers, a disordered peptide, can aggregate into various forms, including oligomers (soluble), protofibrils and amyloid fibrils (insoluble).<sup>60</sup> Different Alzheimer's disease therapies aim to target different species of amyloid. Amyloid plaques contain both  $A\beta_{40}$  and  $A\beta_{42}$ .  **$A\beta_{1-42}$  and  $A\beta_{1-40}$**  are biomarkers in Alzheimer's disease detected in plasma or cerebrospinal fluid, with higher values representing more amyloid.  $A\beta_{1-42}$  is considered to be important for progression as it is more toxic.  **$A\beta_{42/40}$**  is also a biomarker for early detection of amyloid pathology. A lower ratio is indicative of elevated amyloid.

**Tau protein:** A microtubule-associated protein that form insoluble filaments that accumulate as neurofibrillary tangles in Alzheimer's disease.<sup>61</sup> Tau is suggested to help stabilize neurons in the brain and a buildup of tau impacts the function of brain cells. Tau increases with age and has been suggested to be a general marker of neurodegeneration.<sup>62</sup> Tau is important in Alzheimer's disease as models suggest that while amyloid PET may be the earliest detected abnormal biomarker, it is followed closely by CSF tau.<sup>63</sup> Total-tau (t-tau) is used as a key biomarker in Alzheimer's disease research.

**Flortaucipir:** The most widely studied tau-specific radiotracer and is specific to the tau aggregates of AD.

**Phosphorylated tau (P-tau):** Phosphorylated tau are tau in an abnormally hyperphosphorylated state. A buildup of p-tau leads to synaptic impairment and neurofibrillary tangles.<sup>64</sup> P-tau has been considered a more specific marker for Alzheimer's disease as neurofibrillary tangles consist of tau protein in this state.

**Neurogranin:** Calmodulin-binding protein expressed primarily in the brain, particularly in dendritic spines, and participating in the protein kinase C signaling pathway. Neurogranin is considered a biomarker for Alzheimer's disease.

**Plasma:** The liquid component of the blood that is necessary to distribute nutrients, remove waste, and prevent infection. Plasma samples are taken in Alzheimer's disease research to examine biomarkers such as tau, p-tau, and beta-amyloid.

**Cerebrospinal fluid (CSF):** Body fluid found in the tissue that surrounds the brain and spinal cord, providing a cushion from injury and providing nutrients to the brain. CSF samples are taken in Alzheimer’s disease research to examine biomarkers such as tau, p-tau, and beta-amyloid.

**Positron Emission Tomography (PET) scan:** A minimally-invasive functional imaging technique that uses radioactive substances (radiotracers) to visualize and measure changes in activity in organs and tissues. PET scans are used for diagnosing Alzheimer’s disease by measuring the build-up of beta-amyloid in the brain. Amyloid PET is a specific type of PET scan where a ligand that binds to amyloid plaque is labeled with a radioisotope (e.g., fluorine F18) to visualize and measure amyloid.

- **Standardized uptake value ratio (SUVR):** A widely used PET quantifier. This is a method of determining activity in PET imaging and is used as a measure for quantifying the global A $\beta$  and tau burden.
- **Centiloids:** Standardized measure of amyloid PET imaging that scales the outcome of each analysis method or tracer to a 0 to 100 scale. The units of this scale have been named "Centiloids." SUVR can be transformed into centiloids by using individual-level data from cognitive controls and “typical” individuals with AD as anchors.

**Magnetic resonance imaging (MRI):** Medical imaging technique used to create images of organs and tissues in the body. MRIs are used in Alzheimer’s disease research to detect brain abnormalities for diagnosis and in clinical trials to monitor ARIA.

- **Hippocampal volume:** Hippocampus is a brain structure embedded in the temporal lobe that has a major role in learning and memory. Large hippocampal volume is positively associated with memory performance.
- **Whole brain volume:** Collective volume of the entire brain in structural imaging, without considering regionally specific differences in the volume of any individual structures. In Alzheimer’s disease, as connections between networks of neurons break down then brain regions begin to shrink.
- **Ventricular volume:** Ventricles are one of a system of four communicating cavities within the brain and are filled with cerebrospinal fluid. Enlarged ventricles have been associated with decreases in cognitive functioning.

### ***Key Outcome Instruments***

Definitions of cognitive outcomes are described in Table A.1.

**European Quality of Life – 5 dimensions (5 level version) (EQ-5D-5L):** A self-reported visual analog scale that covers dimensions of health such as mobility, self-care, activities, pain, and anxiety/depression.<sup>65</sup>

**Quality of Life in Alzheimer’s Disease (QOL-AD):** A patient-reported (or caregiver reported, e.g., subject by proxy) questionnaire reporting on quality of life in those with Alzheimer’s disease.<sup>66</sup>

**Zarit Burden Interview:** An instrument used to measure stress experienced by caregivers of those with Alzheimer’s disease.<sup>67</sup>

**Table A.1. Definitions of Cognitive Outcomes.**

Cognitive Outcome	Minimal Clinically Important Difference (MCID)
<p>Clinical Dementia Rating – Sum of Boxes (CDR-SB) is a structured interview that assesses three domains of cognition (memory, orientation, judgment/problem-solving) and three domains of function (community affairs, home/hobbies, personal care) based on an interview with the patient or caregiver. The six domains are assigned a severity score ranging from 0 (no performance disability) to 3 (severe performance disability) and summed for a total possible score that ranges from 0 to 18.<sup>23</sup> Higher scores suggest greater disease severity with scores between 0.5-4.0 indicate questionable cognitive impairment, 4.5-9 mild dementia, 9.5-15.5 indicate moderate dementia, and 16.0-18.0 indicate severe dementia.</p>	<p>Change of 1-2 points.<sup>31-33</sup></p>
<p>Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) is an objective neurological assessment that examines the severity of cognitive and non-cognitive function from mild to severe AD. Only the cognitive subscale (ADAS-Cog) was used which includes 11 subject-completed tests and observer-based assessments of memory, language, and praxis. ADAS-Cog-13 includes all 11 items and a test of delayed word recall and number cancellation or maze task with a score ranging from 0-85.<sup>68</sup> Higher scores reflect greater impairment. There are several versions of this measure (11, 12, 13, and 14 items). ADAS-Cog14 includes both the number cancellation or maze tasks and thus scores range from 0-90 with higher scores reflecting greater impairment.</p>	<p>Change of 2 points for MCI due to AD<sup>33</sup> and ≥3 points for mild AD.<sup>34,35</sup></p>
<p>Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (ADCS-ADL) is a caregiver-completed 23-item scale that measures basic and instrumental abilities, with total scores ranging from 0-78.<sup>69</sup> The ADCS-iADL includes only the 11 instrumental items, with scores ranging from 0-56 and lower scores indicating greater functional impairment<sup>36</sup>.</p>	<p>There is no data on MCID.</p>
<p>Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (MCI version) (ADCS-MCI-ADL) is similar to the ADCS-iADL but includes both basic and instrumental items and has been adapted for individuals with mild cognitive impairment.<sup>70</sup> This measure included 18 items with total scores ranging from 0-53, with lower scores representing poorer functioning.</p>	<p>There is no data on MCID.</p>
<p>The Integrated Alzheimer’s Disease (AD) Rating Scale (iADRS) is a combination of two validated scales: ADAS-Cog 13 (or ADAS-Cog 13/14) and ADCS-ADL (ADCS-iADL or ADCS-MCI-ADL) with the following calculation: [-1(ADAS-Cog +90) + ADCS-ADL]. The iADRS scores range from 0-144 with lower scores</p>	<p>Change of 5 points for MCI due to AD and 9 points for AD with mild dementia<sup>36</sup></p>

indicating greater cognitive and functional deficits. A score of 90-105 indicates MCI and score of 100-120 indicates mild AD.	
Mini-Mental State Examination (MMSE) is a 30-point objective test used to measure cognitive impairment in categories such as orientation to time and place, attention and calculation, recall, language, repetition, and complex commands. Total scores range from 0-30 with lower scores indicate more impairment. A score between 0-17 indicates severe cognitive impairment, a score between 18-23 indicates mild cognitive impairment, and a score between 24-30 indicates no impairment.	Change of 1-3 points. <sup>31</sup>
AD Composite Score (ADCOMS) is a weighted score that includes the MMSE (2 items: Constructional praxis and orientation time), CDR-SB (6 items: personal care, home and hobbies, community affairs, judgment and problem solving, orientation, and memory), and ADAS-Cog14 (4 items: word finding difficulty, word recognition, orientation, and delayed word recall). <sup>71</sup> Total scores range from 0-1.97. A score of < 0.29 is indicative of normal cognition, 0.29 to < 0.50 is indicative of MCI, 0.50 to 0.80 is indicative of mild AD, and > 0.80 is indicative of at least moderate AD.	There is no data on MCID.

AD: Alzheimer's Disease, MCI: mild cognitive impairment

Other Relevant Definitions

**Health Improvement Distribution Index:** The Health Improvement Distribution Index identifies a subpopulation that has a higher prevalence of the disease of interest and therefore, creates an opportunity for proportionately more health gains within the subpopulation. This opportunity may be realized by achieving equal access both within and outside the identified subpopulation to an intervention that is known to improve health. The Health Improvement Distribution Index is defined as the disease prevalence in the subpopulation divided by the disease prevalence in the overall population. For example, if the disease prevalence was 10% in poor Americans whereas the disease prevalence across all Americans was 4%, then the Health Improvement Distribution Index would be  $10\%/4\% = 2.5$ . For interventions known to increase health in this disease and that accomplish equal access across the entire population, poor Americans would receive 2.5 times the health improvements as compared to the same sized group of Americans without regard to economic status. Health Improvement Distribution Indexes above 1 suggest that more health may be gained on the relative scale in the subpopulation of interest when compared to the population as a whole. This statistic may be helpful in characterizing a treatment's contextual considerations and potential other benefits (Section 5). For the calculation for the HIDI for African Americans, we used population estimates of clinical AD calculated by Rajan et al., which were based on the Chicago Health and Aging Project and adjusted based on the 2020 US census.<sup>72</sup> The overall 2020 US census adjusted prevalence of clinical AD was 11.3%.

- African American =  $18.6\%/11.3\% = 1.6$

## A2. Potential Cost-Saving Measures in Alzheimer’s Disease

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, see <https://icer.org/our-approach/methods-process/value-assessment-framework/>). These services are ones that would not be directly affected by beta-amyloid therapies for AD (e.g., skilled nursing care), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of mild cognitive impairment or mild AD beyond the potential offsets that arise from a new intervention. During stakeholder engagement and public comment periods, ICER encouraged all stakeholders to suggest services (including treatments and mechanisms of care) currently used for people with Alzheimer’s disease that could be reduced, eliminated, or made more efficient. We received a suggestion that repeating neuropsychological testing to monitor cognitive decline may not be necessary.

# B. Patient Perspectives: Supplemental Information

---

## **B1. Methods**

ICER engaged with people with AD and caregivers, patient groups, including representatives from AD advocacy organizations and caregiver organizations, and clinical experts to gather information to better understand patient and caregiver experiences with the disease. In total, we spoke with nine persons with AD, six caregivers, two advocacy organizations, nine clinical experts, one payer, and four manufacturers via conference calls throughout the review process. We also reviewed research literature suggested by or provided to ICER by advocacy organizations as well as data from qualitative interviews and surveys of people with AD and caregivers provided to us by patient organizations.<sup>73,74</sup>

People living with AD, caregivers, and advocacy groups provided information on the impact of AD on individuals with the disease and caregivers throughout the disease course, particularly concerning aspects of the disease and caregiving that are not well-reflected in the current literature, and their thoughts about current and future treatment options. Patient advocacy organizations also assisted with literature review to find information that was considered for inputs into the economic model.

We spoke with a wide range of people living with AD, mainly people over the age of 50 with mild or moderate AD and mostly living at home. We spoke with both men and women, as well as both White and African American people living with AD. The caregivers we spoke with represented a wide variety of ages (from 30 to above 70) and caregiving experience, caring for loved ones across the disease spectrum (mild to severe) and in various settings (home and long-term care). We spoke with both male and female, and White, Black, and Hispanic caregivers.

Clinical experts were chosen based on their expertise in diagnosing, treating, and/or researching AD, as well as recommendations from other stakeholders. We spoke with neurologists and geriatricians with expertise treating people with AD, as well as epidemiologists and clinical researchers. Clinical experts also believe that the main goal of treatment for AD is to maintain independence, and that disease-modifying drugs would be a welcome addition to the treatment arsenal. However, because there have been multiple purported disease-modifying drugs that have previously failed during the clinical trial phase, they are cautious and feel they need clear evidence demonstrating such an effect from a new therapy. Additionally, clinical experts also cited issues with clinical trial outcome measures, including that CDR-SB may not be sufficiently sensitive to changes in cognition and function.

Payers were concerned about the use of surrogate markers as endpoints in clinical trials, and the lack of clear association between those surrogate markers and clinical outcomes.

Manufacturers noted the urgency of developing new treatments for AD, the disproportionate impact of AD on persons of color and their caregivers, and that better information on the impact of AD treatments on quality of life for both individuals with the disease and caregivers is needed.

## C. Clinical Guidelines

---

Clinical practice guidelines for the treatment of MCI and mild AD have been issued by several US and non-US-based organizations. These guidelines are summarized below.

### **American Academy of Neurology<sup>5</sup>**

In 2018, the American Academy of Neurology published guidelines for the management of MCI. The guidelines recommended that clinicians assess for MCI using validated tools, evaluate individuals with MCI for modifiable risk factors, assess for functional impairment, assess for and treat behavioral symptoms, and consider discontinuing medications that may impair cognition. Furthermore, guidelines suggested that clinicians should counsel patients about the expected course of the disease, encourage long-term planning, and discuss the lack of effective medication options, including the lack of benefit of cholinesterase inhibitors on cognition and progression.

### **National Institute for Health and Care Excellence (NICE)<sup>6</sup>**

Guidelines for the diagnosis and management of dementia were published in June 2018 by NICE in the United Kingdom. The guidelines include recommendations on involving people living with dementia in decisions about their care, assessment and diagnosis of dementia, interventions to promote cognition, independence and well-being, pharmaceutical interventions, managing non-cognitive symptoms, supporting caregivers, and staff training and education. Among the non-pharmacological interventions recommended were group cognitive stimulation and reminiscence therapy and cognitive rehabilitation, and recommendations against acupuncture, herbal supplements, vitamin E, and non-invasive brain stimulation. Consideration should be given to minimizing medications that may impair cognition. Acetylcholinesterase inhibitors were recommended for managing mild-to-moderate AD symptoms, and memantine and/or combination therapy was recommended for moderate-to-severe AD. Recommendations were also made to manage non-cognitive symptoms (e.g., behavioral symptoms, depression, sleep problems), and managing other long-term conditions common in people with AD, such as pain, falls, and incontinence.

### **American Psychiatric Association<sup>75</sup>**

The American Psychiatric Association published practice guidelines for the treatment of individuals with AD in 2014. The guidelines discuss the evidence of efficacy for medications to treat AD, and state that based on the available evidence, memantine, cholinesterase inhibitors, or a combination of the drugs, may be used to treat AD. They also recommend using nonpharmacological interventions and environmental measures to reduce psychosis and agitation before considering use of antipsychotics based on the lack of evidence for efficacy of antipsychotics in this situation.

The guidelines also discuss the evidence for a variety of psychosocial interventions and alternative treatments, and offer guidance on managing caregiver stress.

## **The National Institute on Aging-Alzheimer’s Association**<sup>54,55,76</sup>

In 2011, the [National Institute on Aging and the Alzheimer’s Association](#) convened a workgroup to revise the diagnostic criteria for MCI and AD. These included diagnostic criteria both to be used in the clinical setting and in research settings. Clinical and cognitive criteria were established to differentiate MCI and AD, and to establish the potential etiology of MCI. Furthermore, for AD, diagnostic criteria incorporating biomarkers were defined. Biomarkers to incorporate into research criteria were also discussed, including PET amyloid imaging for beta-amyloid deposition and CSF fluid tau/phosphorylated tau, among others.

In 2018, the National Institute on Aging and the Alzheimer’s Association issued an updated research framework intended to guide observational and interventional research<sup>76</sup>. The objective was to create a scheme for defining and staging AD across the lifespan. The framework establishes a biomarker-based system for classifying the neuropathologic changes seen in AD, including imaging and CSF biomarkers. Biomarkers are separated into those related to beta-amyloid plaques (e.g., CSF A $\beta$ -42, amyloid PET), fibrillar tau (e.g., CSF phosphorylated tau, tau PET), and neurodegeneration or neuronal injury (e.g., anatomic MRI, total CSF tau). Categorization of AD- and non-AD-related pathologic change using biomarkers is discussed. Additionally, the document discusses cognitive staging applicable to research cohorts, including syndromal categorical cognitive staging that uses traditional syndromal categories (cognitively unimpaired, MCI, dementia), and numeric clinical staging (from Stage 1 cognitively normal to Stage 6 severe dementia) for people with the disease in the AD continuum.

## **Aducanumab: Appropriate Use Recommendations**<sup>77</sup>

After FDA approval of aducanumab, a panel of Alzheimer’s disease experts convened to discuss best practices for aducanumab use. The panel defined the appropriate patient population for initiation of treatment, which includes individuals with early AD with positive amyloid via PET scan or CSF investigation, and recommends potential exclusion criteria, including concomitant use of anticoagulation. The expert panel also recommend an MRI monitoring schedule of baseline and surveillance MRIs based on aducanumab titration, and management strategies for ARIA, including MRI monitoring intervals and recommendations for dosing. Finally, the expert panel made recommendations on the healthcare system resources needed for safe and appropriate use of aducanumab, such as clinical expertise, access to testing for amyloid, infusion resources, access to MRI, and access to family and patient education and support.

# D. Comparative Clinical Effectiveness: Supplemental Information

## **D1. Detailed Methods**

### **PICOTS**

#### ***Population***

The population of focus for the review is adults with early AD (i.e., MCI due to AD [also termed “prodromal” Alzheimer’s] and mild AD dementia) with evidence of AD pathology (e.g., amyloid positivity). This population approximates individuals whose condition would be categorized as Stages 3 or 4 using diagnostic criteria outlined by the FDA.<sup>78</sup> Evidence that includes individuals with AD in Stage 2 will only be considered if the sample also includes individuals in Stage 3.

#### ***Interventions***

The interventions of interest for this review will be lecanemab and donanemab in addition to supportive care. Supportive care includes both non-pharmacologic and non-disease-modifying pharmacologic interventions. We will also include available updated evidence for aducanumab that was not covered in the previous August 2021 review.<sup>23</sup>

#### ***Comparators***

We intend to compare lecanemab, donanemab, and aducanumab in addition to supportive care to supportive care alone.

#### ***Outcomes***

The outcomes of interest are described in the list below.

- Patient-centered Outcomes
  - Change in:
    - Ability to maintain independence and autonomy
    - Ability to perform activities of daily living (e.g., as measured by AD Cooperative Study-Activities of Daily Living Inventory-MCI, etc.)
    - Cognitive function (e.g., as measured by Clinical Dementia Rating, Mini-Mental State Examination, AD Composite Score, Alzheimer’s Disease

- Assessment Scale – Cognitive Subscale, Integrated Alzheimer’s Disease Rating Scale, Montreal Cognitive Assessment Test, etc.)
    - Neuropsychiatric symptoms (e.g., as measured by Neuropsychiatric Inventory Questionnaire)
  - Delayed entry into institutional care
  - Disease progression
  - Symptom progression
  - Maintenance of identity and personality
  - Quality of life
  - Emotional wellbeing
  - Caregiver impact
    - Caregiver quality of life
    - Caregiver health
    - Caregiver productivity
  - Behavioral change
  - Ability to communicate
  - Adverse events including but not limited to
    - Serious adverse events
    - Discontinuation due to adverse events
    - Infusion-related reactions
    - Death
    - Symptomatic amyloid-related imaging abnormalities (ARIA-E and ARIA-H)
- Other Outcomes
  - Level of beta-amyloid (e.g., PET, CSF)
    - Percentage of amyloid
      - Percentage reduction
      - Absolute percentage
    - Amyloid clearance
      - Mean reduction in amyloid from baseline
      - Percentage of participants reaching amyloid negativity
      - Rapidity of participants reaching amyloid negativity
    - Durability of biomarker reductions (e.g., tau levels and beta-amyloid)
  - Level of tau proteins (e.g., CSF phosphorylated tau, total tau, PET ligand)
  - Neuroinflammation
  - Brain atrophy
  - Brain volume (e.g., hippocampal volume, ventricular volume, or whole brain volume)
  - Additional biomarkers may be reviewed based on input from manufacturers and clinical experts as the review progresses

### ***Timing***

Evidence on intervention effectiveness and evidence on harms will be derived from studies of any duration.

### ***Settings***

Evidence from all relevant settings will be considered with a particular focus on the outpatient setting.

**Table D1. PRISMA 2009 Checklist**

		Checklist Items
<b>TITLE</b>		
Title	1	Identify the report as a systematic review, meta-analysis, or both.
<b>ABSTRACT</b>		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
<b>INTRODUCTION</b>		
Rationale	3	Describe the rationale for the review in the context of what is already known.
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
<b>METHODS</b>		
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.

Checklist Items		
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
DISCUSSION		
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.
FUNDING		
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

## Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on donanemab, lecanemab, and updated evidence for aducanumab, in addition to supportive care, for the treatment of early Alzheimer’s disease (AD), i.e., MCI due to AD and mild AD dementia followed established best research methods.<sup>79,80</sup> We conducted the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>81</sup> The PRISMA guidelines include a checklist of 27 items, which are described further in [Appendix Table D1](#).

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and Emtree terms in EMBASE), as well as free-text terms.

To supplement the database searches, we performed a manual check of the reference lists of included trials and reviews and invite key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, and information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see <https://icer.org/policy-on-inclusion-of-grey-literature-in-evidence-reviews/>). Where feasible and deemed necessary, we also accepted data submitted by manufacturers “in-confidence,” in accordance with ICER’s published guidelines on acceptance and use of such data (<https://icer.org/guidelines-on-icers-acceptance-and-use-of-in-confidence-data-from-manufacturers-of-pharmaceuticals-devices-and-other-health-interventions/>).

**Table D1.1. Search Strategy of Medline 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials (lecanemab and donanemab)**

1	(lecanemab or 'ban 2401' or ban2401).ti,ab.
2	(donanemab or 'ly 3002813' or ly3002813).ti,ab.
3	1 or 2
4	(addresses or autobiography or bibliography or biography or comment or congresses or consensus development conference or duplicate publication or editorial or guideline or in vitro or interview or lecture or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or personal narratives or portraits or practice guideline or video audio media).pt.
5	3 not 4
6	(exp animals/ or exp animal/ or exp nonhuman/ or exp animal experiment/ or animal model/ or animal tissue/ or non human/ or (rat or rats or mice or mouse or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset\$1 or basic research or cell lines or in vitro or animal model or canine).tw.) not (humans/ or human/ or human experiment/ or (human* or men or women or patients or subjects).tw.)

7	5 not 6
8	Limit 7 to English Language
	Remove duplicates from 8

**Table D1.2. Search Strategy of EMBASE SEARCH (lecanemab and donanemab)**

#1	lecanemab/exp
#2	(lecanemab OR "ban 2401" OR ban2401):ti,ab
#3	#1 OR #2
#4	donanemab/exp
#5	(donanemab OR "ly 3002813" OR ly3002813):ti,ab
#6	#4 OR #5
#7	#3 OR #6
#8	('case report'/de OR 'practice guideline'/de OR 'questionnaire'/de OR 'chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'short survey'/it)
#9	#7 NOT #8
#10	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
#11	#9 NOT #10
#12	#11 AND [english]/lim

**Table D1.3. Search Strategy of Medline 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials (updated evidence for aducanumab)**


1	(aducanumab or BIIB037 or 'BIIB 037' or BIIB-037 or BIIB37 or BIIB-37 or aduhelm).ti,ab.
2	(addresses or autobiography or bibliography or biography or comment or congresses or consensus development conference or duplicate publication or editorial or guideline or in vitro or interview or lecture or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or personal narratives or portraits or practice guideline or review or video audio media).pt.
3	1 NOT 2
4	(exp animals/ or exp animal/ or exp nonhuman/ or exp animal experiment/ or animal model/ or animal tissue/ or non human/ or (rat or rats or mice or mouse or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset\$1 or basic research or cell lines or in vitro or animal model or canine).tw.) not (humans/ or human/ or human experiment/ or (human* or men or women or patients or subjects).tw.)
5	3 NOT 4
6	Limit 5 to English Language
7	Remove duplicates from 6
8	Limit 7 to yr="2020 -Current"

**Table D1.4. Search Strategy of EMBASE SEARCH (updated evidence for aducanumab)**

#1	'aducanumab/'
#2	aducanumab:ti,ab OR biib037:ti,ab OR 'biib 037':ti,ab OR biib37:ti,ab OR 'biib-37':ti,ab OR aduhelm:ti,ab
#3	#1 OR #2
#4	#3 NOT ('case report'/de OR 'human tissue'/de OR 'nonhuman'/de OR 'practice guideline'/de OR 'questionnaire'/de OR 'chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'review'/it OR 'short survey'/it)
#5	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
#6	#4 NOT #5

#7	#6 AND [english]/lim
#8	#7 AND [18/05/2021]/sd

**Figure D1. PRISMA flow Chart Showing Results of Literature Search for Aducanumab, Lecanemab and Donanemab for Alzheimer’s Disease.**



Note: No references were identified for aducanumab.

## Study Selection

We performed screening at both the abstract and full-text level. A single investigator screened all abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. One investigator reviewed full papers and provided justification for exclusion of each excluded study.

## Data Extraction and Quality Assessment

We examined the risk of bias for each trial using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2)<sup>82</sup> and guidance criteria published by Higgins et al (2019).<sup>83</sup> Risk of bias was assessed for each of the following aspects of the trials: randomization process, deviation from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported results, and overall risk of bias. To assess the risk of bias in trials in the report, we rated the categories as: “low risk of bias”, “some concerns”, or “high risk of bias”. Guidance for risk of bias ratings using these criteria is presented below:

**Low risk of bias:** *The study is judged to be at low risk of bias for all domains for this result.*

**Some concerns:** *The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.*

**High risk of bias:** *The study is judged to be at high risk of bias in at least one domain for this result or the study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.*

We examined the risk of bias for the following outcomes: CDR-SB, ADAS-Cog, ADCS-ADL, and ARIA. Since iADRS is a composite of ADAS-Cog and ADCS-ADL, we assessed the components separately. See Table D1.5. Note that case series are not considered under this rating system – because of the lack of comparator, these are generally considered to be of poor quality. We did not assess the risk of bias in trials where we only had access to conference abstracts/presentations.

**Table D1.5. Risk of Bias Assessments**

Trial name	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
<b>CDR-SB</b>						
CLARITY AD <sup>28</sup>	Low	Low	Low	Some concerns	Low	Low
TRAILBLAZER-ALZ <sup>29</sup>	Low	Low	Low	Some concerns	Low	Some concerns
<b>ADAS-Cog*</b>						
CLARITY AD <sup>28</sup>	Low	Some concerns	Low	Low	Low	Some concerns
TRAILBLAZER-ALZ <sup>29</sup>	Low	Low	Low	Low	Low	Some concerns
<b>ADCS-ADL†</b>						
CLARITY AD <sup>28</sup>	Low	Low	Low	Some concerns	Low	Some concerns
TRAILBLAZER-ALZ <sup>29</sup>	Low	Low	Low	Some concerns	Low	Some concerns
<b>ARIA</b>						
CLARITY AD <sup>28</sup>	Low	Low	Low	High	Low	High
TRAILBLAZER-ALZ <sup>29</sup>	Low	Low	Low	High	Low	High

Note: All “some concerns” or “high risk” favored the experimental group.

ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive Subscale, ADCS-ADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory, ARIA: Amyloid-related imaging abnormalities, CDR-SB: Clinical Dementia Rating – Sum of Boxes.

\*ADAS-Cog13 was used in the TRAILBLAZER-ALZ trial, and ADAS-Cog14 was used in the CLARITY AD trial.

†ADCS-iADL was used in the TRAILBLAZER-ALZ trial and ADCS-MCI-ADL was used in the CLARITY AD trial.

## Assessment of Level of Certainty in Evidence

We used the [ICER Evidence Rating Matrix](#) to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus (see Appendix D).<sup>84,85</sup>

## Assessment of Bias

As part of our quality assessment, we evaluated the evidence base for the presence of potential publication bias. Given the emerging nature of the evidence base for these newer treatments, we scanned the [ClinicalTrials.gov](https://clinicaltrials.gov) site to identify studies completed more than two years ago. Search terms included lecanemab, ban2401, donanemab, ly3002813, aducanumab, aduhelm, and biib037. We selected studies which would have met our inclusion criteria, and for which no findings have been published. We will provide qualitative analysis of the objectives and methods of these studies to ascertain whether there may be a biased representation of study results in the published literature.

## Data Synthesis and Statistical Analyses

The studies were summarized in the text and in evidence tables of the Evidence Report. This summary is key to understanding the evidence base pertaining to the topic. Any key differences between the studies in terms of the study design, patient characteristics, interventions (including dosing and frequency), outcomes (including definitions and methods of assessments), and study quality was noted in text of the report.

## D2. Additional Clinical Evidence

### Lecanemab

#### **CLARITY AD**

##### Methods


The inclusion criteria for CLARITY AD were participants aged between 50 and 90 years, had a mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia, objective impairment in episodic memory, amyloid positive as determined by PET or CSF (A $\beta$ 1–42), had Mini-Mental State Exam (MMSE) score of 22-30, BMI 17-35, and, if they were receiving any treatment for AD symptoms, were on a stable dose for 12 weeks prior to baseline. Participants were excluded if they had any other neurological condition that may be contributing to cognitive impairment, any psychiatric diagnosis/symptoms, Geriatric Depression Scale (GDS) score  $\geq$ 8, contraindications to MRI, or lesions on MRI that could indicate dementia diagnosis other than Alzheimer’s disease. Full inclusion and exclusion criteria are described in Table D3.1. in the Supplement.

##### Additional Results

##### **Cognitive outcomes**

Prespecified subgroup analyses were conducted on the cognitive outcomes. In the main report, we described four subgroups that were consistent across the four cognitive outcomes. In this supplement, we also present the race (global) subgroup. Black participants showed a greater slowing of decline compared to White and Asian participants. [See Figure D2](#). A greater slowing of decline in Black participant was also seen in ADCOMS and ADCS-MCI-ADL. [See Supplement Tables D3.23-26](#). However, this group consisted of 44 individuals and thus should be interpreted with caution.

**Figure D2. Forest Plot of Subgroup Analyses for CDR-SB at 18 Months (Age, ApoE ε4 Genotype, Sex, and Race)**



**Beta-amyloid levels**

Changes in beta-amyloid are described in the main report. Changes in plasma Aβ42/40 ratio and CSF values (Aβ1-42 and Aβ1-40) are described in this supplement. For participants who consented to the CSF substudy, CSF samples were taken at baseline, week 53, and week 77, and plasma samples were taken at baseline, week 53, and week 79. Based on an analysis with 73.3% of the total participants (N=1316), plasma Aβ42/40 ratio increased more in the lecanemab group (0.008), compared to the placebo group which remained constant (0.001). Based on an analysis with 11% of the total participants (N=198) participants, there was an increase in CSF Aβ1-42 in the lecanemab group (281.8), compared to a very slight decrease in the placebo group (-6.5). Based on an analysis with 7.9% of the total participants (N=142), there was a decrease in CSF Aβ1-40 in the lecanemab group (-417.9), compared to a decrease in the placebo group (-89.9).<sup>38</sup> The investigators noted that these findings suggest sustained amyloid reversal effects.

Brain volume was assessed using MRI. MRI scans were taken at screening and week 9, 13, 27, 53, and 79 (or at early termination visit). Volumetric MRI data was available for approximately 75% of participants in the CLARITY AD trial at 18 months, and showed increased atrophy in the whole brain and cortical thickness, and decreased atrophy in the hippocampus. Data was digitized from the figures presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2022 conference<sup>38</sup> and are reported in Supplement Table D3.4.

### ***Biomarkers***

T-tau was examined in 199 participants consenting to the tau substudy. Tau was examined by CSF at baseline, week 53, and week 77 and, in those consenting to the PET substudy, via PET at baseline, week 59, and week 79. There was a significant decline in CSF tau in the lecanemab group, compared to an increase in the placebo group (-29.1 vs 95.3,  $p < 0.001$ ).<sup>28</sup> Subgroup analysis conducted examining changes in tau pathology, as measured by PET, across different brain regions showed that the mean difference in tau pathology was significant in the medial temporal (-0.068,  $p = 0.002$ ), meta temporal (-0.07,  $p = 0.012$ ), and temporal areas (-0.065,  $p = 0.016$ ) (Supplement Table D3.4).<sup>38</sup> See Supplement Table D3.4.

P-tau was examined by CSF at baseline, week 53, and week 77, and plasma at baseline, week 53, and week 79. There was a significant reduction in p-tau (p-tau 181), measured via plasma sample and CSF, in the lecanemab group (-0.6 and -15.9 in plasma and CSF, respectively) compared to increases in the placebo group (0.2 and 12.9 in plasma and CSF, respectively) ( $p < 0.001$  in both analyses).<sup>28</sup>

Neurogranin was examined by CSF at baseline, week 53, and week 77. There was a significant decline in neurogranin in the lecanemab group compared to an increase in the placebo group (-71.9 vs 18.9,  $p < 0.001$ ).<sup>38</sup> Neurofilament light chain (NfL) was examined by CSF at baseline, week 53, and week 77, and plasma at baseline, week 53, and week 79. There was no significant treatment effect on both of the NfL measures.<sup>38</sup> All biomarker outcomes are provided in the Supplement Table D3.4.

### **Additional Harms**

ARIA was assessed by MRI at baseline and five additional time points across the study. In terms of radiographic severity, ARIA was measured on a 3-point scale from mild-severe. Symptomatic ARIA-E was assessed by radiographic severity and self-reported symptoms (both participant and assessor were blinded to treatment group). If a patient experienced asymptomatic, radiographically mild ARIA-E, they continued the drug with additional MRIs at 30, 60, and 90 days after ARIA was identified. If ARIA-E worsened or became symptomatic, the study drug would be temporarily discontinued. If symptomatic or radiographically moderate or severe ARIA-E occurred, the study drug would be stopped, and MRI was conducted every 30 days until it had resolved. Upon resolution, participants resumed the study drug. If occurred more than twice, the participant would

be discontinued from the study. If severe ARIA-E was associated with serious adverse event, the study drug would be stopped permanently. Safety was also monitored in an unblinded manner by an independent monitoring committee.

As noted in the main report, participants in the lecanemab group reported more infusion-related reactions compared to the placebo group (26.4% vs 7.4%).<sup>28</sup> These reactions mostly occurred on the first dose (75%) and were mostly mild-moderate in severity (96%), with 0.8% participants in the lecanemab group reporting a severe infusion-related reaction.<sup>42</sup> See Table D3.11. Of those who had an infusion-related reaction, approximately 40% received preventative medications (i.e., anti-inflammatory drugs, antihistamines, or glucocorticoids) and there was a 35% recurrence rate which was similar regardless of whether the participant took the preventive medication or not.

### ***Phase II: G000-201***

G000-201 was a Phase IIb multi-center, placebo-controlled, dose-ranging, randomized control trial that aimed to identify the most effective dose of lecanemab. Six doses of lecanemab (2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly, 10 mg/kg biweekly) were tested versus placebo for 18 months.<sup>86</sup> This trial utilized a Bayesian response-adaptive randomization whereby there was a fixed period of randomization for the first 196 participants (N=28 in each lecanemab arm, and N=56 in placebo) and then the response-adaptive randomization was implemented to minimize the overall sample size and study duration. See section on “Bayesian adaptive randomization” below for additional description of this randomization procedure. The primary outcome was change in ADCOMS at 12 months. This trial also included an extension phase of the 10 mg/kg biweekly lecanemab dose only. Participants had an off-treatment period and then re-initiated treatment for up to 60 months. The primary outcome for the extension phase was to examine adverse events and change from baseline in biomarkers at 60 months. Inclusion/exclusion criteria and baseline characteristics are described in Table D.2.1 in this Supplement.

Participants were included in the Phase IIb study if they were aged between 50 and 90 years with MCI due to Alzheimer’s Disease or mild Alzheimer’s Disease dementia, had objective impairment in episodic memory and MMSE score 22-30, had a positive amyloid loid as determined by PET or CSF [A $\beta$ (1-42)], had a BMI greater than 17 and less than 35 at screening, and had a study partner. Participants were not able to use therapies such as: immunoglobulin therapy (6 months), biologic drugs (6 months), and anticoagulants (e.g., warfarin, dabigatran for 7 days or 5 half-lives). Other exclusion criteria included any neurological condition that may be contributing to cognitive impairment, any psychiatric diagnosis or symptoms, contraindications to MRI, evidence of other clinically significant brain lesions, or being on any Alzheimer’s Disease medication for less than 12 weeks.

There was a total of 854 participants who took part in the G00-201 trial (lecanemab n=609 and placebo n=245). Participants had a median age of 71.7 years (range from 50-90) with 64% described

as MCI due to Alzheimer's Disease. A total of 54.7% of participants were currently on Alzheimer's disease medication and 71.8% were ApoE ε4 carriers. Participants reported a mean ADCOMS of 0.38 (SD=0.17), mean MMSE of 25.7 (SD=2.4), mean CDR-SB of 2.95 (SD=1.42), and mean ADAS-Cog 14 of 22.5 (SD=7.5).<sup>86</sup>

### Bayesian adaptive randomization

The response-adaptive randomization aimed to find the simplest (e.g., monthly vs. biweekly) and most effective (e.g., 10 mg, 5 mg, etc.) dose ( $\geq 90\%$  of the maximum treatment effect) and allocate more participants to this dose at each interim analysis, which was conducted every 50 participants.<sup>87</sup> The trial also monitored for futility ( $<5\%$  posterior probability that most likely effective dose is superior to placebo by 25% for the first three interim analyses and increased to  $<7.5\%$  once they had reached 350 participants) and success (from 350 participants:  $>95\%$  posterior probability that effective dose was better than placebo, or at the end of the trial: lecanemab effect exceeds placebo rate by  $\geq 25\%$ ) during the interim analyses. The modeling had two components used to estimate the primary endpoint at week 52 for the adaptive randomization. First, the investigators used a dose-frequency model that examined mean change from baseline. This Bayesian model used weak prior distributions for mean response and allowed borrowing/smoothing across neighboring doses and frequencies to provide a superior estimate of each treatment arm's effect. Second, the investigators used a longitudinal model that examined correlations between early ADCOMS scores and the 52-week outcome. To do this, the investigators used priors selected from historical data and a Bayesian imputation within Markov chain Monte Carlo to impute the 52-week data and update the dose-frequency response model at each interim analysis.<sup>87</sup> As a result, the size of the individual dose groups differed depending on the interim analyses.

Notable protocol changes occurred during this Phase II trial, during the randomization period of participants 300-350. The regulatory authority requested that ApoE ε4 carriers (approximately 70% of the overall population) no longer be administered the 10 mg/kg biweekly dose of lecanemab going forward, due to increased risk of ARIA. As a result, 25 participants who were ApoE ε4 carriers were discontinued as they were in the trial for less than six months, compared to 46 ApoE ε4 carriers who were already on this dose for longer than six months and were able to continue.<sup>86</sup> The regulatory change may have enriched the intervention arm with participants in the lecanemab group expected to perform better.

### Results

In this supplement, we primarily focus on reporting the results from the lecanemab 10 mg/kg biweekly dose versus placebo, as this is the dose that was used in the Phase III CLARITY AD trial. Where that data is not available, we provide pooled data from the 10 mg/kg biweekly and monthly lecanemab arms versus placebo.

### ***Cognitive outcomes***

The primary outcome in G000-201 trial was the change from baseline in ADCOMS score at 12 months.

Bayesian analysis was used to examine the primary outcome (ADCOMS) at 12 months. The 10 mg/kg biweekly dose was identified as the most effective dose. The 10 mg/kg biweekly group had a 64% probability of being more effective than placebo with 25% less decline on ADCOMS at 12 months. This result did not meet the pre-specified 80% probability threshold and thus the primary outcome was not met. The 10 mg/kg biweekly group had a 76% probability of being more effective than placebo with 25% less decline on ADCOMS at 18 months (secondary outcome), which also did not meet the pre-specified 80% threshold. However, the 10 mg/kg biweekly group had a 97.6% and 97.7% probability of being superior to placebo at any magnitude on the ADCOMS at 12 and 18 months, respectively (Table D3.7-8.). Subgroup analyses were conducted for those who were ApoE  $\epsilon$ 4 carriers and non-carriers. In ApoE  $\epsilon$ 4 carriers, the 10 mg/kg biweekly group had a 93.6% probability of being more effective than placebo with 25% less decline on ADCOMS at 18 months and a 99.2% probability of being superior to placebo at any magnitude on the ADCOMS at 18 months. In contrast, non-carriers had 29% probability of being more effective than placebo with 25% less decline on ADCOMS at 18 months and a 63% probability of being superior to placebo at any magnitude on the ADCOMS at 18 months (Table D3.13). Thus, the analyses suggest a potential differential treatment effect for carriers versus non-carriers, with ApoE  $\epsilon$ 4 carriers experiencing a greater treatment effect. However, this subgroup analysis should be treated as exploratory as the ApoE  $\epsilon$ 4 carrier group consisted of 45 participants (non-carrier n=107) due to the regulatory changes that prevented ApoE  $\epsilon$ 4 carriers being randomized to the highest dose.

Bayesian analysis was also used to examine other secondary outcomes (CDR-SB and ADAS-Cog14 at 18 months). At 18 months, the 10 mg/kg biweekly group had a 96.4% probability of being superior to placebo at any magnitude on the CDR-SB and a 98.8% probability of being superior to placebo at any magnitude on the ADAS-Cog 14 (Table D3.14).

Alongside Bayesian analyses, frequentist mixed effect model with repeated measures (MMRM) were conducted for secondary outcomes comparing placebo to the lecanemab arms at 18 months. The MMRM included the following variables in the analysis: treatment group, visit, clinical subgroup (MCI due to AD, Mild AD dementia), the presence or absence of ongoing AD treatment at baseline, ApoE  $\epsilon$ 4 status, world region, and treatment group by visit interaction as factors, and baseline value of the cognitive outcome as covariate. The analysis did not correct for multiplicity. Additional sensitivity MMRM analyses were conducted, such as including the interaction between ApoE4-by-treatment-by-visit interaction which were important as randomization was broken and would have accounted for baseline risk and rate of change differences. In a manuscript that compared the Bayesian analysis to the MMRM analysis in the G000-201 trial, the authors reported consistency of

the cognitive effects across the two statistical methodologies and that Bayesian analysis was useful in accommodating missing data from the protocol change imposed by the regulatory authority.<sup>88</sup>

Participants who received lecanemab 10 mg/kg biweekly had less cognitive decline in ADCOMS, as represented by a smaller increase in the score, at 12 months compared to placebo, mean difference versus placebo: -0.05; 95% CI: -0.8 to -0.01;  $p=0.027$ .<sup>86</sup> These results were consistent at 18 months with those in the lecanemab group showing 29.7% reduction in cognitive decline as compared to placebo (37.4% in the MMRM analysis that included ApoE4 status and visit interaction)<sup>88</sup>, mean difference versus placebo: -0.06; 95% CI: -0.10 to -0.01;  $p=0.034$  (Tables D2.1. and D3.4-5).

There was no significant treatment benefit of lecanemab 10 mg/kg biweekly on CDR-SB at 18 months, mean difference versus placebo of -0.396; 95% CI: -0.82 to 0.03;  $p=0.13$  (Table D2.1).<sup>86</sup> There was a 26.5% reduction in cognitive decline on CDR-SB in lecanemab 10 mg/kg biweekly at 18 months compared to placebo (32.1% in the MMRM analysis that included ApoE4 status and visit interaction).<sup>88</sup> There was a significant treatment benefit of lecanemab 10 mg/kg biweekly on ADAS-Cog14 at 18 months for lecanemab as compared to placebo, with a mean difference of -2.31; 95% CI: -3.91 to -0.72;  $p=0.017$ .<sup>86</sup> There was a 47.2% reduction in cognitive decline on ADAS-Cog14 in lecanemab 10 mg/kg biweekly at 18 months compared to placebo (55.9% in the MMRM analysis that included ApoE4 status and visit interaction) (Table D3.4-5).<sup>88</sup>

Subgroup analyses reported data on the treatment benefit of lecanemab 10 mg/kg biweekly on cognitive outcomes (CDR-SB, ADCOMS, and ADAS-Cog14) for those with MCI due to AD or mild AD. The subgroup analyses provided conflicting results of efficacy (see Table D3.13.-15 for full details).<sup>86</sup> A subgroup analysis was also conducted on the ADCOMS outcome, specifically, and reported no difference in efficacy for Asian participants as compared to the full sample.<sup>89</sup> These analyses were conducted in small groups, likely underpowered, and thus should be considered exploratory.

### ***Beta-amyloid***

Decreases in beta-amyloid, as measured by Florbetapir PET SUVR, were significantly greater in the lecanemab 10 mg/kg biweekly group compared to placebo at 12 and 18 months (12 months: -0.26 vs placebo: -0.01,  $p<0.001$ ; 18 months: -0.31 vs 0.004,  $p<0.001$ ).<sup>86,90</sup> The investigators reported that 65% of those in the lecanemab 10 mg/kg biweekly group at 12 months and 81% at 18 months were amyloid negative by visual read.<sup>90,91</sup>

Decreases in plasma A $\beta$ 42/40 ratio were significantly greater in lecanemab 10 mg/kg biweekly group compared to placebo at 12 and 18 months ( $p<0.01$ ).<sup>90</sup> There was also a significant increase in A $\beta$  (1–42) in the pooled 10 mg/kg biweekly and monthly lecanemab group, compared to placebo (Table D3.4).<sup>86</sup> The investigators suggested that this increase may reflect changes in amyloid aggregation or normalization of amyloid levels. However, the analyses for these two outcomes

were conducted in a subset of participants and thus it is not possible to infer conclusions about these data.

### ***Other biomarker outcomes***

In the pooled 10 mg/kg biweekly and monthly group, there was a significantly larger decrease in p-tau as compared to placebo at 18 months, mean difference: -12.3; p=0.013 (Table D3.4).<sup>86</sup> However, there were no significant differences in the change in t-tau, neurogranin nor in neurofilament light chain in the pooled group as compared to placebo.<sup>86,92</sup> These analyses were also conducted in a subset of participants and, as previously noted, it is not possible to infer conclusions from these data.

Brain volume was assessed using MRI scans at screening and months 6, 12, and 18. Volumetric MRI data was available for 72 participants in the lecanemab 10 mg/kg biweekly group and 162 participants in the placebo group. There was a greater decrease in whole brain volume in the lecanemab 10 mg/kg biweekly group compared to the placebo group at 18 months (mean difference: -8118.34mm<sup>3</sup>; 95% CI: -10538.26 to -5698.42, p=0.001) (Table D3.4). There was a greater increase ventricular volume in the lecanemab 10 mg/kg biweekly group compared to the placebo group at 18 months (mean difference: 2317.96mm<sup>3</sup>; 95% CI: 1678.88 to 2957.03, p=0.001). There was no significant difference between the groups in change in hippocampus volume at 18 months (mean difference: -19.44mm<sup>3</sup>; 95% CI: -46.77 to 7.88; p=0.24).<sup>86</sup>

**Table D2.1. Key Trial Results**

Measure		Lecanemab (G000-201)	
		Intervention (10 mg/kg Q2W)	Placebo
CDR-SB	Timepoint	12 months	
	Baseline (SD)	3.0 (1.4)	2.9 (1.5)
	N	84	161
	Mean change (SE)	1.10 (0.21)	1.5 (0.16)
	Difference in mean change (95% CI)	-0.396 (-0.82 to 0.03)	REF
ADCOMS	Timepoint	12 months	
	Baseline (SD)	0.37 (0.15)	0.37 (0.17)
	N	93	187
	Mean change (SE)	0.09 (0.02)	0.13 (0.01)
	Difference in mean change (95% CI)	-0.05 (-0.08 to -0.01)	REF
	Timepoint	18 months	
	N	79	160
	Difference in mean change (95% CI)	-0.06 (-0.10 to -0.01)	REF

Note. Ranges for cognitive scores at baseline were not reported. ADCOMS: AD composite score, CDR-SB: Clinical Dementia Rating scale Sum of Boxes, CI: confidence interval, mg: milligram, kg: kilogram, Q2W: every two weeks, SD: standard deviation, SE: standard error

### Harms

Total adverse events, serious events, and deaths were similar across the lecanemab 10 mg/kg biweekly and placebo groups. The rate of total discontinuation was greater in the lecanemab 10 mg/kg biweekly group compared to placebo (14.9% vs 6.1%).<sup>86</sup> There was a higher prevalence of discontinuation due to adverse events in the lecanemab 10 mg/kg biweekly group compared to placebo (13.7% vs 6.1%), with most of the adverse events in the lecanemab group relating to ARIA-E (Supplement Table D.2.2). Several participants discontinued due to “other” reasons which the investigators described as due to the regulatory change (ApoE ε4 carriers in the highest dose and were on treatment for less than six months were discontinued from treatment), subject moving out of the area, or the loss of a study partner. The lecanemab 10 mg/kg biweekly group were also more likely to experience infusion-related reaction compared to placebo (19.9% vs 3.3%). From this, there were 2.5% of participants in lecanemab 10 mg/kg biweekly who discontinued due to infusion-related reactions, compared to 0.80% in the placebo group.<sup>93</sup>

ARIA was assessed by MRI at baseline and seven additional time points across the study. In the core phase, if a patient experienced ARIA-E they would be discontinued from treatment. During the open-label extension phase, if ARIA-E was asymptomatic or radiographically mild-moderate then the participant could continue with monitoring. If symptomatic or radiographically severe, then treatment would be paused until ARIA-E resolved and then treatment could be resumed. If

occurring more than twice, the participant would have been discontinued from the treatment. During the open-label extension phase, the protocol was slightly different to the core phase in that if ARIA-E was mild-moderate or asymptomatic then participants could continue the intervention with monitoring. But, if ARIA-E was severe or symptomatic, then the intervention was temporarily discontinued for these participants until ARIA was resolved and then they restarted on the same dose.

A total of 9.9% participants in the lecanemab 10 mg/kg biweekly group experienced ARIA-E, compared to 0.8% in the placebo group. Due to the protocol change that prevented ApoE  $\epsilon$ 4 carriers being randomized to the highest dose, only 30% of participants in the 10 mg/kg biweekly were ApoE  $\epsilon$ 4 carriers and thus it is not possible to examine the true prevalence of ARIA-E in ApoE  $\epsilon$ 4 carriers in this dose. To provide some estimation as to the prevalence of ARIA-E in ApoE  $\epsilon$ 4 carriers, we reviewed ARIA in the second highest dose. In the 10 mg/kg monthly dose, 9.9% of participants experienced ARIA-E and 92% of those participants were ApoE  $\epsilon$ 4 carriers. All ARIA-E events in the lower lecanemab doses occurred in ApoE  $\epsilon$ 4 carriers. Additionally, there were 6.8% in the lecanemab 10 mg/kg biweekly group and 11.1% in the 10 mg/kg monthly dose who experienced ARIA-H, compared to 5.3% in the placebo group. There were 4.3% and 5.1% of participants in the lecanemab 10 mg/kg biweekly and 10 mg/kg monthly groups who experienced ARIA-E with ARIA-H, compared to 0.4% in placebo (Supplement Table D.2.2).

As noted in the main report, symptomatic ARIA-E was of particular interest. Symptomatic ARIA-E was reported to generally consist of headache, visual disturbances, or confusion.<sup>86</sup> Symptomatic ARIA-E occurred in more participants in the lecanemab 10 mg/kg biweekly group (1.2%) and in 11% of all lecanemab doses, compared to no cases in the placebo group. There were no cases of symptomatic ARIA-H in the lecanemab or placebo groups. Per protocol requirements, all those who experienced symptomatic ARIA-E were discontinued from the treatment. The investigators provided no further information on the prevalence of symptomatic ARIA-E in ApoE  $\epsilon$ 4 carriers and thus we were not able to examine this.

**Table D.2.2. Adverse Events**

Adverse event	Lecanemab (G000-201)					
	Lecanemab 2.5 mg/kg Q2W	Lecanemab 5 mg/kg Q4W	Lecanemab 5 mg/kg Q2W	Lecanemab 10 mg/mg Q4W	Lecanemab 10 mg/kg Q2W	Placebo
<b>Any Adverse Event, n/N (%)</b>	46/52 (88.5%)	48/51 (94.1%)	81/92 (88.0%)	238/253 (94.1%)	139/161* (86.3%)	216/245 (88.2%)
<b>Serious Adverse Event, n/N (%)</b>	10/52 (19.2%)	4/51 (7.8%)	16/92 (17.4%)	31/253 (12.3%)	25/161 (15.5%)	43/245 (17.6%)
<b>Discontinuation Due to Adverse Event, n/N (%)</b>	7/52 (13.5%)	4/51 (7.8%)	10/92 (10.9%)	47/253 (18.6%)	24/161 (14.9%)	15/245 (6.1%)
<b>Any ARIA-E, n/N (%)</b>	1/52 (1.9%)	1/51 (2.0%)	3/92 (3.3%)	25/253 (9.9%)	16/161 (9.9%)	2/245 (0.8%)
<b>Symptomatic ARIA-E, n/N (%)</b>	1/52 (1.9%)	0/51 (0)	1/92 (1.09%)	1/253 (0.4%)	2/253 (0.8%)	0/245 (0)
<b>Any ARIA-H, n/N (%)</b>	2/52 (3.8%)	7/51 (13.7%)	17/92 (18.5%)	28/253 (11.1%)	11/161 (6.8%)	13/245 (5.3%)

ARIA: Amyloid-related imaging abnormalities, mg/kg: milligram per kilogram, N: number of participants, Q2W: biweekly (once every two weeks), Q4W: once every month

\*Incorrectly reported in Swanson et al. (2021) as 39/161.

### ***G000-201 open-label extension phase***

The open-label extension (OLE) phase included 130 participants from the core study. Participants had a gap period off-treatment, with a mean duration off the study drug of 23.7 months (range: 9.2 to 52.5).<sup>90</sup> During the gap period, cognitive ability, as measured by ADCOMS, worsened in all groups and amyloid, A $\beta$ 42/40, and p-tau increased in those treated with lecanemab during the core phase (Table D3.6). During the OLE period, participants received lecanemab 10 mg/kg biweekly, including ApoE  $\epsilon$ 4 carriers, for up to 60 months. Once redosing began during the OLE phase, amyloid, A $\beta$ 42/40, and p-tau decreased in the two groups (those treated with lecanemab or placebo during the core phase).<sup>90</sup> By month 12, 88% and 86% converted to amyloid negative status in the core phase lecanemab treated and core phase placebo treated groups, respectively. However, these analyses were based upon very small numbers and thus caution should be taken in interpreting these values.

In terms of harms, ARIA was managed slightly differently to the core phase. In the OLE phase, if ARIA-E was mild-moderate or asymptomatic then participants could continue with treatment. If severe or symptomatic, dosing was paused until ARIA resolved and then participants could restart treatment. ARIA rates were similar to the core phase with 7.8% of ARIA-E in lecanemab core phase treated participants and 8.9% in placebo core phase treated participants, all of whom were ApoE  $\epsilon$ 4

carriers, with around 2% having symptomatic ARIA.<sup>90,94</sup> Similar to the core phase, most ARIA-E occurred within first 3 months and resolved within 12 weeks. At the time of this report, the investigators reported that 6/14 mild-moderate cases continued treatment through ARIA. A total of 20.6% had infusion-related reactions during the OLE phase that were mostly mild-moderate.<sup>93</sup>

### ***Phase I: Subcutaneous dose***

An open-label parallel-group trial including 59 healthy participants was conducted to examine the bioavailability, pharmacokinetics, safety, and immunogenicity of a single 700 mg subcutaneous (SC) dose of lecanemab. There were 30 participants who received IV infusion and 29 received SC injection. In terms of safety, adverse events were comparable across the two dosage forms and 20.7% in the SC dose group reported injection-site reactions, compared to 33.3% reporting infusion-related reactions in the IV dose group (Table D3.12).<sup>95</sup> Investigators concluded that SC dosing appears to be a potentially feasible option to progress into Phase II trials.

## **Donanemab**

### ***TRAILBLAZER-ALZ***

#### ***Methods***

The inclusion criteria for TRAILBLAZER-ALZ were aged 60-85 years with mild cognitive impairment due to AD or mild AD with dementia. Participants were included if they had an MMSE score of 20-28 or had a recent flortaucipir PET scan with adequate tau deposition (defined as SUVR between 1.10-1.46) or if level less than SUVR of 1.10, had topographic deposition pattern consistent with Alzheimer's disease. Participants also had to meet florbetapir PET criteria (amyloid SUVR  $\geq 1.17$  or 37 centiloids). Exclusion criteria included: history of long QT syndrome, were on an unstable dose of acetylcholinesterase inhibitor (AChEI) and/or memantine (defined as taking the medication for less than two months), or were unable to complete MRI or PET scans. Full inclusion and exclusion criteria are described in Supplement Table D3.1.

#### ***Additional Results***

##### ***Cognitive outcomes***

The findings for the cognitive outcomes (iADRS, CDR-SB, ADAS-Cog 13, ADCS-iADL, and MMSE) described in the main report were based upon mixed model for repeated measures (MMRM) analyses. The investigators also examined these outcomes using a Bayesian disease progression model. The model assumed a proportional treatment effect relative to placebo and included non-informative priors. A posterior probability distribution of the disease progression ratio was generated, which was defined as the proportional decline in the cognitive measures in donanemab

versus placebo. The investigators reported that a disease progression ratio of <1 would favor donanemab and if the posterior probability was greater than prespecified threshold (25% slowing of cognitive disease progression) then donanemab could be reported as superior to placebo.<sup>29</sup> When the primary outcome was analyzed using this Bayesian disease progression model, the posterior probability of at least 25% slower disease progression in donanemab versus placebo was 0.78 based on the iADRS. The cognitive score findings were similar for estimated percent change for donanemab versus placebo in the Bayesian disease progression analysis compared to the MMRM analysis.<sup>29</sup> However, the model was not adjusted for multiple comparisons and credible intervals were narrower. Thus, the investigators noted that clinical conclusions should not be drawn from these data.

### ***Beta-amyloid Levels***

Beta-amyloid levels were examined by assessing centiloids using Florbetapir PET in the TRAILBLAZER-ALZ trials. Centiloids is a standardized measure of amyloid imaging scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale. Florbetapir PET scans were taken at baseline and 24, 52, and at 76 weeks after starting treatment.

As noted in the main report, change in beta-amyloid were significantly greater in the donanemab group compared to placebo at week 76 in the TRAILBLAZER-ALZ trial. Significant differences in change in beta amyloid were also reported from week 24 (adjusted mean difference from placebo: -67.83; 95% CI: -74.04 to -61.61). At weeks 28 and 56, 27.4% and 54.7% (respectively) had lowering of beta-amyloid that warranted switching to placebo. At week 76, 67.8% of those in the donanemab group were amyloid negative, defined as beta amyloid plaque levels <24.10 centiloids.<sup>29</sup>

A $\beta$ 42/40 ratio, described to be a more sensitive measure of amyloid positivity<sup>96</sup>, was measured via plasma samples collected at baseline, weeks 12, 24, 36, 52, 64 and 76. At week 76, there was no significant difference between those who received donanemab (0.02) or placebo (0.01) at week 76, mean difference: 0.01; 95% CI: -0.01, 0.03; p=0.26, with both groups reporting an increase (4% in donanemab and 2% in placebo).<sup>41</sup>

Beta-amyloid levels were measured in a total of 140 participants in the TRAILBLAZER-ALZ 4 trial, 71 in the donanemab group and 69 in the aducanumab group. As noted in the main report, more participants in the donanemab group met the threshold of amyloid clearance, defined as <24.1 centiloids, compared to the aducanumab group (37.9% vs 1.6%) at 6 months, p<0.001. Percentage change in beta-amyloid was significantly greater in the donanemab group compared to the aducanumab group (-65.2% vs -17.0%) at 6 months, p<0.001.<sup>40</sup> Absolute changes in beta-amyloid were significantly greater in the donanemab group compared to the aducanumab group (-62.10 vs -16.41) at 6 months (p<0.001).<sup>40</sup>

### Correlations

Correlations between cognitive measures and biomarkers were limited. A simulation model in Shcherbinin et al. (2022) reported that a 100% decrease in amyloid plaque from baseline would reduce the rate of disease progression on the iADRS scale by 23% (95% CI: 3% to 40%;  $p < 0.001$ ). However, the simulation model predicted that this would only be significant in ApoE  $\epsilon 4$  carriers (44% decrease in disease progression; 95% CI: 24% to 59%;  $p < 0.001$ ).<sup>39</sup> Another secondary analysis of the TRAILBLAZER-ALZ trials reported that, in a subgroup of participants, change in iADRS at week 76 was not significantly associated with amyloid levels as measured by A $\beta$ 42/40 or p-tau.<sup>41</sup> But change in iADRS at week 76 was significantly associated with change in neurofilament light chain (NfL),  $r = -0.18$ ,  $p = 0.02$ . The investigators noted that the lack of correlations may be the result of participants with the highest baseline assay values having higher levels of ongoing pathology and more cognitive decline. See Supplement Table D3.29 for detailed data.

### **Other biomarker outcomes**

T-tau was measured by Flortaucipir PET scans performed at baseline and week 76. The Flortaucipir PET images were corrected for motion, averaged and registered into a standard brain space.<sup>29</sup> There were five calculations of tau in the TRAILBLAZER-ALZ trial (Table D2.3).

**Table D2.3. Definitions of Tau Measurements Used in the TRAILBLAZER-ALZ Trial**

Tau measurement method	Definition
TauIQ algorithm	This calculation involves performing an image-based regression to model a Standardized Uptake Value Ratio (SUVR) image as the combination of two canonical images (the non-specific binding image and the tau carrying capacity image) to measure global tau load. <sup>29,97</sup>
AD signature-weighted neocortical SUVR	Average posterior neocortical region measurement using the weighted average of parietal, temporal, and occipital volumes of interest (VOI). The number of voxels was used to weight the contribution of each of the VOI to the combined neocortical VOI. <sup>98</sup> The secondary analysis of the TRAILBLAZER-ALZ study also used the temporal, parietal, and frontal cortical areas as those lobes have been associated with tau accumulation. <sup>97</sup>
Multi-block barycentric discriminant analysis (MUBADA) SUVRPERSI	MUBADA is a mean-centered partial least-squares correlation used for SUVR images to identify which regions provide group differences. <sup>98</sup>  MUBADA SUVRPERSI refers to SUVR values with respect to signal intensity in the white matter as a reference. <sup>97</sup>
MUBADA SUVRCGM	MUBADA SUVRCGM refers to SUVR values with respect to signal intensity in the cerebellar grey matter region as a reference. <sup>97</sup>
Extent	Extent is considered that ratio of voxels in a predefined mask that have abnormally elevated tau, defined by the investigators as 2.32 multiplied by the standard deviation above the mean of healthy individuals (values range between 0-1). <sup>99</sup>

MUBADA: Multi-block barycentric discriminant analysis, SUVR: Standardized Uptake Value Ratio, VOI: volumes of interest

Three out of the five tau measures reported significant differences between donanemab and placebo. A significant reduction in tau deposition, measured by MUBADA SUVRCGM, was reported in the donanemab group (-33.98%,  $p=0.013$ ), specifically in nine bilateral frontal ROIs (e.g., frontal middle and medial orbitofrontal).<sup>97</sup> A significant reduction in tau deposition, measured by Extent, was reported in donanemab group versus placebo (0.07 vs. 0.09),  $p<0.05$ , specifically in the inferior temporal, parahippocampal, supramarginal, middle, medial and superior frontal regions.<sup>99</sup> There was a significantly less tau accumulation, as measured by weighted neocortical SUVR, over 76 weeks in temporal, parietal, and frontal lobes in those who received donanemab compared to placebo.<sup>39</sup> The remaining two measures (TauIQ and MUBADA SUVRPERSI) reported no significant difference in

change from baseline between donanemab and placebo groups.<sup>97</sup> Thus, tau appeared to change following donanemab in specific brain regions. Additionally, in participants who received donanemab and who had complete amyloid clearance at 24 weeks, there was less tau accumulation in temporal, parietal, and frontal lobes across 76 weeks compared with those with partial amyloid clearance. However, there was no significant difference in the mean change in tau, as measured by weighted neocortical SUVR, at week 76 in participants who had complete or partial amyloid clearance.<sup>39</sup>

P-tau (p-tau 217) was measured via plasma samples collected at baseline, weeks 12, 24, 36, 52, 64, and 76. A significant 23% reduction in p-tau was reported in the donanemab group compared to a 6% increase in the placebo group, mean difference from placebo: -0.14; 95% CI: -0.18, -0.10,  $p < 0.001$ .<sup>41</sup> In addition, in the donanemab group, there was no difference in p-tau at week 76 in those who were switched to placebo earlier in the trial versus those who continued receiving donanemab (Supplement Table D3.3).<sup>41</sup> In the TRAILBLAZER-ALZ 4 trial, 74% of the total sample had outcome data on plasma p-tau. There was a greater decline in p-tau in the donanemab group compared to a slight increase in the aducanumab group (-25% vs 2.8%),  $p < 0.001$ .<sup>40</sup>

Neurofilament light chain was measured via plasma samples collected at baseline, weeks 12, 24, 36, 52, 64, and 76. There was no significant difference between those who received donanemab or placebo at week 76, mean difference: -0.01; 95% CI: -0.06, 0.03;  $p = 0.49$ , with both groups showing an increase (0.06 for donanemab vs. 0.07 for placebo).<sup>41</sup>

Brain volume was assessed using MRI scans taken at baseline and weeks 24, 56, and 76. Volumetric MRI data was available for 82 participants in the donanemab group and 83 participants in the placebo group. There was a greater decrease in whole brain volume in the donanemab group compared to the placebo group at week 76 (-24.72 mL vs -20.00 mL). There was also a greater increase in ventricular volume in the donanemab group compared to the placebo group at week 76 (8.44 mL vs 5.55 mL). There was no difference between the groups in change in hippocampus volume (-0.22 mL in both groups) from baseline to week 76.<sup>29</sup> The association between changes in amyloid and/or tau with change in brain volume are not well known and may depend on stage of AD.<sup>100</sup> A minor reduction in whole brain volume and an increase in ventricular volume has been associated with healthy aging.<sup>101</sup> Therefore, these brain changes reported in those with donanemab may be opposite to what may be expected if cognitive decline was slowing.

### Additional Harms

ARIA was assessed by MRI at baseline and seven additional time points across the study. In terms of radiographic severity, ARIA was measured on a 5-point scale from mild-severe. Symptomatic ARIA-E was assessed by central review of MRI studies and self-reported symptoms (both participant and assessor were blinded to treatment group). If radiographically mild ARIA occurred with no

symptoms, treatment continued. If radiographically mild ARIA occurred with mild symptoms or radiographically moderate ARIA occurred with no symptoms, then treatment would continue but at a reduced dose (1400 mg to 700 mg or 700 mg to placebo). If radiographically moderate (with mild-severe symptoms) or severe ARIA occurred, then participants would be temporarily discontinued.<sup>29</sup> Participants were monitored every 4-6 weeks until ARIA-E resolved or ARIA-H stabilized. If no symptoms or MRI findings occurred within 16 weeks of temporary discontinuation, dosing could restart at 700 mg. If participants experienced ARIA twice, then they were permanently discontinued from treatment. Safety was also reviewed in an unblinded manner by an independent monitoring committee.

Mintun et al.<sup>29</sup> reported that 8 participants experienced symptomatic ARIA-E. However, the manufacturers reported that 3 participants in the donanemab group had been inaccurately classified as experiencing “symptomatic” ARIA and these participants were later determined to have asymptomatic ARIA. The manufacturers also noted that all participants (n=5) who experienced symptomatic ARIA-E discontinued treatment permanently as they met other permanent discontinuation rules.

## **TRAILBLAZER-ALZ 4**

### Methods

The inclusion criteria for TRAILBLAZER-ALZ 4 were participants aged 50-85 years, had gradual change in memory function for six months or more, met florbetapir F18 PET scan criteria, and had cognitive difficulties as measured by CDR-Global Score of 0.5 or 1 and MMSE of 20-30. Exclusion criteria included significant neurological, medical illness, or drug allergies, history of bleeding disorder, or use of medications with platelet anti-aggregant or anti-coagulant properties other than aspirin  $\leq$ 325 mg. Full exclusion criteria and baseline characteristics of this trial are described in Supplement Table D3.1 & D3.2.

### Additional Harms

In the Phase II TRAILBLAZER-ALZ trial, participants had seven MRI scans to detect potential ARIA. In the Phase III TRAILBLAZER-ALZ 4 trial, there were fewer (5) MRI scans to detect ARIA. Due to the dosing regime and quicker titration for donanemab, there was a higher rate of ARIA-E detected earlier in the study, compared to aducanumab, but rates of ARIA-E equalized over time.<sup>40</sup> Adverse events for TRAILBLAZER-ALZ 4 are reported in the main report and Table 3.4. and Supplement Table D3.11. Notable differences between groups include: Infusion-related reactions (all grade 1 or 2) occurred in 7% of the donanemab group, compared to 2.9% of the aducanumab group, and those in the donanemab group were more likely to experience COVID-19 during the trial (15.5%) compared to the aducanumab group (5.8%). Participants in the aducanumab group were more likely to experience headache (11.6%) compared to those in the donanemab group (8.5%).

## D3. Evidence Tables

Table D3.1. Study Design

Trial	Study Design	Treatment Arms	Prohibited Therapy	Included Participants	Excluded Participants	Key Outcomes [Timepoints]
<b>Lecanemab</b>						
AHEAD 3-45 ClinicalTrials.gov	Phase III, QB, RCT	LCB 5 mg/kg + 10 mg/kg Q2W LCB 5 mg/kg + 10 mg/kg Q4W PBO	Anti-amyloids, immunoglobulin therapy, lecanemab, new chemical entities, investigational medications	- Aged 55 to 80 years - 55 to 64 must have additional risk factors such as first degree relative diagnosed with dementia, possesses at least one ApoE ε4 - CDR score of 0 - MMSE score >= 27 - WMS-R LM II >6	- History of ischemic attacks - Current history of psychiatric diagnosis or symptoms that could interfere with study procedures - HIV positive	Primary: Change in PACCS, change in PET [216 weeks] Secondary: Change in PET, CFI [96/216 weeks]
CLARITY AD <sup>28</sup>	Phase III, PC + OLE phase	LCB 10 mg/kg Q2W LCB 10 mg/kg Q2W (extension phase) PBO	Immunoglobins, systemic monoclonal antibodies,	<u>Core Study</u> -Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory -Positive biomarker for brain amyloid pathology - 50 - 90 years -Mini mental state examination (MMSE) score 22-30 -Body mass index (BMI) > 17, <35 <u>OLE phase</u> - Completed core study <u>Other:</u>	-Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease. -History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening -Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) -Geriatric Depression Scale (GDS) score >=8 -Contraindications to MRI scanning, including cardiac	Primary (core study): Change from baseline in CDR-SB [18 months] Primary (extension): AEs, change in CDR-SB [ 45 months] Secondary (core): Change in amyloid PET, ADAS-Cog14, ADCOMS, and ADCS MCI-ADL at 18 months

				- Positive biomarker MMSE >22 <30 BMI > 17, <35	pacemaker/defibrillator, ferromagnetic metal implants	
Phase II G000-201 86	Phase IIb, MC, DB, PC	LCB 2.5 mg/kg Q2W LCB 5.0 mg/kg Q4W LCB 5.0 mg/kg Q2W LCB 10 mg/kg Q4W LCB 10 mg/kg Q2W PBO	Immunoglobulin therapy (6 months), Biologic drugs (6 months), and Anticoagulants (e.g., warfarin, dabigatran for 7 days or 5 half-lives, whichever is longer)	- AD due to MCI or mild AD dementia - Confirmed amyloid positive via Aβ1-42: PET or CSF - Impairment in episodic memory (WMS-IV LMII) - MMSE >= 22 - Naïve or stable dose of approved ALZ medications	- Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment - Have had a stroke or Transient Ischemic Attack, stroke, or seizures in the past 1 year - Any psychiatric diagnosis or symptoms that could interfere with study procedures - GDS score >=8 - Contraindications to MRI scanning - Evidence of other clinically significant lesions that could indicate a dementia diagnosis other than AD - Prolonged QT/QTc interval via ECG - Other medical conditions that could prevent patient performing tests accurately	Primary: Change from baseline on ADCOMS [12 months] Secondary: Change from baseline in ADCOMS [18 months], CDR-SB, ADAS-cog14, brain amyloid PET, hippocampal, ventricular, and whole-brain volume via MRI [12 and 18 months], and exploratory biomarkers [12 and 18 months]

Phase II G000-201 OLE Clinicaltrials.gov	Phase II, DB, PC, OLE	LCB 10 mg/kg Q2W Off-treatment period (9-59 months, average 24 months) before re-initiating treatment for 60 months	Immunoglobulin therapy (6 months), Biologic drugs (6 months), if on thrombolytic drugs study drug will be temporarily suspended until resolution of the condition, if on anticoagulants at OLE baseline then anticoagulation status optimized and stable for at least 4 weeks before OLE screening.	- AD due to MCI or mild AD dementia - Confirmed amyloid positive via Aβ1-42: PET or CSF - Impairment in episodic memory - MMSE >= 22 - Naïve or stable dose of approved AD medications	- Any medical or neurological condition that might be a contributing to cognitive impairment - Have had a stroke or Transient Ischemic Attack, stroke, or seizures in the past 1 year - Any psychiatric diagnosis or symptoms that could interfere with study procedures - GDS score >=8 - Contraindications to MRI scanning - Other significant lesions that could indicate other diagnosis - Prolonged QT/QTc interval via ECG	Primary: Safety data and MRI assessments of ARIA [up to 78 months] Secondary: Change from baseline on brain amyloid levels [3, 6, 12, and 24 months], change in brain amyloid from end of core study to baseline of extension phase, percentage of amyloid positive participants over time [up to 60 months]. Change in ADCOMS, CDR-SB, ADAS-cog14 [up to 60 months].
Phase 1 - Single, Fixed Subcutaneous Dose <sup>95</sup>	Phase I, open-label, parallel-group study	Single fixed 700 mg SC dose in the abdomen; IV dose after single dose of 10 mg/kg IV infused over approximately 1 hour	NR	Healthy participants.	NR	Outcomes: Absolute bioavailability (BA), pharmacokinetics(PK), safety and immunogenicity

Donanemab						
TRAILBLAZER-ALZ <sup>29</sup>	Phase II, multicenter, RCT	DNB 700 mg for 3 doses and then 1400 mg after (N= 131) PBO (N= 126)	Depigmenting agents, CYP3A, drugs of abuse, drugs that prolong the QT interval	<ul style="list-style-type: none"> <li>- Aged 60-85 years with early symptomatic AD (prodromal) or mild AD with dementia</li> <li>- MMSE score of 20-28 OR must have a PET scan with evidence of tau deposition within 6 months</li> <li>- Met Flortaucipir PET scan criteria (1.10-1.46) OR &lt;1.10 with topographic deposition pattern consistent with AD.</li> <li>- Met florbetapir PET (37 centiloids)</li> </ul>	<ul style="list-style-type: none"> <li>- High tau (above 1.46)</li> <li>- Low tau (&lt;1.10 or a deposition pattern not consistent with ALZ)</li> <li>- Have a history of long QT syndrome</li> <li>- Received acetylcholinesterase inhibitor (AChEI) and/or memantine for &lt; two months</li> <li>- Contradiction to MRI</li> <li>- Unable to complete PET scans</li> </ul>	<p>Primary: Change from baseline in iADRS score [76 weeks] Secondary: Change from baseline in CDR-SB, the ADAS-Cog, ADCS-iADL, and MMSE [76 weeks]. Change from baseline in amyloid plaque, brain tau, and brain volume [76 weeks].</p>
TRAILZBLAZER-ALZ 2 ClinicalTrials.gov	Phase III, RCT	DNB PBO	Immunoglobulin G therapy	<ul style="list-style-type: none"> <li>- Aged 60 to 85</li> <li>- Gradual and progressive change in memory function &gt;6 months</li> <li>- MMSE score of 20 to 28</li> <li>- Net 18F PET scan criteria</li> </ul>	<ul style="list-style-type: none"> <li>- Contradiction MRI or PET scans</li> <li>- Current treatments with immunoglobulin G therapy</li> </ul>	<p>Primary: Change from baseline in iADRS [76 weeks]  Secondary: Change from baseline in MMSE, ADAS-cog 13, CDR-SB, ADCS-iADL</p>
TRAILBLAZER-ALZ 3 Clinicaltrials.gov	DB, parallel assignment	DNB	Prior anti-amyloid immunotherapy, prescription medicines for MCI	<ul style="list-style-type: none"> <li>- Preclinical AD</li> <li>- Telephone interview for cognitive status-modified</li> <li>- P-Tau consistent with presence of amyloid and early-tau pathology</li> <li>- Adequate literacy, vision, and hearing</li> </ul>	<ul style="list-style-type: none"> <li>- Mild cognitive impairment or dementia, or significant other neurodegenerative disease</li> <li>- Current serious or unstable illness</li> <li>- History of clinically significant multiple or severe drug allergies</li> <li>- Prior treatment with a passive anti-amyloid beta or immunotherapy</li> </ul>	<p>Primary: Time to clinical progression in CDR (global score) [ 182 weeks]  Secondary: Change from baseline in other cognitive measures.</p>

TRAILBLAZER-ALZ 4 Clinicaltrials.gov; <sup>40</sup>	DB, parallel assignment	DNB Aducanumab	Use of medications with platelet anti-aggregant or anti-coagulant properties	<ul style="list-style-type: none"> <li>- Aged 50-85 years</li> <li>- Gradual and progressive change in memory function reported by the participant or informant for ≥6 months.</li> <li>- Meet florbetapir F18 PET scan criteria.</li> <li>- CDR-Global Score of 0.5 or 1</li> <li>- MMSE score between 20 and 30</li> <li>- Study partner who will provide written informed consent to participate</li> <li>- Adequate literacy, vision, and hearing for neuropsychological testing</li> <li>- Not of childbearing potential</li> </ul>	<ul style="list-style-type: none"> <li>- Significant neurological disease affecting the central nervous system</li> <li>- Current serious or unstable medical illnesses</li> <li>- History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions</li> <li>- History of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties</li> <li>- Prior experience with study drugs</li> </ul>	Primary: Percentage reaching complete amyloid clearance on donanemab versus aducanumab at 6 months and percentage in the intermediate tau subpopulation reaching complete amyloid clearance on donanemab versus aducanumab [6 months] Secondary: Absolute change from baseline in amyloid plaque and time to reach amyloid clearance. [6, 12, and 18 months]
---	-------------------------	-------------------	--	--	--	---

AChEIs: acetylcholinesterase inhibitor, AD: Alzheimer’s disease, ADCOMS: AD Composite Score, ADAS-Cog 13: Alzheimer’s Disease Assessment Scale – Cognitive Subscale 13-item, ADAS-Cog 14: Alzheimer’s Disease Assessment Scale – Cognitive Subscale 14-item, ADCS-iADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory, ARIA: amyloid-related imaging abnormalities, ADCS MCI-ADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), CFI: Cognitive Function Index, CDR: Clinical Dementia Rating, CDR-SB: Clinical Dementia Rating – Sum of Boxes, DB: double-blind, DNB: donanemab, ECG: electrocardiogram, iADRS: The Integrated Alzheimer’s Disease (AD) Rating Scale, IV: intravenous, LCB: lecanemab, MMSE: mini mental state examination, MG: milligram, MC: multicenter, MCI: mild cognitive impairment, mg/kg: milligram per kilogram, MRI: magnetic resonance imaging, NR: not reported, OLE: open-label extension, PACC5: Preclinical Alzheimer Cognitive Composite 5, PC: placebo-controlled, PET: Positron Emission Tomography, Q2W: every two weeks, Q4W: every four weeks, SC: subcutaneous, WMS-IV: Wechsler Memory Scale – Fourth Edition.

**Table D3.2. Baseline Characteristics**

Trial		TRAILBLAZER ALZ		TRAILBLAZER-ALZ 4		G000-201			CLARITY AD	
Source		Mintun et al. 2021 <sup>29</sup> ; Pontecorvo et al. 2022 <sup>41</sup>		CTAD conference 2022 <sup>40</sup>		Swanson et al. 2021 <sup>86</sup>			van Dyck et al. 2022 <sup>28</sup> ; CTAD conference 2022 (Iziarry et al. 2022) <sup>102</sup>	
Study Arms		DNB	PBO	DNB	Aducanumab	LCB 10 mg/kg Q4W	LCB 10 mg/kg Q2W	PBO	LCB 10 mg/kg Q4W	PBO
N		131	126	71	69	246	152	238	859 <sup>§</sup>	875
Age, mean (SD)		75 (5.6)	75.4 (5.4)	74.1 (6.9)	72.7 (6.8)	71 (53-90) ‡	73 (51-88) ‡	72 (50-89)	71.4 (7.9)	71.0 (7.8)
Female, n (%)		68 (51.9)	65 (51.6)	38 (53.5)	42 (60.9)	110 (45)	64 (42)	137 (58)	443 (51.6)	464 (53.0)
Race, n (%)	Asian	1 (0.8)	2 (1.6)	0 (0.0)	2 (2.9)	NR	NR	NR	147 (17.1)	148 (16.9)
	Black	5 (3.8)	3 (2.4)	0 (0.0)	5 (7.2)	NR	NR	NR	20 (2.3)	24 (2.7)
	White	122 (93.1)	121 (96.0)	71 (100)	61 (88.4)	NR	NR	NR	655 (76.3)	677 (77.4)
	Other	3 (2.3)*	0 (0)*	0 (0.0)	1 (1.4)†	NR	NR	NR	37 (4.3) <sup>#</sup>	26 (3.0)
Ethnicity, n (%)	Hispanic/Latino	5 (3.8)	3 (2.4)	3 (4.2)	4 (5.8)	NR	NR	NR	107 (12.5)	108 (12.3)
	Non-Hispanic/Latino	NR	NR	NR	NR	NR	NR	NR	NR	NR
Education years, ≥13 years, n (%)		97 (74.0)	102 (81.0)	NR	NR	NR	NR	NR	NR	NR
Long-term care, n (%)		0	0	NR	NR	NR	NR	NR	NR	NR
Weight, kg, mean (SD)		73.75	73.34	NR	NR	NR	NR	NR	NR	NR
Concomitant AD Medication, n (%)	Cholinesterase Inhibitors	78 (59.5)	74 (58.7)	29 (40.8)	37 (53.6)	NR	NR	NR	NR	NR
	Memantine	31 (23.7)	28 (22.2)	13 (18.3)	18 (26.1)	NR	NR	NR	NR	NR
	Cholinesterase Inhibitors	109 <sup>¶</sup>	102	NR	NR	131 (53)	79 (52)	128 (54)	447 (52.0)	468 (53.5)

	<b>and/or Memantine</b>									
<b>Other medication, n (%)</b>	<b>Anticoagulants</b>	NR	NR	0	0	NR	NR	NR	80/1795 (4.5)	
<b>ApoE ε4 Status, n (%)</b>	<b>Carrier</b>	95/131 (72.5)	92/124 (74.2)	49 (69.0)	49 (71.0)	218 (89)	46 (30)	169 (71)	592 (68.9)	600 (68.6)
<b>ApoE Genotype, n/N (%)</b>	<b>ε2/ε3</b>	1/131 (0.8)	1/124 (0.8)	1 (1.4)	0 (0.0)	NR	NR	NR	NR	NR
	<b>ε2/ε4</b>	2/131 (1.5)	2/124 (1.6)	2 (2.8)	3 (4.3)	NR	NR	NR	NR	NR
	<b>ε3/ε3</b>	35/131 (26.7)	31/124 (25)	21 (29.6)	20 (29.0)	NR	NR	NR	NR	NR
	<b>ε3/ε4 (heterozygote)</b>	68/131 (51.9)	62/124 (50.0)	38 (53.5)	36 (52.2)	NR	NR	NR	456 (53.1)	468 (53.5)
	<b>ε4/ε4 (homozygote)</b>	25/131 (19.1)	28/124 (22.6)	9 (12.7)	10 (14.5)	NR	NR	NR	136 (15.8)	132 (15.1)
<b>Clinical Stage, n (%)</b>	<b>MCI due to AD</b>	NR	NR	NR	NR	166 (68)	90 (59)	154 (65)	528 (61.5)	544 (62.2)
	<b>Mild AD</b>	NR	NR	NR	NR	NR	NR	NR	331 (38.5)	331 (37.8)
<b>Comorbidities, n (%)</b>	<b>Hypertension</b>	NR	NR	NR	NR	NR	NR	NR	993/1795 (55.3)	
	<b>Hyperlipidemia</b>	NR	NR	NR	NR	NR	NR	NR	1085/1795 (60.4)	
	<b>Ischemic heart disease</b>	NR	NR	NR	NR	NR	NR	NR	291/1795 (16.2)	
	<b>Diabetes</b>	NR	NR	NR	NR	NR	NR	NR	271/1795 (15.1)	
	<b>Obesity</b>	NR	NR	NR	NR	NR	NR	NR	298/1795 (16.6)	
	<b>2+ comorbidities</b>	NR	NR	NR	NR	NR	NR	NR	917/1795 (51.1)	
	<b>3+ comorbidities</b>	NR	NR	NR	NR	NR	NR	NR	441/1795 (24.6)	
	<b>4+ comorbidities</b>	NR	NR	NR	NR	NR	NR	NR	139/1795 (7.7)	
<b>5+ comorbidities</b>	NR	NR	NR	NR	NR	NR	NR	25/1795 (1.4)		

CDR Global Score, n (%)	0.5	NR	NR	55 (77.5)	46 (67.6)	210 (85)	133 (88)	200 (84)	694 (80.8)	706 (80.7)
	1	NR	NR	16 (22.5)	22 (32.4)	NR	NR	NR	165 (19.2)	169 (19.3)
iADRS Score, mean (SD)		106.2 (13.0)	105.9 (13.2)	NR	NR	NR	NR	NR	106.75 $\bar{x}$	106.53 $\bar{x}$
MMSE Score, mean (SD)		23.6 (3.1)	23.7 (2.9)	24.96 (2.72)	24.43 (2.95)	25.7 (2.4)	25.6 (2.4)	26.0 (2.3)	25.5 (2.2), 22 to 30	25.6 (2.2) 22 to 30
CDR-SB Score, mean (SD), range		3.6 (2.1)	3.4 (1.7)	NR	NR	2.9 (1.3)	3.0 (1.4)	2.9 (1.5)	3.17 (1.34), 0.5 to 8.0	3.22 (1.34), 0.5 to 8.5
ADAS-Cog 13 Score, mean (SD)		27.6 (7.7)	27.5 (7.6)	NR	NR	NR	NR	NR	NR	NR
ADAS-Cog 14 Score, mean (SD)		NR	NR	NR	NR	21.9 (7.3)	22.1 (7.7)	22.6 (7.7)	24.45 (7.08)	24.37 (7.56)
ADCS-ADL Score, mean (SD)		67.4 (8.6)	67.0 (8.1)	NR	NR	NR	NR	NR	NR	NR
ADCS-iADL Score, mean (SD)		48.9 (7.6)	48.4 (7.5)	NR	NR	NR	NR	NR	NR	NR
ADCS-MCI-ADL Score, mean (SD)		NR	NR	NR	NR	NR	NR	NR	41.2 (6.6)	40.9 (6.9)
ADCOMS Score, mean (SD)		NR	NR	NR	NR	0.37 (0.15)	0.37 (0.15)	0.37 (0.17)	0.398 (0.147)	0.400 (0.147)
CSF	A $\beta$ 42/40, pg/ml, mean (SD)	0.05 (0.01), n=104	0.05 (0.01), n=103	NR	NR	NR	NR	NR	0.047	0.044
	A $\beta$ 1-42, pg/ml, mean (SD)	NR	NR	NR	NR	NR	NR	NR	547.00	514.40
	A $\beta$ 1-40, pg/ml, mean (SD)	NR	NR	NR	NR	NR	NR	NR	11987.00	12334.00
	t-tau, pg/ml, mean (SD)	1.21 (0.14), n=122	1.22 (0.13), n=113	NR	NR	NR	NR	NR	585.00	615.00
	p-tau, pg/ml, mean (SD)	0.42 (0.17), n=119	0.41 (0.23), n=123	NR	NR	NR	NR	NR	84.92	92.08

	<b>Neurogranin, pg/ml, mean (SD)</b>	NR	NR	NR	NR	NR	NR	NR	NR	NR
	<b>Neurofilament light chain, pg/ml, mean (SD)</b>	21.91 (8.49), n=121	26.82 (24.8), n=119	NR	NR	NR	NR	NR	1201	1109
<b>Plasma</b>	<b>Aβ42/40, mean (SD)</b>	NR	NR	NR	NR	NR	NR	NR	0.088	0.088
	<b>Neurofilament light chain, mean (SD)</b>	NR	NR	NR	NR	NR	NR	NR	21.9	22.2
	<b>p-tau, mean (SD)</b>	NR	NR	NR	NR	NR	NR	NR	3.70	3.74
<b>Florbetapir PET</b>	<b>Centiloids, mean (SD), range</b>	107.6 (36.0)	101.1 (33.3)	97.22 (26.16)	102.29 (34.55)	NR	NR	NR	77.92 (44.84), -16.6 to 213.2††	75.03 (41.82), -17.0 to 179.6††
	<b>SUVr, Mean (SD)</b>	NR	NR	NR	NR	1.42 (0.18)	1.37 (0.16)	1.40 (0.16)	NR	NR
<b>Flortaucipir PET</b>	<b>Global tau load, mean (SD)</b>	0.47 (0.19)	0.46 (0.15)	1.27 (0.32)*	1.26 (0.26)**	NR	NR	NR	NR	NR

AD: Alzheimer's disease, ADCOMS: AD Composite Score, ADAS-Cog 13: Alzheimer's Disease Assessment Scale – Cognitive Subscale 13-item, ADAS-Cog 14: Alzheimer's Disease Assessment Scale – Cognitive Subscale 14-item, ADCS-iADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory, ApoE: Apolipoprotein E, MMSE: mini mental state examination, ADCS MCI-ADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), CSF: cerebrospinal fluid, CTAD: Clinical Trials on Alzheimer's Disease, CDR: Clinical Dementia Rating, CDR-SB: Clinical Dementia Rating – Sum of Boxes, DNB: donanemab, kg: kilogram, iADRS: The Integrated Alzheimer's Disease (AD) Rating Scale, mg/kg: milligram per kilogram, MCI: mild cognitive impairment, NR: not reported, N: number, PBO: placebo, PET: positron emission tomography scan, p-tau: phosphorylated tau, pg/ml: picograms per milliliter, SD: standard deviation, SUVr: standardized uptake value ratio, %: percent

\*: includes multiple and American Indian and Alaskan Native, †: multiple, ‡: median (range), §: mITT, #: other/ multiple, ¤: calculated, \*\*: PET MUBASA SUVr, ††: PET substudy population n= 354 (lecanemab) n = 344 (placebo).

**Table D3.3 Outcomes Lecanemab**

Trial		G000-201				CLARITY AD	
Source		Swanson et al. 2021 <sup>86</sup> ; Dhadda et al. 2022 <sup>88</sup> ; Berry et al. CTAD conference 2021 <sup>103</sup> ; Swanson et al. CTAD conference 2021 <sup>90</sup> ; Swanson 2018 ALZ & Dementia <sup>91</sup> ; Molinuevo et al. 2019 <sup>92</sup>				van Dyck et al. 2022; CTAD conference 2022 <sup>28,44</sup>	
Study Arms		Lecanemab 10 mg/kg monthly	Lecanemab 10 mg/kg biweekly	Placebo	Lecanemab pooled 10 mg/kg	Lecanemab 10 mg/kg Q4w	Placebo
Baseline N		246	152	238	398	1795	
Timepoint		18 months				18 months	
<b>Cognitive Outcomes</b>							
iADRS Score	N	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	-24.39†	-27.61†
	Difference in Mean Change (95% CI)	NR	NR	NR	NR	3.22	NR
	P-value	NR	NR	NR	NR	NR	NR
CDR-SB Score	N	149	84	161	233	714	757
	LS Mean Change (SE)	1.248 (0.17)	1.102 (0.21)	1.499 (0.16)	1.171 (0.136)	1.21	1.66
	Diff (95% CI)	-0.250 (-0.613 to 0.112)*	-0.396 (-0.821 to 0.028)*	REF	-0.302 (-0.620 to 0.017)*	-0.45 (-0.67 to -0.23)	REF
	P-value	0.255	0.125	REF	0.119	p<0.001	REF
	Reduction in cognitive decline vs. PBO	16.7%; p=0.255	26.5%; p=0.125	NR	NR	27%	REF
ADAS-Cog13 Score	N	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
ADAS-Cog14 Score	N	146	79	158	225	703	738
	LS Mean Change (SE)	4.624 (0.65)	2.588 (0.81)	4.902 (0.62)	3.735 (0.549)	4.14	5.58
	Diff (95% CI)	-0.278 (-1.635 to 1.079)*	-2.313 (-3.910 to -0.717)*	REF	-1.064 (-2.290 to 0.163)*	-1.44 (-2.27 to -0.61)	REF
	P-value	0.736	0.017	REF	0.154	p<0.001	REF

	Reduction in cognitive decline vs. PBO	5.7%; p=0.736	47.2%; p=0.017	NR	NR	26%	REF
ADCOMS	Timepoint	12 months				NR	NR
	N	165	93	187	258	NR	NR
	LS Mean Change (SE)	0.102 (0.01)	0.085 (0.02)	0.131 (0.01)	0.093 (0.012)	NR	NR
	Diff (90% CI)	-0.029 (-0.057, 0.000)	-0.046 (-0.079 to -0.012)	REF	-0.035 (-0.060 to -0.010)	NR	NR
	P-value	0.101	0.027	REF	0.019	NR	NR
	Timepoint	18 months				18 months	
	N	146	79	160	225	708	749
	LS Mean Change (SE)	0.166 (0.02)	0.136 (0.02)	0.193	0.152 (.014)	0.164	0.214
	Diff (90% CI)	-0.028 (-0.065 to 0.010)	-0.057 (-0.102 to -0.013)	REF	-0.039 (-0.071 to -0.006)	-0.05 (-0.074 to -0.027)	REF
	P-value	0.228	0.034	REF	0.053	p<0.001	REF
Reduction in cognitive decline vs. PBO	14.3%, p=0.228	29.7%, p=0.034	REF	NR	24%	REF	
ADCS-iADL Score	N	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
ADCS-MCI-ADL Score	N	NR	NR	NR	NR	676	707
	LS Mean Change (SE)	NR	NR	NR	NR	-3.5	-5.5
	Diff (95% CI)	NR	NR	NR	NR	2.0 (1.2 to 2.8)	REF
	P-value	NR	NR	NR	NR	p<0.001	REF
		NR	NR	NR	NR	37%	
MMSE Score	N	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
<b>Amyloid Outcomes</b>							
	Timepoint	NR	NR	NR	NR	NR	NR

Florbetapir PET centiloids	N	NR	NR	NR	NR	NR	NR
	Mean (SD)	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Difference in Mean Change (SE)	NR	NR	NR	NR	NR	NR
	95% CI	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
	Percent of reduction	NR	NR	NR	NR	NR	NR
	Effect size	NR	NR	NR	NR	NR	NR
	Amyloid Negative, n(%)	NR	NR	NR	NR	NR	NR
	Switched to placebo					NR	NR
	Timepoint	NR	NR	NR	NR	NR	NR
	N	NR	NR	NR	NR	NR	NR
	Mean (SD)	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Difference in Mean Change (SE)	NR	NR	NR	NR	NR	NR
	95% CI	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
	Percent of reduction	NR	NR	NR	NR	NR	NR
	Effect size	NR	NR	NR	NR	NR	NR
	Amyloid Negative, n(%)	NR	NR	NR	NR	NR	NR
	Switched to placebo					NR	NR
	Timepoint	NR	NR	NR	NR	18 months	
	N	NR	NR	NR	NR	210‡	205‡
	Mean (SD)	NR	NR	NR	NR	22.99	
	LS Mean Change (SE)	NR	NR	NR	NR	-55.48	3.64
	Difference in Mean Change (SE)	NR	NR	NR	NR	-59.12	REF
	95% CI	NR	NR	NR	NR	-62.64 to -55.60	REF
	P-value	NR	NR	NR	NR	p<0.001	REF

	Percent of reduction	NR	NR	NR	NR	NR	NR
	Effect size	NR	NR	NR	NR	NR	NR
	Amyloid Negative, n(%)	NR	NR	NR	NR	68 (32.4%)§	16 (7.8%)§
Florbetapir PET SUVr	Timepoint	NR	NR	NR	NR	NR	NR
	N	NR	43	96	NR	NR	NR
	Adjusted Mean Change	NR	-0.26	-0.01	NR	NR	NR
	95% CI	NR	NR	NR	NR	NR	NR
	Percentage reduction	NR	NR (65)	NR	NR	NR	NR
	P-Value	NR	p<0.001	REF	NR	NR	NR
	Timepoint	NR	NR	NR	NR	NR	NR
	N	82	37	88	119	NR	NR
	Adjusted Mean Change	-0.225	-0.3	0.004	-0.253	NR	NR
	95% CI	NR	NR	REF	NR	NR	NR
	Amyloid negative, n(%)	NR	NR (81)	NR	NR	NR	NR
	P-Value	NR	p<0.001	REF	p<.001	NR	NR
Re-Accumulation	Timepoint	NR	NR	NR	NR	NR	NR
	N	NR	NR	NR	NR	NR	NR
	No reaccumulation, cl/wk mean (SD)	NR	NR	NR	NR	NR	NR
	Timepoint	NR	NR	NR	NR	NR	NR
	N	NR	NR	NR	NR	NR	NR
	No reaccumulation, cl/wk mean (SD)	NR	NR	NR	NR	NR	NR
	Rate of CL reaccumulation per year, m (SD)	NR	NR	NR	NR	NR	NR
	Median time to reaccumulate amyloid to amyloid + status,	NR	NR	NR	NR	NR	NR

	median (95% prediction intervals)						
<b>PET Tau Outcomes</b>							
Flortaucipir Global Tau Load (TauIQ)	N	NR	NR	NR	NR	NR	NR
	LS Mean Change	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	Percent reduction	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
Tau deposition (MUBADA SUVRPERSI)	N	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	Percent reduction	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
Tau deposition (MUBADA SUVRCGM)	N	NR	NR	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	Percent reduction	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
Tau deposition (Extent)	LS mean change from baseline	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
Tau deposition (MUBADA)	LS mean change from baseline	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
<b>MRI Outcomes</b>							
Volumetric MRI: Whole Brain	N	144	72	162	NR	644	667
	LS Mean Change in mm3 (SE)	-25030.19 (1017.49)	-29894.19 (1300.82)	-21775.86 (921.13)	NR	-21392.2	-17227.6
	Diff (95% CI)	-3254.34 (-5101.23 to -1407.44)*	-8118.34 (-10538.26 to -5698.42)*	REF	NR	NR	NR

	P-value (Dunnett p-value)	0.004 (0.066)	0.001 (0.000)	REF	NR	p<0.001	REF
Volumetric MRI: Ventricular Volume	N	144	72	161	NR	644	667
	LS Mean Change in mm3 (SE)	6504.05 (267.76)	7662.46 (343.22)	5344.503	NR	7434.8	5655.7
	Diff (95% CI)	1159.55 (671.83 to 1647.27)*	2317.96 (1678.88 to 2957.03)*	REF	NR	NR	NR
	P-value (Dunnett p-value)	0.001 (0.002)	0.001 (0.000)	REF	NR	p<0.001	REF
Volumetric MRI: Hippocampus volume	N	144	72	162	216	643	667
	LS Mean Change in mm3 (SE)	-264.87 (11.45)	-276.74 (14.68)	-2.57.297	-266.644 (10.321)	-186.1	-205.2
	Diff (95% CI)	-7.57 (-28.42 to 13.28)*	-19.44 (-46.77 to 7.88)*	REF	-11.324 (-30.434 to 7.787)*	NR	NR
	P-value (Dunnett p-value)	0.550 (1.000)	0.24 (0.99)	REF	0.330 (0.909)	p=0.0039	REF
<b>CSF &amp; Plasma Outcomes</b>							
CSF Aβ1-42, pg/ml	N	NR	NR	NR	NR	101	97
	Adjusted Mean Change	NR	NR	NR	205.6	281.8	-6.5
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	<.001	NR	NR
CSF Aβ1-40, pg/ml	N	NR	NR	NR	NR	71	71
	Adjusted Mean Change	NR	NR	NR	NR	-417.9	-89.9
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
Plasma Aβ42/40 ratio	Timepoint	NR	12 months		NR	NR	NR
	N	NR	39	82	NR	648	668
	Adjusted Mean Change	NR	0.005	0	NR	0.008	0.001
	Percent reduction	NR			NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	p<0.01	REF	NR	NR	NR
	Timepoint	NR	18 months		NR	NR	NR
N	NR	33	39	NR	NR	NR	

	Adjusted Mean Change	NR	0.008	0.002	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	p<0.01	REF	NR	NR	NR
CSF A $\beta$ 42/40 ratio	N	NR	NR	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	NR	NR
CSF T-tau pg/ml	N	NR	NR	NR	NR	101	98
	Adjusted Mean Change	NR	NR	NR	18.8	-29.1	95.3
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	0.67	p<0.001	REF
Plasma P-tau, pg/ml	N	NR	NR	NR	NR	590	609
	LS Mean Change	NR	NR	NR	NR	-0.6	0.2
	Percent reduction	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR
	P-value	NR	NR	NR	NR	p<0.001	REF
CSF P-tau181	N	NR	NR	NR	23	101	98
	LS Mean Change	NR	NR	NR	-13.3	-15.9	12.9
	Percent reduction	NR	NR	NR	13%	NR	NR
	Diff (95% CI)	NR	NR	NR	-12.3 (4.7)	NR	NR
	P-value	NR	NR	NR	0.013	p<0.001	REF
CSF neurogranin, pg/ml	N	NR	NR	16	23	104	97
	Adjusted Mean Change	NR	NR	7.089	-36.962	-71.6	18.9
	Percent reduction	NR	NR	NR	11%	NR	NR
	Diff (95% CI)	NR	NR	NR	-43.8 (29.5)	NR	NR
	P-value	NR	NR	NR	0.145	p<0.001	REF
Plasma neurofilament light chain, pg/ml	N	NR	NR	NR	NR	529	574
	Adjusted Mean Change	NR	NR	NR	NR	1.8	2.9
	Percent reduction	NR	NR	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR	NR	NR

	P-value	NR	NR	NR	NR	p=0.06	REF
CSF neurofilament light chain, pg/ml	N	NR	NR	16	23	104	97
	Adjusted Mean Change	NR	NR	68.497	10.405	52.00	78.00
	Percent reduction	NR	NR	NR	48%	NR	NR
	Diff (95% CI)	NR	NR	NR	-58.7 (57.5)	NR	NR
	P-value	NR	NR	NR	0.313	NS	REF
<b>Health-Related Quality of Life Measures</b>							
EQ-5D-5L (participant)	N	NR	NR	NR	NR	715	754
	Adjusted Mean Change	NR	NR	NR	NR	-2.1	-4.2
	P value	NR	NR	NR	NR	p<0.01	REF
	Percent decline	NR	NR	NR	NR	-49%	REF
QOL-AD (participant)	N	NR	NR	NR	NR	715	753
	Adjusted Mean Change	NR	NR	NR	NR	-0.5	-1.2
	P value	NR	NR	NR	NR	p<0.01	REF
	Percent decline	NR	NR	NR	NR	-56%	REF
QOL-AD (participant by proxy)	N	NR	NR	NR	NR	713	754
	Adjusted Mean Change	NR	NR	NR	NR	-1.8	-2.3
	P value	NR	NR	NR	NR	p<0.05	REF
	Percent decline	NR	NR	NR	NR	-23%	REF
Zarit Burden Interview (Study partner burden)	N	NR	NR	NR	NR	712	755
	Adjusted Mean Change	NR	NR	NR	NR	3.6	5.8
	P value	NR	NR	NR	NR	p<0.001	REF
	Percent decline	NR	NR	NR	NR	-38%	REF

<b>Follow-Up Rates</b>						
Discontinuation of treatment	92/253 (36.4)	71/161 (44.1)	57/247 (23.1)	NR	NR	NR
Discontinuation of trial	NR	NR	NR	NR	169/898 (18.8)	140/897 (15.6)

A $\beta$ : beta-amyloid, AD: Alzheimer’s disease, ADCOMS: AD Composite Score, DAS-Cog 13: Alzheimer’s Disease Assessment Scale – Cognitive Subscale 13-item, ADAS-Cog 14: Alzheimer’s Disease Assessment Scale – Cognitive Subscale 14-item, ADCS-iADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory, ADCS MCI-ADL: Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), CDR-SB: Clinical Dementia Rating – Sum of Boxes, CSF: cerebrospinal fluid, CTAD: Clinical trials of Alzheimer disease, CI: confidence interval, DNB: donanemab, EQ-5D-5L: European Quality of Life – 5 dimensions (5 level version), iADRS: The Integrated Alzheimer’s Disease (AD) Rating Scale, LS; least squares, mg/kg: milligram per kilogram, MMSE: mini mental state examination, MRI: magnetic resonance imaging, N: number, NR: not reported, RD: redacted, PBO: placebo, pg/ml: picograms per milliliter, PET: Positron Emission Tomography, p-tau: phosphorylated tau, QOL-AD: Quality of Life in Alzheimer’s Disease, REF: reference, SUVr: standardized uptake value ratio  
 \*: 90% CI, †: calculated, ‡:N= 688 in substudy (354 in lecanemab and 344 in placebo), §: <30 cL

**Table D3.4 Outcomes Donanemab**

Trial		TRAILBLAZER ALZ		TRAILBLAZER-ALZ 4	
<b>Source</b>		Mintun et al. 2021 <sup>29</sup> ; Shcherbinin et al 2021; Shcherbinin 2022- JAMA neurology <sup>39,97</sup> ; Kotari et al. 2022_AAIC <sup>99</sup> ; Pontecorvo et al. 2022. <sup>41</sup>		Lee 2022 CTAD Conference 2022 <sup>104</sup>	
<b>Study Arms</b>		<b>Donanemab</b>	<b>Placebo</b>	<b>Donanemab</b>	<b>Aducanumab</b>
<b>Baseline N</b>		<b>131</b>	<b>126</b>	<b>71</b>	<b>69</b>
<b>Timepoint</b>		<b>76 weeks</b>		<b>6 months</b>	
<b>Cognitive Outcomes</b>					
iADRS Score	N	93	91	NR	NR
	LS Mean Change (SE)	-6.86 (1.14)	-10.06 (1.14)	NR	NR
	Difference in Mean Change (95% CI)	3.2 (0.12 to 6.27)	REF	NR	NR
	P-value	0.04	REF	NR	NR
CDR-SB Score	N	93	90	NR	NR
	LS Mean Change (SE)	1.22 (0.18)	1.58 (0.18)	NR	NR

	Diff (95% CI)	-0.36 (-0.83 to 0.12)	REF	NR	NR
	P-value	NS	REF	NR	NR
	Reduction in cognitive decline vs. PBO	NR	NR	NR	NR
ADAS-Cog13 Score	N	93	93	NR	NR
	LS Mean Change (SE)	2.91 (0.66)	4.77 (0.66)	NR	NR
	Diff (95% CI)	-1.86 (-3.63 to -0.09)	REF	NR	NR
	P-value	NR	REF	NR	NR
ADAS-Cog14 Score	N	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
	Reduction in cognitive decline vs. PBO	NR	NR	NR	NR
ADCOMS	Timepoint	NR	NR	NR	NR
	N	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR
	Diff (90% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
	Timepoint	NR	NR	NR	NR
	N	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR
	Diff (90% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
	Reduction in cognitive decline vs. PBO	NR	NR	NR	NR
ADCS-iADL Score	N	93	91	NR	NR
	LS Mean Change (SE)	-3.98 (0.74)	-5.2 (0.74)	NR	NR
	Diff (95% CI)	1.21 (-0.77 to 3.20)	REF	NR	NR
	P-value	NS	REF	NR	NR
ADCS-MCI-ADL Score	N	NR	NR	NR	NR
	LS Mean Change (SE)	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR

	P-value	NR	NR	NR	NR
		NR	NR	NR	NR
MMSE Score	N	91	90	NR	NR
	LS Mean Change (SE)	-2.35 (0.39)	-2.98 (0.39)	NR	NR
	Diff (95% CI)	0.64 (-0.40 to 1.67)	REF	NR	NR
	P-value	NS	REF	NR	NR
Amyloid Outcomes					
Florbetapir PET centiloids	Timepoint	24 weeks		6 months	
	N	115	111	66	64
	Mean (SD)	[REDACTED]		NR	NR
	LS Mean Change (SE)	-69.64	-1.82	NR	NR
	Difference in Mean Change (SE)	-67.83 (95% CI: -74.04, -61.61)	REF	-62.10 (3.9)	-16.41 (3.77)
	95% CI	[REDACTED]		NR	NR
	P-value	[REDACTED]		<0.001	REF
	Percent of reduction	[REDACTED]		REF	-65.2% (3.9)
	Effect size	[REDACTED]		REF	NR
	Amyloid Negative, n(%)	46 (40.0%)	0	27 (37.9), DIFF p<0.001	1 (1.6)
	Switched to placebo	27.40%	NA	NA	NA
	Timepoint	52 weeks		NR	NR
	N	92	91	NR	NR
	Mean (SD)	[REDACTED]		NR	NR
	LS Mean Change (SE)	-82.93	0.20	NR	NR
	Difference in Mean Change (SE)	-82.30 (95% CI: -89.02, -75.59)	REF	NR	NR
	95% CI	[REDACTED]		NR	NR
	P-value	[REDACTED]		NR	NR
	Percent of reduction	[REDACTED]		REF	NR
	Effect size	[REDACTED]		REF	NR
	Amyloid Negative, n(%)	55 (59.8%)	NR	NR	NR

	Switched to placebo	54.70%	NA	NR	NR
	Timepoint	76 weeks		NR	NR
	N	90	91	NR	NR
	Mean (SD)			NR	NR
	LS Mean Change (SE)	-84.13	0.93	NR	NR
	Difference in Mean Change (SE)	-85.06 (95% CI: -92.68, -77.43)	REF	NR	NR
	95% CI			NR	NR
	P-value			NR	NR
	Percent of reduction			NR	NR
	Effect size			NR	NR
	Amyloid Negative, n(%)	61 (67.8%)	NR	NR	NR
Florbetapir PET SUVr	Timepoint	NR	NR	NR	NR
	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	95% CI	NR	NR	NR	NR
	Percentage reduction	NR	NR	NR	NR
	P-Value	NR	NR	NR	NR
	Timepoint	NR	NR	NR	NR
	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	95% CI	NR	NR	NR	NR
	Amyloid negative, n(%)	NR	NR	NR	NR
	P-Value	NR	NR	NR	NR
Re-Accumulation	Timepoint	24-76 weeks		NR	NR
	N	19*	NR	NR	NR
	No reaccumulation, cl/wk mean (SD)	0.0 (0.1)	NR	NR	NR
	Timepoint	52 - 76 weeks		NR	NR
	N	19*	NR	NR	NR

	No reaccumulation, cl/wk mean (SD)	-0.1 (0.2)	NR	NR	NR
	Rate of CL reaccumulation per year, m (SD)	0.02 (7.75)	NR	NR	NR
	Median time to accumulate amyloid to amyloid + status, median (95% prediction intervals)†	3.9 years (1.9-8.3)	NR	NR	NR
PET Tau Outcomes					
Flortaucipir Global Tau Load (TauIQ)	N	90	87	NR	NR
	LS Mean Change	0.09	0.099 (0.008)	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	Percent reduction	-3.60%	REF	NR	NR
	P-value	NS	REF	NR	NR
Tau deposition (MUBADA SUVRPERSI)	N	NR	NR	NR	NR
	LS Mean Change (SE)	NR	0.055 (0.005)	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	Percent reduction	3.67%	REF	NR	NR
	P-value	NS	REF	NR	NR
Tau deposition (MUBADA SUVRGM)	N	NR	NR	NR	NR
	LS Mean Change (SE)	NR	0.104 (0.010)	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	Percent reduction	-33.98%	REF	NR	NR
	P-value	0.0125	REF	NR	NR
Tau deposition (Extent)	LS mean change from baseline	0.07	0.09	NR	NR
	P-value	<0.05	REF	NR	NR
Tau deposition (MUBADA)	LS mean change from baseline	0.07	0.1	NR	NR
	P-value	<0.05	REF	NR	NR
MRI Outcomes					
Volumetric MRI: Whole Brain	N	82	83	NR	NR
	LS Mean Change in mL (SE)	-24.72	-20.00	NR	NR
	Diff (95% CI)	NR	NR	NR	NR

	P-value (Dunnett p-value)	NR	NR	NR	NR
Volumetric MRI: Ventricular Volume	N	82	83	NR	NR
	LS Mean Change in mL (SE)	8.44	5.55	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value (Dunnett p-value)	NR	NR	NR	NR
Volumetric MRI: Hippocampus volume	N	82	83	NR	NR
	LS Mean Change in mL (SE)	-0.22	-0.22	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value (Dunnett p-value)	NR	NR	NR	NR
CSF & Plasma Outcomes					
CSF A $\beta$ 1-42, pg/ml	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
CSF A $\beta$ 1-40, pg/ml	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
Plasma A $\beta$ 42/40 ratio	Timepoint	76 weeks		NR	NR
	N	69	67	NR	NR
	Adjusted Mean Change	0.02 (0.007)	0.01 (0.007)	NR	NR
	Percent reduction	+4%	+2%	NR	NR
	Diff (95% CI)	0.01 (-0.01, 0.03)	REF	NR	NR
	P-value	0.26	REF	NR	NR
	Timepoint	NR	NR	NR	NR
	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
	CSF A $\beta$ 42/40 ratio	N	NR	NR	NR

	Adjusted Mean Change	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
CSF T-tau pg/ml	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
Plasma P-tau, pg/ml	N	86	86	53	51
	LS Mean Change	-0.11 (0.01)	0.03 (0.01)	-0.12	0.01
	Percent reduction	-23%	+6%	-25.0%	+2.8%
	Diff (95% CI)	-0.14 (-0.18, -0.10)	REF	NR	NR
	P-value	<.0001	REF	<0.001	REF
CSF P-tau181	N	NR	NR	NR	NR
	LS Mean Change	NR	NR	NR	NR
	Percent reduction	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
CSF neurogranin, pg/ml	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	Percent reduction	NR	NR	NR	NR
	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
Plasma neurofilament light chain, pg/ml	N	69	67	NR	NR
	Adjusted Mean Change	0.06 (0.015)	0.07 (0.015)	NR	NR
	Percent reduction	+15%	+19%	NR	NR
	Diff (95% CI)	-0.01 (-0.06, 0.03)	REF	NR	NR
	P-value	0.49	REF	NR	NR
CSF neurofilament light chain, pg/ml	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	Percent reduction	NR	NR	NR	NR

	Diff (95% CI)	NR	NR	NR	NR
	P-value	NR	NR	NR	NR
Health-Related Quality of Life Measures					
EQ-5D-5L (participant)	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	P value	NR	NR	NR	NR
	Percent decline	NR	NR	NR	NR
QOL-AD (participant)	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	P value	NR	NR	NR	NR
	Percent decline	NR	NR	NR	NR
QOL-AD (participant by proxy)	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	P value	NR	NR	NR	NR
	Percent decline	NR	NR	NR	NR
Zarit Burden Interview (Study partner burden)	N	NR	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR	NR
	P value	NR	NR	NR	NR
	Percent decline	NR	NR	NR	NR
Follow-Up Rates					
Discontinuation of treatment		49/131 (37.4)	34/126 (27.2)	NR	NR
Discontinuation of trial		37/131 (28.2)	32/126 (25.6)	NR	NR

A $\beta$ : beta-amyloid, AD: Alzheimer's disease, ADCOMS: AD Composite Score, DAS-Cog 13: Alzheimer's Disease Assessment Scale – Cognitive Subscale 13-item, ADAS-Cog 14: Alzheimer's Disease Assessment Scale – Cognitive Subscale 14-item, ADCS-iADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory, ADCS MCI-ADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), CDR-SB: Clinical Dementia Rating – Sum of Boxes, CSF: cerebrospinal fluid, CTAD: Clinical trials of Alzheimer disease, CI: confidence interval, DNB: donanemab, EQ-5D-5L: European Quality of Life – 5 dimensions (5 level version), iADRS: The Integrated Alzheimer's Disease (AD) Rating Scale, LS; least squares, N: number, NR: not reported, MMSE: mini mental state examination, MRI: magnetic resonance imaging, , RD: redacted, PBO: placebo, pg/ml: picograms per milliliter, PET: Positron Emission Tomography, p-tau: phosphorylated tau, QOL-AD: Quality of Life in Alzheimer's Disease, REF: reference, SUVr: standardized uptake value ratio  
\*donanemab then switched to placebo, †: Predictive model based on data from 304 participants.

**Table D3.5 Outcomes (Lower doses of G000-201 Study)**

Source		Swanson et al. 2021 <sup>86</sup>		
Study Arms		LCB 2.5 mg/kg biweekly	LCB 5 mg/kg monthly	LCB 5 mg/kg biweekly
Baseline N		52	48	89
Timepoint		18 months		
<b>Cognitive Outcomes</b>				
CDR-SB Score	N	34	36	67
	LS Mean Change (SE)	1.227 (0.34)	1.713 (0.33)	1.463 (0.25)
	Diff (95% CI)	-0.271 (-0.875 to 0.332)*	0.214 (-0.384 to 0.812)*	-0.036 (-0.510 to 0.439)*
	P-value	0.459	0.555	0.901
	Reduction in cognitive decline vs. PBO	NR	NR	NR
ADAS-Cog14 Score	N	33	34	61
	LS Mean Change (SE)	5.574 (1.28)	5.746 (1.28)	4.506 (0.96)
	Diff (95% CI)	0.672 (-1.586 to 2.930)*	0.844 (-1.422 to 3.111)*	-0.395 (-2.192 to 1.401)*
	P-value	0.624	0.539	0.717
	Reduction in cognitive decline vs. PBO			
	Percent improvement vs. placebo	NR	NR	NR
ADCOMS	Timepoint	12 months		
	N	38	42	67
	LS Mean Change (SE)	0.158 (0.03)	0.149 (0.03)	0.139 (0.20)
	Diff (90% CI)	0.028 (-0.020 to 0.076)	0.019 (-0.029 to 0.066)	0.008 (-0.030 to 0.046)
	P-value	0.336	0.514	0.731
	Reduction in clinical decline vs. PBO	NR	NR	NR
	Timepoint	18 months		
	N	33	35	61

	LS Mean Change (SE)	0.173 (0.04)	0.192 (0.04)	0.199 (0.03)
	Diff (90% CI)	-0.202 (-0.083 to 0.042)	-0.001 (-0.064 to 0.061)	0.006 (-0.044 to 0.055)
	P-value	0.592	0.971	0.855
	Percent improvement vs. placebo	NR	NR	NR
	Reduction in cognitive decline vs. PBO	NR	NR	NR
<b>Amyloid Outcomes (SUVR)</b>				
	N	23	23	24
	Adjusted Mean Change	-0.094	-0.131	-0.197
	Difference in Mean Change (SD)	-0.099	-0.136	-0.201
	95% CI	NR	NR	NR
	P-Value	NR	NR	NR
<b>MRI Outcomes</b>				
Volumetric MRI: Whole Brain	N	32	38	55
	LS Mean Change (SE)	-26987.11 (1805.22)	-27972.21 (1706.45)	-26520.54 (1413.53)
	Diff (95% CI)	-5211.254 (-8291.455 to -2131.053)*	-6196.353 (-9115.840 to -3276.866)*	-4744.689 (-7242.988 to -2246.390)*
	P-value (Dunnett p-value)	0.005 (0.093)	0.001 (0.009)	0.002 (0.032)
Volumetric MRI: Ventricular Volume	N	34	39	55
	LS Mean Change (SE)	6250.43 (469.844)	7265.785 (445.381)	6338.779 (373.274)
	Diff (95% CI)	905.926 (103.475 to 1708.377)*	1921.281 (1157.356 to 2685.206)*	994.276 (334.281 to 1654.271)*
	P-value (Dunnett p-value)	0.063 (0.690)	0.001 (0.001)	0.013 (0.213)
Volumetric MRI: Hippocampus volume	N	34	39	55
	LS Mean Change (SE)	-305.254 (20.161)	-304.600 (19.053)	-297.469 (15.955)
	Diff (95% CI)	-47.958 (-82.366 to -13.549)*	-47.304 (-79.974 to -14.634)*	-40.173 (-68.411 to -11.934)*
	P-value (Dunnett p-value)	0.022 (0.328)	0.017 (0.269)	0.019 (0.296)

AD: Alzheimer's disease, ADCOMS: AD Composite Score, ADAS-Cog 14: Alzheimer's Disease Assessment Scale – Cognitive Subscale 14-item, CDR-SB: Clinical Dementia Rating – Sum of Boxes, CI: confidence interval, LS; least squares, LCB: lecanemab, mg/kg: milligrams per kilogram, MRI: magnetic resonance imaging  
N: number, NR: not reported, PBO: placebo, REF: reference, SD: standard error, SE: standard error

\*: 90% CI

**Table D3.6 Lecanemab OLE Outcomes**

Trial		G000-201 OLE		
Source		Swanson et al. CTAD conference 2021; Swanson et al. 2020 <sup>105</sup> ; Swanson et al. 2021 Neurology; Swanson et al. CTAD conference 2021 * <sup>86,90,91</sup>		
Study Arms		Lecanemab 10 mg/kg Q2W	Lecanemab 10 mg/kg Q4W	Core placebo-treated
Baseline N		38	60	45
<b>Cognitive Outcomes</b>				
ADCOMS	Timepoint	Core baseline to OLE baseline		
	N	30	NR	40
	LS Mean Change (SE)	0.18	NR	0.28
	P-value	NR	NR	p<0.05
	Timepoint	NR	NR	NR
<b>Amyloid Outcomes</b>				
Florbetapir PET SUVr	Timepoint	Core baseline to OLE baseline		
	N	12		
	Adjusted Mean Change	-0.29		NR
	Timepoint	12 Months		
	N	6	NR	7
	Adjusted Mean Change	-0.32	NR	-0.26
	Difference in Mean Change (SD)	NR	NR	NR
	Amyloid negative, n(%)	88%	NR	86%
P-Value	NR	NR	NR	
<b>CSF Outcomes</b>				
Aβ1-42, pg/ml	N	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR
	Diff (95% CI)	NR	NR	NR
	P-value	NR	NR	NR
Aβ42/40 ratio	Timepoint	Core baseline to OLE baseline		
	N	25	NR	32
	Adjusted Mean Change	0.0045	NR	-0.0012*

	P-value	NR	NR	NR
	Timepoint	Core baseline to OLE 12 months		
	N	25	NR	31
	Adjusted Mean Change	0.007	NR	0.008
	P-value	NR	NR	NR
T-tau pg/ml	N	NR	NR	NR
	Adjusted Mean Change	NR	NR	NR
	Diff (95% CI)	NR	NR	NR
	P-value	NR	NR	NR
P-tau, pg/ml	N	20	NR	25
	LS Mean Change	-1.06	NR	-1.17
	P-value	NR	NR	NR

A $\beta$ : beta-amyloid, ADCOMS: AD Composite Score, CI: confidence interval, CSF: cerebrospinal fluid, LS: least squares, mg/kg: milligram per kilogram, N: number, NR: not reported, OLE: open-label extension, PET: Positron Emission Tomography, p-tau: phosphorylated tau, Q2W: every two weeks, Q4W: Every four weeks, SE: standard error, SD: standard deviation, pg/ml: picograms per milliliter, SUVR: standardized uptake value ratio, t-tau: total tau

\*: these arms are based on the core study allocation

**Table D3.7 Lecanemab Bayesian Analysis – ADCOMS Primary Analysis<sup>86</sup>**

Lecanemab	Total N	ADCOMS - Primary Analysis									
		Δ from Baseline			Diff from Control		Posterior Quantities				
		Mean	SD	95% CI	Mean	95% CI	Pr (Max)	Pr (ED90)	Pr SUP	Pr (CSD)	
Timepoint	12 months										
All Participants											
PBO	229	0.113	0.012	NR	NR	NR	--	--	--	--	
2.5 mg/kg Q2W	51	0.134	0.024	NR	NR	NR	0.009	0.009	0.216	0.028	
5 mg/kg Q4W	48	0.119	0.021	NR	NR	NR	0.022	0.031	0.416	0.07	
5 mg/kg Q2W	87	0.116	0.016	NR	NR	NR	0.01	0.01	0.4467	0.053	
10 mg/kg Q4W	242	0.084	0.011	NR	NR	NR	0.318	0.386	0.961	0.479	
10 mg/kg Q2W	143	0.077	0.014	NR	NR	NR	0.642	0.563	0.976	0.638	

ADCOMS: AD Composite Score, ApoE: Apolipoprotein E, CI: confidence interval, CSD: clinically significant difference (25% better than placebo), Diff: difference, ED90: dose regimen with at least 90% of the dmax treatment effect, Max: maximum treatment effect, mg/kg: milligram per kilogram, NR: not reported, PBO: placebo, Pr: probability, Pr (Max): probability of being maximal effective dose, Pr (ED90): probability of being the ED90 dose, Pr SUP: probability to be superior to placebo by any magnitude, Pr (CSD): probability to be better than placebo by at least 25%, Q2W: every two weeks, Q4W: Every four weeks, SD: standard deviation, Δ: change

**Table D3.8 Lecanemab Bayesian Analysis – ADCOMS Secondary Analysis<sup>86</sup>**

Lecanemab	Total N	ADCOMS - Secondary Analysis									
		Δ from Baseline			Diff from Control		Posterior Quantities				
		Mean	SD	95% CI	Mean	95% CI	PR (Max)	Pr (ED90)	Pr SUP	Pr (CSD)	
Timepoint	18 months										
<b>All Participants</b>											
PBO	238	0.172	NR	0.142 to 0.202	REF	REF	--	--	--	--	
2.5 mg/kg Q2W	52	0.156	NR	0.101 to 0.210	-0.017	-0.079 to 0.045	0.128	0.138	0.702	0.333	
5 mg/kg Q4W	48	0.156	NR	0.108 to 0.206	-0.016	-0.073 to 0.041	0.097	0.129	0.719	0.32	
5 mg/kg Q2W	89	0.165	NR	0.127 to 0.205	-0.007	-0.056 to 0.043	0.018	0.019	0.622	0.183	
10 mg/kg Q4W	246	0.142	NR	0.113 to 0.171	-0.031	-0.072 to 0.011	0.155	0.194	0.927	0.513	
10 mg/kg Q2W	152	0.126	NR	0.090 to 0.160	-0.047	-0.093 to -0.001	0.603	0.52	0.977	0.76	
<b>ApoE ε4 Carriers</b>											
PBO	168	0.18	NR	0.144 to 0.216	REF	REF	--	--	--	--	
2.5 mg/kg Q2W	38	0.149	NR	0.085 to 0.213	-0.031	-0.105 to 0.042	0.09	0.106	0.804	0.515	
5 mg/kg Q4W	37	0.155	NR	0.098 to 0.214	-0.026	-0.092 to 0.043	0.048	0.072	0.778	0.452	
5 mg/kg Q2W	81	0.158	NR	0.116 to 0.202	-0.023	-0.078 to 0.034	0.012	0.013	0.789	0.4	
10 mg/kg Q4W	218	0.139	NR	0.108 to 0.171	-0.041	-0.089 to 0.006	0.058	0.08	0.956	0.679	
10 mg/kg Q2W	45	0.096	NR	0.027 to 0.154	-0.084	-0.161 to -0.015	0.792	0.728	0.992	0.936	

ApoE ε4 non-carriers										
PBO	70	0.146	NR	0.092 to 0.201	REF	REF	--	--	--	--
2.5 mg/kg Q2W	14	0.154	NR	0.068 to 0.243	0.008	-0.094 to 0.111	0.209	0.209	0.442	0.23
5 mg/kg Q4W	11	0.149	NR	0.074 to 0.226	0.002	-0.090 to 0.096	0.191	0.215	0.481	0.241
5 mg/kg Q2W	8	0.161	NR	0.092 to 0.245	0.014	-0.074 to 0.113	0.082	0.076	0.386	0.166
10 mg/kg Q4W	28	0.143	NR	0.082 to 0.205	-0.003	-0.085 to 0.079	0.218	0.226	0.531	0.257
10 mg/kg Q2W	107	0.135	NR	0.095 to 0.174	-0.011	-0.079 to 0.056	0.3	0.274	0.63	0.29

ADCOMS: AD Composite Score, ApoE: Apolipoprotein E, CI: confidence interval, CSD: clinically significant difference (25% better than placebo), Diff: difference, ED90: dose regimen with at least 90% of the dmax treatment effect, Max: maximum treatment effect, mg/kg: milligram per kilogram, NR: not reported, PBO: placebo, Pr: probability, Pr (Max): probability of being maximal effective dose, Pr (ED90): probability of being the ED90 dose, Pr SUP: probability to be superior to placebo by any magnitude, Pr (CSD): probability to be better than placebo by at least 25%, Q2W: every two weeks, Q4W: Every four weeks, SD: standard deviation, Δ: change,

**Table D3.9 Lecanemab Bayesian Analysis – CDR-SB<sup>86</sup>**

Lecanemab	Total N	CDR-SB								
		Δ from Baseline			Diff from Control		Posterior Quantities			
		Mean	SD	95% CI	Mean	95% CI	PR (Max)	Pr (ED90)	Pr SUP	Pr (CSD)
18 months										
<b>All Participants</b>										
PBO	238	1.248	NR	0.952 to 1.543	REF	REF	--	--	--	NR
2.5 mg/kg Q2W	52	1.053	NR	0.520 to 1.579	-0.195	-0.802 to 0.404	0.176	0.183	0.74	NR
5 mg/kg Q4W	48	1.25	NR	0.783 to 1.777	0.002	-0.552 to 0.602	0.031	0.046	0.509	NR
5 mg/kg Q2W	89	1.157	NR	0.793 to 1.547	-0.09	-0.560 to 0.394	0.028	0.027	0.65	NR
10 mg/kg Q4W	246	0.923	NR	0.637 to 1.206	-0.325	-0.733 to 0.083	0.245	0.304	0.941	NR
10 mg/kg Q2W	152	0.835	NR	0.481 to 1.174	-0.413	-0.870 to 0.038	0.52	0.44	0.964	NR
<b>ApoE ε4 Carriers</b>										
PBO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
2.5 mg/kg Q2W	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
5 mg/kg Q4W	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

5 mg/kg Q2W	NR									
10 mg/kg Q4W	NR									
10 mg/kg Q2W	NR									
<b>ApoE ε4 non-carriers</b>										
PBO	NR									
2.5 mg/kg Q2W	NR									
5 mg/kg Q4W	NR									
5 mg/kg Q2W	NR									
10 mg/kg Q4W	NR									
10 mg/kg Q2W	NR									

ApoE: Apolipoprotein E, CDR-SB: Clinical Dementia Rating – Sum of Boxes, CI: confidence interval, CSD: clinically significant difference (25% better than placebo), Diff: difference, ED90: dose regimen with at least 90% of the dmax treatment effect, Max: maximum treatment effect, mg/kg: milligram per kilogram, NR: not reported, PBO: placebo, Pr: probability, Pr (Max): probability of being maximal effective dose, Pr (ED90): probability of being the ED90 dose, Pr SUP: probability to be superior to placebo by any magnitude, Pr (CSD): probability to be better than placebo by at least 25%, Q2W: every two weeks, Q4W: Every four weeks, SD: standard deviation, Δ: change,

**Table D3.10 Lecanemab Bayesian Analysis – ADAS-Cog 14<sup>86</sup>**

Lecanemab	Total N	ADAS-Cog14									
		Δ from Baseline			Diff from Control		Posterior Quantities				
		Mean	SD	95% CI	Mean	95% CI	Pr (Max)	Pr (ED90)	Pr SUP	Pr (CSD)	
18 months											
<b>All Participants</b>											
PBO	237	3.632	NR	2.501 to 4.766	REF	REF	--	--	--	NR	
2.5 mg/kg Q2W	52	3.857	NR	1.748 to 6.007	0.225	-2.164 to 2.333	0.03	0.038	0.428	NR	
5 mg/kg Q4W	47	3.859	NR	1.910 to 5.921	0.228	-2.030 to 2.333	0.022	0.031	0.426	NR	
5 mg/kg Q2W	89	3.221	NR	1.711 to 4.750	-0.411	-2.299 to 1.483	0.037	0.046	0.668	NR	
10 mg/kg Q4W	246	2.91	NR	1.808 to 4.016	-0.721	-2.296 to 0.855	0.049	0.068	0.817	NR	
10 mg/kg Q2W	152	1.611	NR	0.234 to 2.952	-2.021	-3.795 to -0.273	0.861	0.817	0.988	NR	
<b>ApoE ε4 Carriers</b>											
PBO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
2.5 mg/kg Q2W	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	

5 mg/kg Q4W	NR										
5 mg/kg Q2W	NR										
10 mg/kg Q4W	NR										
10 mg/kg Q2W	NR										
<b>ApoE ε4 non-carriers</b>											
PBO	NR										
2.5 mg/kg Q2W	NR										
5 mg/kg Q4W	NR										
5 mg/kg Q2W	NR										
10 mg/kg Q4W	NR										
10 mg/kg Q2W	NR										

ADAS-Cog 14: Alzheimer’s Disease Assessment Scale – Cognitive Subscale 14-item, ApoE: Apolipoprotein E, CI: confidence interval, CSD: clinically significant difference (25% better than placebo), Diff: difference, ED90: dose regimen with at least 90% of the dmax treatment effect, Max: maximum treatment effect, mg/kg: milligram per kilogram, NR: not reported, PBO: placebo, Pr: probability, Pr (Max): probability of being maximal effective dose, Pr (ED90): probability of being the ED90 dose, Pr SUP: probability to be superior to placebo by any magnitude, Pr (CSD): probability to be better than placebo by at least 25%, Q2W: every two weeks, Q4W: Every four weeks, SD: standard deviation, Δ: change

**Table D3.11 Safety**

Trial	TRAILBLAZER ALZ		TRAILBLAZER ALZ 4		G000-201						CLARITY AD	
Source	Mintun et al. 2021 <sup>29</sup> ; Data from manufacture		CTAD conference 2022 <sup>40</sup>		Swanson et al. 2021 <sup>86</sup> ; Landry 2022 <sup>90</sup> ; CTAD conference 2022 <sup>28</sup>						van Dyck et al., 2022 <sup>28</sup> ; Sabbagh et al. CTAD conference 2022 <sup>106</sup>	
Study Arms	DNB	PBO	DNB	ADU	2.5 mg/kg biweekl y	5 mg/kg monthl y	5 mg/kg biweekl y	10 mg/kg monthl y	10 mg/kg biweekl y	Placebo	10 mg/kg biweekl y	PBO
N	131	125*	71	69	52	51	92	253	161	245	898†	897
<b>Adverse Events</b>												

Any adverse event	119 (90.8)	113 (90.4)	44 (62)	46 (66.70)	46 (88.5)	48 (94.1)	81 (88.0)	238 (94.1)	139 (86.3)	216 (88.2)	798 (88.9)	735 (81.9)
Treatment-related TEAE	NR	NR	22 (31)	23 (33.3)	23 (44.2)	25 (49.0)	31 (33.7)	135 (53.4)	76 (47.2)	65 (26.5)	798 (88.9)	735 (81.9)
Death	1 (0.8)	2 (1.6)	0 (0.0)	0 (0.0)	2 (3.8)	0 (0)	1 (1.1)	2 (0.8)	0 (0)	2 (0.8)	6 (0.7)	7 (0.8)
ARIA-E Leading to death	0 (0)	0 (0)	0 (0.0)	0 (0.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	NR	NR
ARIA-H Leading to death	0 (0)	0 (0)	0 (0.0)	0 (0.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2‡	NR
Serious adverse event	23 (17.6)	22 (17.6)	6 (8.5)	6 (8.7)	10 (19.2)	4 (7.8)	16 (17.4)	31 (12.3)	25 (15.5)	43 (17.6)	126 (14.0)	101 (11.3)
AE leading to D/C of treatment	40 (30.5)	9 (7.2)	2 (2.8)	1 (1.4)	NR	NR	NR	NR	NR	NR	62 (6.9)	26 (2.9)
Infusion-related reaction leading to D/C of treatment	NR	NR	NR	NR	NR	NR	NR	NR	2.50%	0.80%	NR	NR
AE leading to D/C of trial	20 (15.3)	6 (4.8)	1 (1.4)	0 (0.0)	7 (13.5)§	4 (7.8)	10 (10.9)	47 (18.6)	24 (14.9)	15 (6.1)	51 (5.7)	28 (3.1)
AE occurring during treatment	119 (90.8)	113 (90.4)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ARIA-E leading to D/C	7/131 (5.3)	NR	0 (0.0)	0 (0.0)	1/52 (1.9)	1/51 (2.0)	3/92 (3.3)	25/253 (9.9)	16/161 (9.9)	NR	NR	NR
<b>Other Adverse Events</b>												
Injection-site reaction	NA	NA	NR	NR	NA	NA	NA	NA	NA	NA	NA	NA
Infusion-related reaction	10 (7.6)	0	5 (7)	2 (2.9)	5.80%	7.80%	12.00%	22.90%	19.90%	3.30%	237 (26.4)#	66 (7.4)
Infusion-related reaction (Grade 1 or 2)	NR	NR	5 (7)	2 (2.9)	NR	NR	NR	NR	NR	NR	96%	
Infusion-related reaction (First dose)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	75%	
Fall	17 (13)	19 (15.2)	1 (1.4)	0 (0.0)	NR	NR	NR	NR	NR	NR	93 (10.4)	86 (9.6)

Dizziness	11 (8.4)	15 (12)	NR	NR	NR	NR	NR	NR	NR	NR	49 (5.5)	46 (5.1)
Headache	10 (7.6)	15 (12)	6 (8.5)	8 (11.6)	NR	NR	NR	NR	NR	NR	100 (11.1)	73 (8.1)
Superficial siderosis of CNS	18 (13.7)	4 (3.2)	0 (0.0)	5 (7.2)	NR	NR	NR	NR	NR	NR	50 (5.6)	22 (2.5)
Arthralgia	10 (7.6)	10 (8.0)	NR	NR	NR	NR	NR	NR	NR	NR	53 (5.9)	62 (6.9)
Nausea	14 (10.7)	4 (3.2)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
URTI	9 (6.9)	9 (7.2)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
UTI	13 (9.9)	5 (4.0)	NR	NR	NR	NR	NR	NR	NR	NR	78 (8.7)	82 (9.1)
Diarrhea	11 (8.4)	5 (4.0)	NR	NR	NR	NR	NR	NR	NR	NR	48 (5.3)	58 (6.5)
Pneumonia	7 (5.3)	5 (4.0)	2 (2.8)	0 (0.0)	NR	NR	NR	NR	NR	NR	NR	NR
Depression	6 (4.6)	8 (6.4)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Confusion	0	10 (8.0)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Vomiting	7 (5.3)	3 (2.4)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Anxiety	7 (5.3)	2 (1.6)	NR	NR	NR	NR	NR	NR	NR	NR	45 (5.0)	38 (4.2)
Back pain	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	60 (6.7)	52 (5.8)
COVID-19	NR	NR	11 (15.5)	4 (5.8)	NR	NR	NR	NR	NR	NR	64 (7.1)	60 (6.7)
Anti-drug antibodies (ADA)	NR	NR	NR	NR	NR	NR	NR	NR	40.90%	NA	NR	NR
NAb Positive	NR	NR	NR	NR	NR	NR	NR	NR	25.40%	NA	NR	NR
<b>Serious AEs</b>												
Infusion-related reactions	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	11 (1.2)‡	0
ARIA-E	NR	NR	0 (0.0)	1 (1.4)	NR	NR	NR	NR	NR	NR	7 (0.8)	0

ARIA-H		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	5 (0.6)	1 (0.1)	
Serious AEs without ARIA or infusion-related reactions		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	111 (12.4)	101 (11.3)	
<b>ARIA Events</b>														
ARIA-E	Any	36 (27.5)	1 (0.8)	15 (21.1)	16 (23.2)	1/52 (1.9)	1/51 (2.0)	3/92 (3.3)	25/253 (9.9)	16/161 (9.9)	2/245 (0.8)	113 (12.6)	15 (1.7)	
	Asymptomatic	28 (21.4)	0	13 (18.3)	13 (18.8)	NR	NR	NR	NR	NR	NR	NR	NR	
	ApoE ε4 positive	32 (24.4)	1 (0.8)	13/49 (26.5)	15/49 (30.6)	1/1 (100)	1/1 (100)	3/3 (100)	23/25 (92)	7/16 (44)	2/2 (100)	98/620 (15.8)	14/61 (2.3)	
	ApoE ε4 positive heterozygote	21/68 (30.9)	0/62	10/40 (25.0)	9/39 (23.1)	NR	NR	NR	NR	NR	NR	52/479 (10.9)	9/478 (1.9)	
	ApoE ε4 positive homozygote	11/25 (44.0)	1/28 (3.6)	3/9 (33.3)	6/10 (60)	NR	NR	NR	NR	NR	NR	46/141 (32.6)	5/133 (3/8)	
	ApoE ε4 negative	4/36 (11.1)	0/32	2/22 (9.1)	1/20 (5.0)	0/112 (0)	0/112 (0)	0/112 (0)	0/112 (0)	2/112 (7.1)	9/112 (8.0)	15/278 (5.4)	1/286 (0.3)	
	Recurrent ARIA-E	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	28 (3.1)	1 (0.1)
	Radiographic severity: mild	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	37	9
	Radiographic severity: moderate	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	66	6
	Radiographic severity: severe	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	9	0
	Clinical severity: mild	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	10	NA
	Clinical severity: moderate	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	12	NA
	Clinical severity: severe	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	3	NA

	Median time to complete resolution of ARIA-E	9.6 weeks	NR	NR	NR	NR	NR	NR	NR	NR	NR	81% resolution within 4 months; 64% by 90 days; 81% by 120 days; 92% by 6 months with lecanemab.**	
	Median time to complete resolution of serious ARIA-E	18 weeks	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Symptomatic ARIA-E	Symptomatic	5 (3.8)	1 (0.8)	2 (2.8)	3 (4.3)	1 (1.9)	0 (0)	1 (1.1)	1 (0.4)	2 (1.2)	NR	25 (2.8) ††	0
	Symptomatic: ApoE ε4 positive	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	21/620 (3.4)	0/611
	Symptomatic: ApoE ε4 positive heterozygote	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	8/479 (1.7)	0/478
	Symptomatic: ApoE ε4 positive homozygote	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	13/141 (9.2)	0/133
	Symptomatic: ApoE ε4 negative	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	4/278 (1.4)	0/286
ARIA-H, n(%)	Any	40 (30.5)	9 (7.2)	14 (19.7)	12 (17.4)	2 (3.8)	7 (13.7)	17 (18.5)	28 (11.1)	11 (6.8)	13 (5.3)	155 (17.3) ††	81 (9.0)
	Microhemorrhage	26 (19.8)	6 (4.8)	NR	NR	NR	NR	NR	NR	NR	NR	126 (14.0)	68 (7.6)
	Superficial siderosis	23 (17.6)	3 (2.4)	NR	NR	NR	NR	NR	NR	NR	NR	50 (5.6)	21 (2.3)
	Macrohemorrhage	0	0	NR	NR	NR	NR	NR	NR	1/161 (0.6) †	0/245 (0)	5 (0.6) 6 (0.7) †††	1 (0.1) 2 (0.2) †
	ApoE ε4 positive	NR	NR	12/49 (24.5)	11/49 (22.4)	57/436 (13.1)					NR	122/620 (19.7)	69/611 (11.3)

	ApoE ε4 positive heterozygote	NR	NR	9/40 (22.5)	7/39 (17.9)	NR	NR	NR	NR	NR	NR	67/479 (14.0)	41/478 (8.6)
	ApoE ε4 positive homozygote	NR	NR	3/9 (33.3)	4/10 (40)	NR	NR	NR	NR	NR	NR	55/141 (39.0)	28 (133) (21.1)
	ApoE ε4 negative	NR	NR	2/22 (9.1)	1/20 (5.0)	8/173 (4.6)§§					NR	33/278 (11.9)	12/286 (4.2)
	Symptomatic	NR	NR	0 (0.0)	0 (0.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		
Deaths with cerebral macro hemorrhage		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	0	1/897 (0.1)
ARIA-E or ARIA-H		51 (38.9)	10 (8.0)	18 (25.4)	18 (26.1)	NR	NR	NR	NR	NR	NR	193 (21.5)	85 (9.5)
ARIA-E with ARIA-H		NR	NR	NR	NR	0 (0)	1 (2.0)	1 (1.1)	13 (5.1)	7 (4.3)	1 (0.4)	74 (8.2)	9 (1.0)
ARIA-H without ARIA-E		NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	80 (8.9)	70 (7.8)

AE: adverse event, ADU: aducanumab, ApoE: Apolipoprotein E, ARIA-E: amyloid-related imaging abnormalities due to edema/effusion, ARIA-H: amyloid-related imaging abnormalities due to hemorrhage or superficial siderosis, CNS: central nervous system, DNB: donanemab, D/C: discontinuation, mg/kg: milligram per kilogram, NA: not applicable, NAb: neutralizing antibody, NR: not reported, PBO: placebo, TEAE: treatment-emergent adverse events, URTI: upper respiratory tract infection, UTI: Urinary tract infection

\* One participant in the placebo group was not included in the modified intention-to treat population, †safety population, ‡: Reported in the core and OLE phase, §: reporting of these values was inconsistent in manuscript and supplement. We report values from the main report, #: 56% of the participants did not take preventative medications (i.e., nonsteroidal anti-inflammatory drugs, antihistamines, or glucocorticoids) for infusion-related reactions. \*\*: Those who had mild ARIA-E who continued dosing resolved in a similar time frame to those who discontinued dosing (3 months), ††: symptoms were headache, visual disturbance, and confusion, ‡‡: Timing of ARIA-H occurs randomly during treatment course but ARIA-H with ARIA-E occurs early, §§: across all lecanemab doses, ##: Values represent all adverse events (includes adverse events beyond 30 days after taking the study drug) which includes one non-treatment emergent case in placebo and one case in lecanemab on anticoagulation.

**Table D3.12. Additional Safety**

Trial		Lecanemab: Phase 1- SC	
Source		Rawal et al. 2022 <sup>95</sup>	
Study Arms		IV infusion	SC injection
N		30	29
Treatment-related TEAE		0.03%	0.07%
Injection-site reaction		NA	20.70%
Infusion-related reaction (Grade 1 or 2)		33.30%	
Anti-drug antibodies (ADA)		0.03%	0.07%
Trial		G000-201 OLE	
Source		Landry 2022; Reyderman et al. 2022	
Study Arms		10 mg/kg biweekly	Core placebo-treated
Infusion-related reaction		20.60%	
Anti-drug antibodies (ADA)		6.10%	NA
NAb Positive		0.00%	NA
ARIA-E	Any	7.80%	8.90%
	ApoE ε4 positive	NR	4/33 (12.1%)*
	ApoE ε4 negative	NR	0/14 (0%)
ARIA-H	Macrohemorrhage	1/180 (0.6)	NA

ApoE: Apolipoprotein E, ARIA-E: amyloid-related imaging abnormalities due to edema/effusion, ARIA-H: amyloid-related imaging abnormalities due to hemorrhage or superficial siderosis, IV: intravenous, N: number, NA: not applicable, NR: not reported, NAb: neutralizing antibody, SC: subcutaneous, TEAE: treatment-emergent adverse event

\*: ApoE ε4 and core placebo-treated participants. 25% homozygous and 11.1% heterozygous.

**Table D3.13 Subgroup Data – Lecanemab Phase II ADCOMS by Disease Severity**

Trial	Timepoint	Study Arms	Subgroups	ADCOMS			
				n/N	LSM (SE)	LSM Diff (90% CI)	P-Value
<b>Lecanemab</b>							
<b>G000-201 (MMRM Analysis)<sup>86</sup></b>	18 months	2.5 mg/kg Q2W	MCI Due to AD	22/52	0.106 (0.037)	-0.062 (-0.128 to 0.004)	0.12
			Mild AD	11/52	0.3 (0.075)	0.069 (-0.066 to 0.205)	0.397
		5 mg/kg Q4W	MCI Due to AD	30/48	0.154 (0.034)	-0.014 (-0.076 to 0.047)	0.7
			Mild AD	5/48	0.297 (0.092)	0.067 (-0.095 to 0.229)	0.493
		5 mg/kg Q2W	MCI Due to AD	37/89	0.16 (0.029)	0.008 (-0.063 to 0.046)	0.8
			Mild AD	24/89	0.248 (0.052)	0.018 (-0.084 to 0.119)	0.776
		10 mg/kg Q4W	MCI Due to AD	101/246	0.14 (0.019)	0.029 (-0.068 to 0.010)	0.227
			Mild AD	45/246	0.205 (0.039)	-0.026 (-0.109 to 0.058)	0.615
		10 mg/kg Q2W	MCI Due to AD	47/152	0.113 (0.025)	-0.056 (-0.105 to -0.007)	0.058
			Mild AD	32/152	0.149 (0.043)	-0.081 (-0.171 to 0.009)	0.14
PBO	MCI Due to AD	111/238	0.169 (0.018)	REF	REF		
	Mild AD	49/238	0.23 (0.036)	REF	REF		

AD: Alzheimer’s disease, ADCOMS: AD Composite Score, Diff: difference, LSM: least squares mean, MCI: mild cognitive impairment, mg/kg: milligram per kilogram, n/N: number/ total number, PBO: placebo, Q2W: every two weeks, Q4W: every four weeks, REF: reference, SE: standard error

**Table D3.14 Subgroup Data – Lecanemab Phase II CDR-SB by Disease Severity**

Trial	Timepoint	Study Arms	Subgroups	CDR-SB			
				n/N	LSM (SE)	LSM Diff (90% CI)	P-Value
<b>Lecanemab</b>							
<b>G000-201 (MMRM Analysis)<sup>86</sup></b>	18 months	2.5 mg/kg Q2W	MCI Due to AD	23/52	0.757 (0.341)	-0.411 (-1.014 to 0.192)	0.262
			Mild AD	11/52	2.242 (0.740)	0.117 (-1.224 to 1.458)	0.885
		5 mg/kg Q4W	MCI Due to AD	30/48	1.402 (0.313)	0.233 (-0.331 to 0.798)	0.496
			Mild AD	6/48	2.634 (0.887)	0.509 (-1.054 to 2.072)	0.591
		5 mg/kg Q2W	MCI Due to AD	39/89	1.08 (0.266)	-0.089 (-0.585 to 0.408)	0.769
			Mild AD	28/89	1.948 (0.500)	-0.177 (-1.166 to 0.812)	0.768

	10 mg/kg Q4W	MCI Due to AD	101/246	1.072 (0.171)	-0.096 (-0.455 to 0.262)	0.658
		Mild AD	48/246	1.578 (0.377)	-0.547 (-1.373 to 0.280)	0.275
	10 mg/kg Q2W	MCI Due to AD	49/152	1.01 (0.230)	-0.159 (-0.603 to 0.286)	0.557
		Mild AD	35/152	1.042 (0.416)	-1.083 (-1.967 to -0.198)	0.044
	PBO	MCI Due to AD	112/238	1.168 (0.162)	REF	REF
		Mild AD	49/238	2.125 (0.354)	REF	REF

AD: Alzheimer's disease, CDR-SB: Clinical Dementia Rating – Sum of Boxes, Diff: difference, LSM: least squares mean, MCI: mild cognitive impairment, mg/kg: milligram per kilogram, n/N: number/ total number, PBO: placebo, Q2W: every two weeks, Q4W: every four weeks, REF: reference, SE: standard error

**Table D3.15 Subgroup Data – Lecanemab Phase II ADAS-Cog 14 by Disease Severity**

Trial	Timepoint	Study Arms	Subgroups	ADAS-Cog 14			
				n/N	LSM (SE)	LSM Diff (90% CI)	P-Value
<b>Lecanemab</b>							
<b>G000-201 (MMRM Analysis)<sup>86</sup></b>	18 months	2.5 mg/kg Q2W	MCI Due to AD	22/52	3.572 (1.428)	-1.061 (-3.571 to 1.450)	0.486
			Mild AD	11/52	9.443 (2.469)	4.083 (-0.367 to 8.532)	0.131
		5 mg/kg Q4W	MCI Due to AD	29/48	5.168 (1.331)	0.535 (-1.840 to 2.910)	0.719
			Mild AD	5/48	6.72 (3.054)	1.360 (-3.980 to 6.699)	0.675
		5 mg/kg Q2W	MCI Due to AD	37/89	4.042 (1.119)	-0.591 (-2.659 to 1.477)	0.638
			Mild AD	24/89	4.891 (1.734)	-0.469 (-3.825 to 2.886)	0.817
		10 mg/kg Q4W	MCI Due to AD	101/246	3.63 (0.722)	1.002 (-2.486 to 0.482)	0.266
			Mild AD	45/246	6.424 (1.294)	1.053 (-1.699 to 3.825)	0.525
		10 mg/kg Q2W	MCI Due to AD	47/152	1.925 (0.968)	-2.707 (-4.559 to -0.855)	0.016
			Mild AD	32/152	3.172 (1.426)	-2.188 (-5.170 to 0.793)	0.227
PBO	MCI Due to AD	112/238	4.633 (0.684)	REF	REF		
	Mild AD	46/238	5.36 (1.216)	REF	REF		

ADAS-Cog 14: Alzheimer's Disease Assessment Scale – Cognitive Subscale 14-item, AD: Alzheimer's disease, Diff: difference, LSM: least squares mean, MCI: mild cognitive impairment, mg/kg: milligram per kilogram, n/N: number/ total number, PBO: placebo, Q2W: every two weeks, Q4W: every four weeks, REF: reference, SE: standard error

**Table D3.16 Subgroup Data – TRAILBLAZER-ALZ P-tau by Amyloid**

Trial	Timepoint	Study Arms	Subgroup	P-tau (pairwise comparison vs Placebo)				P-tau (pairwise comparison vs DNB Amyloid+)		
				n/N	LSM (SE)	LSM Diff (90% CI)	P-Value	LSM Diff (90% CI)	P-Value	
<b>Donanemab</b>										
TRAILBLAZER-ALZ	Week 12	Placebo				REF	REF	NA	NA	
		Donanemab	Amyloid -					REF	REF	
				Amyloid +						
	Week 24	Placebo					REF	REF	NA	NA
		Donanemab	Amyloid -						REF	REF
				Amyloid +						
	Week 36	Placebo					REF	REF	NA	NA
		Donanemab	Amyloid -						NA	NA
				Amyloid +						
	Week 52	Placebo					REF	REF	NA	NA
		Donanemab	Amyloid -						REF	REF
				Amyloid +						
	Week 64	Placebo					REF	REF	NA	NA
		Donanemab	Amyloid -						REF	REF
				Amyloid +						
	Week 76	Placebo					REF	REF	NA	NA
		Donanemab	Amyloid -						REF	REF
				Amyloid +						

All data presented here is data in-confidence provided by Lilly. CI: confidence interval, LSM: least square mean, NA: not applicable, n/N: number/ total number, p-tau: phosphorylated tau, RD: redacted, REF: reference, SE: standard error

**Table D3.17 Subgroup Data – TRAILBLAZER-ALZ Clinical Decline by ApoE Carrier Status**

Trial	Timepoint	Study Arms	Subgroups	Clinical Decline (iADRS)	
				% Reduction	P-value vs. PBO
TRAILBLAZER-ALZ Gueorguieva et al 2022 <sup>45</sup>	Week 76	Donanemab	Overall	28%	<.001
			ApoE ε4 carrier	42%	<.001
			ApoE ε4 noncarrier	NR	NR

ApoE: Apolipoprotein E, iADRS: The Integrated Alzheimer's Disease (AD) Rating Scale, NR: not reported, PBO: placebo, %: percent.

**Table D3.18 Subgroup Data – TRAILBLAZER-ALZ Clearance at 24 weeks**

Trial	Characteristics	Placebo	Donanemab (overall)	Complete clearance at week 24 with donanemab	Partial clearance at week 24 with donanemab
TRAILBLAZER-ALZ Shcherbinin et al 2022 (JAMA Neurology) <sup>39</sup>	<b>Baseline</b>				
	Age, m (SD)	75.29 (5.49), n=120	75.05 (5.56), n=115	76.78 (5.17), n=46	73.90 (5.54), n=69, p=0.006
	MMSE, m (SD)	23.77 (2.88), n=115	23.52 (3.03), n= NR	23.55 (3.08), n=44	23.51 (3.03), n=67, p<0.001
	ADAS-Cog13, m (SD)	27.53 (7.55), n=120	27.81 (7.76), n=115	28.41 (8.32), n=46	27.41 (7.4), n=69, p=ns
	iADRS, m (SD)	106.06 (13.05), n=120	106.31 (12.47), n=115	104.15 (12.89), n=46	107.75 (12.06), n=69, p=ns
	ApoE ε4 carrier, n (%)	88 (73.9%)	85 (73.9%)	36 (78.3%)	49 (71.0%), p=ns
	<b>LS Mean Change in tau SUVR outcomes at week 76</b>				
	Weighted neocortical SUVR, m (SD)	0.10 (0.01), n=84	0.07 (0.1), n=89	0.06 (0.02), n=38	0.07 (0.01), n=50, p=ns
	Occipital SUVR (SD)	0.08 (0.01), n=84	0.06 (0.01), n=89	0.05 (0.01), n=38	0.06 (0.01), n=50, p=ns
	Lateral temporal SUVR (SD)	0.096 (0.01), n=84	0.06 (0.01), n=89	0.05 (0.02), n=38	0.07 (0.01), n=50, p=ns
	Parietal SUVR (SD)	0.09 (0.01), n=84	0.05 (0.01), n=89	0.04 (0.01), n=38	0.05 (0.01), n=50, p=ns
	Frontal SUVR (SD)	0.06 (0.01), n=84	0.02 (0.01), n=89	0.02 (0.01), n=38	0.03 (0.01), n=50, p=ns

<b>Amyloid centiloids, mean (SD)</b>					
Baseline: Amyloid centiloids, mean (SD)	103.09 (33.84), n=112	107.56 (34.03), n=115	92.83 (28.7), n=46	117.38 (33.94), n=69, p=ns	
Week 24: Amyloid centiloids, mean (SD)	102.08 (36.6), n=111	37.07 (30.9), n=115	7.70 (10.85), n=46	56.65 (23.5), n=69, p=ns	
Week 52: Amyloid centiloids, mean (SD)	102.97 (32.8), n=91	24.10 (29.04), n=91	4.28 (11.5), n=38	38.32 (29.5), n=53, p=ns	
Week 76: Amyloid centiloids, mean (SD)	103.86 (35.05), n=91	20.50 (27.98), n=89	4.87 (12.2), n=39	32.76 (30.7) n=50,p=ns	
<b>AD-signature weighted neocortical SUVR, mean (SD)</b>					
Baseline: Weighted neocortical SUVR, m (SD)	1.48 (0.21), n=113	1.50 (0.24), n=112	1.51 (0.26), n=45	1.49 (0.23), n=67, p=ns	
Week 76: Weighted neocortical SUVR, m (SD)	1.57 (0.25), n=84	1.56 (0.26), n=88	1.53 (0.25), n=38	1.58 (0.26), n=50, p=ns	

ADAS-Cog 13: Alzheimer's Disease Assessment Scale – Cognitive Subscale 13-item, ApoE: Apolipoprotein E, iADRS: The Integrated Alzheimer's Disease (AD) Rating Scale, m: mean, MMSE: mini mental state examination, NS: not significant, N: number, NR: not reported, P: p value, SD: standard deviation, SUVR: standardized uptake value ratio

**Table D3.19 Subgroup Data – TRAILBLAZER-ALZ P-tau at 24 weeks**

<b>Trial</b>	<b>Outcome</b>	<b>Placebo</b>	<b>Donanemab (overall)</b>	<b>Donanemab Stopped after 24 weeks</b>	<b>Donanemab Continued after 24 weeks</b>
TRAILBLAZER-ALZ Pontecorvo et al 2022	<b>P-tau (log10 transformed) at week 76</b>				
	P-tau (log10 transformed)	0.023 (0.01), n=82	NR	-0.12 (0.03), n=22	-0.109 (0.02), n=63
	P-tau (log10 transformed) no ARIA-E	0.023 (0.01), n=86	NR	-0.12 (0.03), n=17	-0.139 (0.02), n=45
	<b>P-tau (log10 transformed) mean change at week 76</b>				
	P-tau (log10 transformed)	REF	NR	-0.143 (-0.204, -0.083), p<0.001	-0.1321 (-0.174, -0.09), p<0.001
	P-tau (log10 transformed) no ARIA-E	REF	NR	-0.141 (-0.203, -0.078), p<0.001	-0.162 (-0.204, -0.119), p<0.001

ARIA-E: amyloid-related imaging abnormalities due to edema/effusion, p-tau: phosphorylated tau, N: number, NR: not reported, REF: reference.

**Table D3.20 Subgroup Data – TRAILBLAZER-ALZ 4 Florbetapir PET in Intermediate tau population**

Trial	Outcome	Donanemab	Aducanumab
TRAILBLAZER-ALZ 4 Salloway 2022 CTAD conference 2022 <sup>40</sup>	<b>Florbetapir PET Centiloids at 6 months in intermediate tau population</b>		
	N	26	26
	LS Mean (SE)	-63.9 (7.4)	-25.4 (7.8)
	Difference in mean change (SE)	-64.08 (7.34)	-23.82 (7.70)
	Amyloid Negative, n(%)	10 (35.8)	1 (3.8)
	P-value	0.008	REF

CTAD: Clinical trials on Alzheimer’s Disease, LS: least squares, n: number, PET: Positron Emission Tomography, REF: reference, SE: standard error.

**Table D3.21 Subgroup Data – CLARITY AD Tau Pathology by Brain Region**

Trial	Brain Region	N placebo, N Lecanemab	Adjusted Mean Difference in Tau Pathology	P value
CLARITY AD (CTAD conference 2022) <sup>38</sup>	Medial temporal	122, 135	-0.068	0.0024
	Meta temporal	122, 135	-0.071	0.012
	Temporal	132, 136	-0.065	0.016
	Frontal	122, 135	-0.023	0.22
	Cingulate	132, 135	-0.034	0.13
	Parietal	122, 135	-0.029	0.25
	Occipital	132, 135	-0.003	0.91
	Whole cortical gray matter	122, 443	-0.035	0.1

CTAD: Clinical trials on Alzheimer’s Disease, N: number

**Table D3.22 Subgroup Data – CLARITY AD CDR-SB by Comorbidities and Anticoagulant Use**

Trial	Comorbidities and Anticoagulant Use	N Placebo, N Lecanemab	CDR-SB Placebo Decline	Difference vs. Placebo	% Slowing
CLARITY AD (Cohen et al. CTAD conference 2022)	Overall	875, 859	1.66	-0.45	27
	Hypertension	486, 471	1.56	-0.47	30
	Diabetes	130, 130	1.75	-0.58	33
	Heart disease	131, 142	1.7	-0.88	52
	Hypercholesterolemia	518, 533	1.75	-0.55	32
	Obesity	136, 145	1.38	-0.53	38
	Anticoagulants	72, 80	2.07	-0.74	36

CTAD: Clinical trials on Alzheimer’s Disease, CDR-SB: Clinical Dementia Rating – Sum of Boxes, %: percent, N: number

**Table D3.23 Subgroup Data – CLARITY AD CDR-SB at 18 months by Various Subgroups<sup>28</sup>**

Trial	Subgroups		Adjusted Mean Difference in CDR-SB at 18 months	% Slowing	N Placebo, N Lecanemab
CLARITY AD (van Dyck et al. 2022)	<b>Use of symptomatic AD medication at baseline</b>	Yes	-0.48	25	468, 447
		No	-0.39	28	407, 412
	<b>Clinical subgroup</b>	MCI	-0.35	28	544, 528
		Mild AD	-0.62	27	331, 331
	<b>ApoE ε4 status</b>	Carrier	-0.33	21	600, 592
		Non carrier	-0.75	41	275, 267
	<b>Region</b>	North America	-0.52	34	516, 514
		Asia	-0.33	25	146, 141
		Europe	-0.33	14	213, 204
	<b>ApoE ε4 genotype status</b>	Non-carrier	-0.75	41	275, 267
		Heterozygote	-0.5	30	468, 456
		Homozygote	0.28	-22	132, 136
	<b>Sex</b>	Female	-0.2	12	464, 443

	Male	-0.73	43	411, 416
<b>Age</b>	<65	-0.08	6	178, 166
	65-74	-0.37	23	381, 368
	≥75	-0.72	40	316, 325
<b>Ethnicity</b>	Hispanic	-0.5	52	108, 107
	Non-Hispanic	-0.46	25	743, 715
<b>Race</b>	White	-0.49	27	677, 655
	Asian	-0.35	19	148, 147
	Black	-0.72	63	24, 20
<b>Ethnicity - USA</b>	Hispanic	-0.53	113	99, 100
	Non-Hispanic	-0.58	31	356, 354
<b>Race - USA</b>	White	-0.58	36	431, 431
	Black	-0.55	63	21, 19

AD: Alzheimer's disease, ApoE: Apolipoprotein E, CDR-SB: Clinical Dementia Rating – Sum of Boxes, MCI: mild cognitive impairment, N: number, USA: United States of America

**Table D3.24 Subgroup Data – CLARITY AD ADAS-Cog14 at 18 months by Various Subgroups<sup>28</sup>**

Trial	Subgroups		Adjusted Mean Difference in ADAS-Cog14 at 18 months	% Slowing	N Placebo, N Lecanemab
CLARITY AD (van Dyck et al. 2022)	<b>Use of symptomatic AD medication at baseline</b>	Yes	-2.06	29	466, 445
		No	-0.64	16	406, 409
	<b>Clinical subgroup</b>	MCI	-0.93	23	542, 525
		Mild AD	-2.46	30	330, 329
	<b>ApoE ε4 status</b>	Carrier	-1.11	21	599, 588
		Non carrier	-2.19	35	273, 266
	<b>Region</b>	North America	-1.43	31	514, 512
		Asia	-1.38	25	146, 140
		Europe	-1.71	22	212, 202
	<b>ApoE ε4 genotype status</b>	Non-carrier	-2.19	35	273, 266

		Heterozygote	-1.28	23	467, 453
		Homozygote	-0.53	13	132, 135
<b>Sex</b>		Female	-0.98	18	462, 441
		Male	-1.97	34	410, 413
<b>Age</b>		<65	-0.92	14	177, 165
		65-74	-1.47	29	380, 365
		≥75	-1.67	30	315, 324
<b>Ethnicity</b>		Hispanic	-2.06	387	108, 107
		Non-Hispanic	-1.37	21	740, 711
<b>Race</b>		White	-1.65	28	674, 652
		Asian	-1.46	25	148, 146
		Black	-1.59	280	24, 20
		Hispanic	-2.18	-222	99, 100
<b>Ethnicity - USA</b>		Non-Hispanic	-1.34	21	354, 353
		White	-1.65	33	429, 430
<b>Race - USA</b>		Black	-1.00	209	21, 19

AD: Alzheimer's disease, ADAS-Cog 14: Alzheimer's Disease Assessment Scale – Cognitive Subscale 14-item, ApoE: Apolipoprotein E, MCI: mild cognitive impairment, N: number, USA: United States of America

**Table D3.25 Subgroup Data – CLARITY AD ADCOMS at 18 months by Various Subgroups<sup>28</sup>**

Trial	Subgroups		Adjusted Mean Difference in ADCOMS at 18 months	% Slowing	N Placebo, N Lecanemab
CLARITY AD (van Dyck et al. 2022)	<b>Use of symptomatic AD medication at baseline</b>	Yes	-0.058	23	468, 446
		No	-0.039	22	407, 411
	<b>Clinical subgroup</b>	MCI	-0.042	25	544, 527
		Mild AD	-0.067	23	331, 330
	<b>ApoE ε4 status</b>	Carrier	-0.041	20	600, 590
		Non carrier	-0.072	32	275, 267
	<b>Region</b>	North America	-0.048	26	516, 513
		Asia	-0.05	24	146, 141

	Europe	-0.049	17	213, 203
<b>ApoE ε4 genotype status</b>	Non-carrier	-0.072	32	275, 267
	Heterozygote	-0.056	25	468, 454
	Homozygote	0.009	-5	132, 136
<b>Sex</b>	Female	-0.022	10	464, 442
	Male	-0.082	38	411, 415
<b>Age</b>	<65	-0.009	5	178, 166
	65-74	-0.049	25	381, 367
	≥75	-0.075	31	316, 324
<b>Ethnicity</b>	Hispanic	-0.052	44	108, 107
	Non-Hispanic	-0.049	21	743, 714
<b>Race</b>	White	-0.050	22	677, 654
	Asian	-0.053	19	148, 147
	Black	-0.041	30	24, 20
<b>Ethnicity - USA</b>	Hispanic	-0.051	103	99, 100
	Non-Hispanic	-0.052	23	356, 353
<b>Race - USA</b>	White	-0.054	28	431, 430
	Black	-0.019	20	21, 19

AD: Alzheimer's disease, ADCOMS: AD Composite Score, ApoE: Apolipoprotein E, MCI: mild cognitive impairment, N: number, USA: United States of America

**Table D3.26 Subgroup Data – CLARITY AD ADAS-MCI-ADL at 18 months by Various Subgroups<sup>28</sup>**

Trial	Subgroups		Adjusted Mean Difference in ADAS-MCI-ADL at 18 months	% Slowing	N Placebo, N Lecanemab
CLARITY AD (van Dyck et al. 2022)	<b>Use of symptomatic AD medication at baseline</b>	Yes	2.39	37	423, 404
		No	1.53	33	373, 379
	<b>Clinical subgroup</b>	MCI	1.64	38	499, 492
		Mild AD	2.71	38	297, 291
	<b>ApoE ε4 status</b>	Carrier	1.72	33	551, 549
		Non carrier	2.73	47	245, 234
	<b>Region</b>	North America	1.9	42	473, 473
		Asia	1.31	23	130, 121

	Europe	2.76	41	193, 189
<b>ApoE ε4 genotype status</b>	Non-carrier	2.73	47	245, 234
	Heterozygote	1.97	36	430, 422
	Homozygote	1.03	25	121, 127
<b>Sex</b>	Female	1.01	19	416, 399
	Male	3.17	54	380, 384
<b>Age</b>	<65	1.28	26	166, 151
	65-74	2.02	38	356, 343
	>=75	1.48	40	274, 289
<b>Ethnicity</b>	Hispanic	2.22	92	95, 95
	Non-Hispanic	1.98	33	677, 653
<b>Race</b>	White	2.20	40	616, 604
	Asian	1.26	23	132, 127
	Black	1.08	184	22, 17
<b>Ethnicity - USA</b>	Hispanic	1.92	318	86, 90
	Non-Hispanic	2.29	40	329, 325
<b>Race - USA</b>	White	2.23	45	392, 395
	Black	1.5	-221	20, 16

AD: Alzheimer's disease, ADCS MCI-ADL: Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory (MCI version), ApoE: Apolipoprotein E, MCI: mild cognitive impairment, N: number, USA: United States of America.

**Table D3.27 Subgroup Data – CLARITY AD CDR-SB Sensitivity Analyses<sup>44</sup>**

Trial	CDR-SB Sensitivity Analyses	Adjusted Mean Change from Baseline at 18 Months (Placebo)	Adjusted Mean Change from Baseline at 18 Months (Lecanemab)	Treatment Difference at 18 Months (95% CI), p value
CLARITY AD (CTAD conference 2022)	Rank ANCOVA with missing data imputed via mITT	NA	NA	-0.456 (95% CI: -0.737, -0.176), p<0.001
	MMRM repeated on all randomized subjects (ITT)	1.659	1.225	-0.434 (95% CI: -0.644, -0.224), p<0.001

	Primary MMRM repeated censoring assessments after ARIA-E	1.672	1.169	-0.503 (95% CI: -0.726, -0.279), p<0.001
	Primary MMRM repeated to evaluate the impact of COVID-19	1.603	1.208	-0.394 (95% CI: -0.613, -0.176), p<0.001

ARIA-E: amyloid-related imaging abnormalities due to edema/effusion, CDR-SB: Clinical Dementia Rating – Sum of Boxes, CI: confidence interval, ITT: intent-to-treat analysis, mITT: modified intent-to-treat analysis, MMRM: mixed models for repeated measure, NA: not applicable

**Table D3.28 Subgroup Data – CLARITY AD CDR-SB Subdomains<sup>37</sup>**

Trial	CDR-SB Subdomains	N Placebo, N Lecanemab	Adjusted Mean Difference	% Slowing	P value
CLARITY AD (Cohen et al. 2022 CTAD conference)	Memory	875, 859	-0.077	27.5	0.0012
	Orientation	875, 859	-0.081	28.1	0.0004
	Judgement/Problem Solving	875, 859	-0.053	23.6	0.01
	Community Affairs	875, 859	-0.07	21.2	0.005
	Home and Hobbies	875, 859	-0.098	28.8	0.0002
	Personal Care	875, 859	-0.067	29.9	0.013

CTAD: Clinical trials on Alzheimer’s Disease, CDR-SB: Clinical Dementia Rating – Sum of Boxes, N: number, %: percent.

**Table D3.29 Correlations**

Trial		TRAILBLAZER ALZ		G000-201			
Source		Pontecorvo et al. 2022 <sup>41</sup>		Swanson et al. CTAD conference 2021 <sup>90</sup>			
Study Arms		DNB	PBO	10 mg/kg monthly	10 mg/kg biweekly	PBO	Pooled 10 mg/kg
Baseline N		131	126	246	152	238	398
<b>Correlations</b>							
Change in ADCOMS vs change in PET SUVR at 18 months (population level)	R	NR	NR	NR	0.832	NR	NR
	P-value	NR	NR	NR	p=0.08	NR	NR
	R	NR	NR	NR	0.199	NR	NR

Change in ADCOMS vs change in PET SUVr at 18 months (individual level)	P-value	NR	NR	NR	p=0.036	NR	NR
Change in ADCOMS vs change in Plasma A $\beta$ 42/40 at 18 months (population level)	R	NR	NR	NR	-0.306	NR	NR
	P-value	NR	NR	NR	NS	NR	NR
Change in ADCOMS vs change in Plasma A $\beta$ 42/40 at 18 months (individual level)	R	NR	NR	NR	-0.208	NR	NR
	P-value	NR	NR	NR	p=0.05	NR	NR
Change in iADRS at week 76 and p-tau	N	170		NR	NR	NR	NR
	R	-0.04		NR	NR	NR	NR
	P-value	p=0.61		NR	NR	NR	NR
Change in iADRS at week 76 and NfL	N	177		NR	NR	NR	NR
	R	-0.18		NR	NR	NR	NR
	P-value	p=0.02		NR	NR	NR	NR
Change in iADRS at week 76 and A $\beta$ 42/40	N	135		NR	NR	NR	NR
	R	-0.076		NR	NR	NR	NR
	P-value	p=0.38		NR	NR	NR	NR

ADCOMS: AD Composite Clinical Outcome, A $\beta$ : beta-amyloid, DNB: donanemab, iADRS: Integrated Alzheimer's Disease (AD) Rating Scale, mg/kg: milligram / kilogram, NfL: neurofilament light, NR: not reported, NS: not significant, PBO: placebo, PET: Positron Emission Tomography, p-tau: Phosphorylated tau, R: Regression coefficient, SUVr: Standardized uptake value ratio

## D4. Ongoing Studies

Table D3.30. Ongoing Studies

Title / Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Dates
Donanemab					
A Study of Donanemab in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)  Eli Lilly & Co  <a href="https://clinicaltrials.gov/ct2/show/study/NCT04437511">NCT04437511</a>	Phase III, DB, PC, RCT with LTE	Donanemab Placebo  N= 1800	Inclusion - 60 to 85 years - Gradual change in memory function > 6 months - MMSE score of 20 to 28 - Meet 18F PET criteria Exclusion - Contradiction to MRI or PET scans - Current treatment with IgG Therapy	Change from baseline in iADRS at week 76	August 22, 2025  <i>Estimated primary completion: April 14, 2023</i>
A Donanemab Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)  Eli Lilly & Co  <a href="https://clinicaltrials.gov/ct2/show/study/NCT05026866">NCT05026866</a>	Phase III, DB, PC, RCT	Donanemab Placebo  N= 3300	Inclusion - 55 to 80 years - Telephone interview for cognitive status - Adequate vision, literacy, and hearing Exclusion - MCI or dementia - Current serious or unstable illnesses - History of cancer with high risk of recurrence - Any clinically important abnormality - Conflicting MRI - Previous treatment with anti-amyloid therapy	Time to clinical progression as measured by CDR-GS at 182 weeks	September 25, 2027

<p>A Study of Donanemab Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)</p> <p>Eli Lilly &amp; Co</p> <p><a href="https://clinicaltrials.gov/ct2/show/study/NCT05108922">NCT05108922</a></p>	<p>Phase III, OL, Head to head, parallel group</p>	<p>Donanemab Aducanumab</p> <p>N= 200</p>	<p>Inclusion</p> <ul style="list-style-type: none"> <li>- 50 to 85 years</li> <li>- Gradual change in memory function &gt;6 months</li> <li>- CDR of 0.5 or 1</li> <li>- MMSE score between 20 and 30</li> <li>- Adequate vision, literacy, hearing</li> </ul> <p>Exclusion</p> <ul style="list-style-type: none"> <li>- Significant neurological disease other than AD</li> <li>- Current serious or unstable illnesses</li> <li>-Bleeding disorder</li> <li>-Prior treatment with donanemab or aducanumab</li> </ul>	<p>Percentage of participants who complete PET scan on donanemab vs. aducanumab at 6 months</p> <p>Percentage of participants who complete PET scan in the intermediate subpopulation on donanemab vs. aducanumab at 6 months</p>	<p>June 17, 2023</p> <p><i>Estimated primary completion date: June 17, 2022*</i></p> <p><i>*Preliminary results were presented at CTAD 2022 in November.</i></p>
<p>A Follow-On Study of Donanemab With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)</p> <p>Eli Lilly &amp; Co</p> <p><a href="https://clinicaltrials.gov/ct2/show/study/NCT04640077">NCT04640077</a></p>	<p>Phase II, OL</p>	<p>Part A: Group 1: Cognitive/functional scale assessment at the study site followed by an at-home assessment</p> <p>Group 2: Cognitive/functional scale assessment at home followed by assessment on-site</p> <p>Part B: donanemab</p>	<p>Inclusion</p> <ul style="list-style-type: none"> <li>- 60 to 90</li> <li>- Participated in a double-blind treatment period of a sponsor-approved originating donanemab trial</li> <li>- Have a study partner</li> <li>- Stable symptomatic AD medications</li> </ul> <p>Exclusion</p> <ul style="list-style-type: none"> <li>-Current serious or unstable illnesses</li> <li>- Have received treatment with a passive anti-amyloid immunotherapy after completion of originating donanemab study or received active immunization against A<math>\beta</math> in any other study.</li> <li>- Poor venous access</li> <li>- Contraindication to PET or MRI imaging</li> </ul>	<p>Part A: correlation between VTC and onsite assessment for PAIR 1 in ADAS-Cog 13, ADCS-ADL, MMSE, CDR-SB (1 month)</p> <p>Part B: Adverse events.</p>	<p>October 24, 2023</p> <p><i>Estimated primary completion date: May 9, 2023</i></p>

Lecanemab					
<p>A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (AHEAD 3-45)</p> <p>Eisai &amp; Biogen</p> <p><a href="#">NCT04468659</a></p>	Phase III, QB, RCT	Lecanemab (5 mg/kg + 10 mg/kg biweekly and 5 mg/kg +10 mg/kg monthly,) or PBO for up to 216 weeks.	<p>Inclusion</p> <ul style="list-style-type: none"> <li>- aged 55 to 80 years</li> <li>- 55 to 64 must have additional risk factors such as first degree relative diagnosed with dementia, possesses at least 1 ApoE ε4</li> <li>- CDR score of 0</li> <li>- MMSE score &gt;= 27</li> <li>- WMS-R LM II &gt;6</li> </ul> <p>Exclusion:</p> <ul style="list-style-type: none"> <li>- history of ischemic attacks, psychiatric diagnosis or symptoms that could interfere with study procedures</li> <li>- HIV positive</li> </ul>	Change in PACC5, change in PET at week 216 weeks	October 25, 2027
<p>A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease (Phase II G000-201)</p> <p>Eisai &amp; Biogen</p> <p><a href="#">NCT01767311</a></p>	Phase IIb, MC, DB, PC, OLE	OLE: Off-treatment period (9-59 months, average 24 months) before re-initiating treatment (10 mg/kg biweekly) for 60 months.	<p>Inclusion</p> <ul style="list-style-type: none"> <li>- AD due to MCI or mild AD dementia</li> <li>- confirmed amyloid positive via PET or CSF</li> <li>- impairment in episodic memory (WMS-IV LMII)</li> <li>- MMSE &gt; 22</li> <li>- naïve or stable dose of approved AD medications</li> </ul> <p>Exclusion:</p> <ul style="list-style-type: none"> <li>- Any medical or neurological condition (other than AD) that might be a contributing cause of the subject's cognitive impairment</li> </ul>	OLE: Safety data, MRI assessments of amyloid related to imaging abnormalities, and change from baseline in biomarkers up to 60 months	OLE extension ongoing estimated completion by February 20, 2025. Interim results have been presented.

			<ul style="list-style-type: none"> <li>- Have had a stroke or Transient Ischemic Attack, stroke, or seizures in the past 1 year</li> <li>- Any psychiatric diagnosis or symptoms that could interfere with study procedures</li> <li>- GDS score &gt;=8</li> <li>- Contraindications to MRI scanning</li> <li>- Evidence of other clinically significant lesions that could indicate a dementia diagnosis other than AD</li> <li>- Prolonged QT/QTc interval via ECG</li> <li>- Other medical conditions that could prevent patient performing tests accurately</li> </ul>		
--	--	--	--	--	--

AD: Alzheimer’s disease, ADAS-Cog13: Alzheimer’s Disease Assessment Scale - Cognitive Subscale, ADCS-ADL: Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory, ALZ: Alzheimer’s, ApoE ε4: Apolipoprotein ε4, CDR-GS: Clinical Dementia Rating - Global Score, CDR-SB: Clinical Dementia Rating Scale-Sum of Boxes, CNS: central nervous system, CSF: cerebrospinal fluid, DB: double blind, ECG: electrocardiogram, GDS: Geriatric Depression Scale, iADRS: integrated Alzheimer’s Disease Rating Scale, LTE: long term extension, MC: multicenter, MMSE: Mini-Mental State Examination, MRI: magnetic resonance imaging, OLE: open-label extension, PC: placebo-controlled, PET: Positron Emission Tomography, RCT: randomized controlled trial, OL: open label, VTE: video teleconference. Source: [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (NOTE: studies listed on site include both clinical trials and observational studies)

## D5. Previous Systematic Reviews and Technology Assessments

We identified one ongoing health technology assessment (HTA) conducted by NICE and two previously conducted systematic literature reviews (SLR). Both are summarized below.

### NICE

[Gantenerumab for Treatment Early Alzheimer's Disease \[ID 10668\]](#)

As of June 2022, NICE is awaiting development to conduct an appraisal of the clinical and cost-effectiveness of gantenerumab for the treatment of MCI in early AD.

### **Pang, M. et al. (2022). "Effect of Reduction in Brain Amyloid Levels on Change in Cognitive and Functional Decline in Randomized Clinical Trials: An Instrumental Variable Meta-Analysis"<sup>107</sup>**

Investigators reviewed the data of a 2021 variable meta-analysis<sup>108</sup> that tested the amyloid hypothesis and resolved data quality issues in an update to ascertain the impact of the reduction in amyloid beta on clinical outcome measures in Alzheimer's disease. In addition to the 14 RCTs from the original publication, Pang et al. included data from the aducanumab-3 PRIME trial and the donanemab TRAILBLAZER-ALZ trial. The authors addressed several consistency issues from the original analysis regarding 12 of the 14 trials related to standard errors and misattributed data points. The included interventions and population characteristics have been summarized previously.<sup>23</sup>

The primary outcome of this analysis was the change in CDR-SB, ADAS-Cog, and MMSE, using the same representation of effect as the original meta-analysis. Sensitivity analyses were performed for 1) all published data, 2) only antibody data, and 3) only published antibody data. In the updated analysis, pooled results for "all data" showed statistically significant evidence of a causal relationship between a reduction in amyloid plaque and a reduction in cognitive and functional decline measured by CDR-SB (0.09; 95% CI: 0.034- 0.15; p=0.0016). This was an improved result over the original meta-analysis, and the sensitivity analyses performed showed similar estimates. There were additional statistically significant causal effects for ADAS-Cog (0.33; 95% CI: 0.12 – 0.55; p=0.0025) and MMSE (0.13; 95% CI, 0.017- 0.24; p=0.024). The investigators conclude that amyloid plaque is still the best target for the prevention and treatment of AD.

While the study addresses the issues of bias, and the addition of updated data improves the statistical precision of the estimated effect of treatment, there are still limitations to this study. The participants included in the various trials are at different stages of cognitive decline and amyloid beta positivity was not a defined inclusion criterion for many of the included studies. Additionally,

not much is known about the relationship between amyloid deposits and cognitive and functional decline. Outcomes such as the change in SUVR may not adequately measure the relationship.

**Villain, N. et al. (2022). “High-clearance Anti-amyloid Immunotherapies in Alzheimer’s Disease. Part 1: Meta-analysis and Review of Efficacy and Safety Data, and Medicoeconomical Aspects”<sup>109,110</sup>**

Investigators reviewed the currently available evidence on the biological and clinical efficacy of high-clearance anti-amyloid immunotherapies in Alzheimer’s disease. Using the data available from high-dose aducanumab (ENGAGE and EMERGE), donanemab (TRAILBLAZER-ALZ), high-dose lecanemab (G000-201 and CLARITY AD), and gantenerumab (GRADUATE 1 & 2), the investigators performed a meta-analysis on two cognitive measures (CDR-SB, ADAS-Cog). Data from CLARITY AD and GRADUATE 1 and 2 were only included in the CDR-SB and ARIA-E analyses. MMSE was not available for lecanemab.

The meta-analysis results concluded that there was a significant effect of high clearance amyloid therapies on disease progression for CDR-SB (mean difference: -0.31; 95% CI: -0.50, -0.11;  $p=0.002$ ), ADAS-Cog (mean difference: -1.25; 95% CI: -1.93, -0.57;  $p<0.001$ ) but not for MMSE (mean difference: 0.31; 95% CI: -0.19, 0.82;  $p=0.23$ ). These results were confirmed with fixed effects and Bayesian analyses and when assessed based on disease severity (MCI and mild AD) the improvements were maintained. While the results for CDR-SB support the theory that high-clearance anti-amyloid immunotherapies have a statistically significant effect after 18-27 months, the effect did not reach the established minimal clinically important difference (-1.63, -0.98). To address safety concerns, the investigators also performed a meta-analysis on ARIA. ARIA occurred at a significantly higher rate for participants on high-clearance anti-amyloid therapies, with the highest magnitude of the effect occurring for ARIA-E (RR = 10.98; 95% CI: 7.06- 17.08;  $p<0.001$ ). Despite in-trial monitoring and management, safety remains a concern.

The investigators maintain that a meta-analysis should not replace the FDA’s gold standard for approval, however, the results do confirm the trend regarding high-clearance anti-amyloid therapy’s efficacy in removing amyloid. Additionally, the risk/benefit ratio for this class of drugs is still unknown and additional research needs to be done to identify responders. Longer follow-up data is also needed to improve their clinical relevance.

# E. Long-Term Cost-Effectiveness: Supplemental Information

## E1. Detailed Methods

**Table E1. Impact Inventory**

Sector	Type of Impact (Add additional domains, as relevant)	Included in This Analysis from [...] Perspective?		Notes on Sources (if quantified), Likely Magnitude & Impact (if not)
		Health Care Sector	Societal	
<b>Formal Health Care Sector</b>				
Health Outcomes	Longevity effects	X	X	
	Health-related quality of life effects	X	X	
	Adverse events	X	X	
Medical Costs	Paid by third-party payers	X	X	
	Paid by patients out-of-pocket	X	X	
	Future related medical costs	X	X	
	Future unrelated medical costs	X	X	
<b>Informal Health Care Sector</b>				
Health-Related Costs	Patient time costs	NA	<input type="checkbox"/>	
	Unpaid caregiver-time costs	NA	X	
	Transportation costs	NA	<input type="checkbox"/>	
<b>Non-Health Care Sector</b>				
Productivity	Labor market earnings lost	NA	X	
	Cost of unpaid lost productivity due to illness	NA	X	
	Cost of uncompensated household production	NA	<input type="checkbox"/>	
Consumption	Future consumption unrelated to health	NA	<input type="checkbox"/>	
Social services	Cost of social services as part of intervention	NA	<input type="checkbox"/>	
Legal/Criminal Justice	Number of crimes related to intervention	NA	<input type="checkbox"/>	
	Cost of crimes related to intervention	NA	<input type="checkbox"/>	
Education	Impact of intervention on educational achievement of population	NA	<input type="checkbox"/>	
Housing	Cost of home improvements, remediation	NA	<input type="checkbox"/>	

Environment	Production of toxic waste pollution by intervention	NA	<input type="checkbox"/>	
Other	Other impacts (if relevant)	NA	<input type="checkbox"/>	

NA: not applicable

Adapted from Sanders et al<sup>111</sup>

## Target Population

The model included a hypothetical cohort of individuals with MCI due to AD or mild AD entering the model and receiving either the intervention or comparator treatments. In alignment with the clinical evidence, the starting population for the economic evaluation included adults with early AD, defined as MCI due to AD or mild AD. Consistent with population estimates, slightly more than half (55%) of the cohort started in the MCI due to AD health state, with the remaining cohort (45%) starting in the mild AD health state. Individuals could progress to more severe AD health states over the model time horizon. The majority of the cohort (92%) started the model in a community setting of care.

Table E2 details the baseline patient characteristics for the model. Age influenced mortality and quality of life; sex influenced mortality. The baseline clinical stage and setting of care determined which health state and setting of care an individual started the model in.

**Table E2. Base-Case Model Cohort Characteristics**

	Value	Source	Notes
<b>Mean Age, years</b>	72 years	Mintun et al., 2021 <sup>29</sup> & van Dyck et al., 2022 <sup>28</sup>	Weighted average based on sample size of trials
<b>Female, %</b>	52%		
<b>Clinical Stage, %</b> MCI Due to AD Mild AD	55% 45%	Potashman et al., 2020 <sup>112</sup>	AD population with underlying amyloid-beta pathology
<b>Setting of Care, %</b> Community Long-Term Care	92% 8%	Johnson, 2019 <sup>113</sup>	Percent of population ages 65-74 who received long-term services and supports

AD: Alzheimer's disease, MCI: mild cognitive impairment

## Treatment Strategies

The list of interventions was developed with input from patient organizations, clinicians, and manufacturers on which treatments to include. Donanemab and lecanemab were identified as interventions to be included in the economic evaluation. Each treatment was evaluated in addition to supportive care, which could include non-pharmacologic and pharmacologic, but not disease-modifying, interventions. The comparator was supportive care alone.

## E2. Model Inputs and Assumptions

Table E3 reports model assumptions along with their rationale that are important to consider when interpreting the findings.

**Table E3. Key Model Assumptions**

Assumption	Rationale
The treatments were effective at slowing the progression of disease while a patient had MCI due to AD or mild AD. The treatments were no longer effective once a patient reached moderate AD.	The evidence on clinical outcomes that exists for these treatments is in early AD. Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts suggested there is likely no effect with these treatments at reducing disease progression once a patient has reached moderate AD. This assumption was tested in scenario analyses.
Donanemab’s effectiveness on slowing the progression of disease was equivalent to lecanemab’s effectiveness on slowing the progression of disease.	There is no evidence for donanemab on how donanemab influences the progression to the next stage of dementia. Evidence for lecanemab suggests a hazard ratio of 0.69 for the progression to the next stage of dementia. The hazard ratio for lecanemab is similar to the relative change in the primary endpoint for donanemab; therefore, we are making a very big and very optimistic assumption that donanemab’s effectiveness on slowing progression to the next stage of dementia is the same as lecanemab. Further research must be conducted to determine donanemab’s effectiveness on slowing progression of disease before a health benefit price benchmark can be calculated for donanemab.
Individuals stopped receiving lecanemab treatment once they reached moderate AD.	Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts suggested there is likely no effect with these treatments at reducing disease progression once a patient has reached moderate AD, and therefore in our model, treatment stopped once a patient reached moderate AD. In a scenario analysis, we modeled individuals stopping treatment once they reached severe AD. Robust evidence is lacking on a treatment’s effect on clinical outcomes after a patient has stopped the treatment, and thus no additional clinical benefit was assumed after a patient stopped treatment.
Individuals stopped receiving donanemab treatment once they reached complete amyloid clearance or moderate AD, whichever happened first.	The mechanism of action for donanemab suggests that stopping treatment at the point of amyloid clearance could be a reasonable strategy. From currently available evidence on complete amyloid clearance following treatment with donanemab, we modeled 60% of individuals treated with donanemab stopped treatment within the first model cycle and 68% stopped treatment within the second model cycle. <sup>29</sup> Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts suggested there is likely no effect with these

	<p>treatments at reducing disease progression once a patient reached moderate AD, and therefore in our model, treatment stopped once a patient reached moderate AD. Alternative treatment stopping scenarios for donanemab were explored in scenario analyses.</p>
<p>Donanemab’s effectiveness on slowing progression of disease was applied throughout MCI due to AD and mild AD for those who stopped treatment due to achieving complete amyloid clearance.</p>	<p>If donanemab’s effectiveness is driven by its ability to achieve amyloid clearance, then the benefit could persist even while off treatment so long as amyloid remains cleared. Modeling continued treatment benefit even while off treatment but will complete amyloid clearance is a very big and very optimistic assumption. Further research must be conducted to determine donanemab’s effectiveness for those that stop treatment due to complete amyloid clearance before a health benefit price benchmark for donanemab can be calculated.</p>
<p>Individuals who stopped receiving treatment with donanemab due to complete amyloid clearance restarted donanemab once amyloid was detected again and if they had not reached moderate AD. The second course of donanemab was modeled as a fixed duration of 6 months.</p>	<p>The mechanism of action for donanemab suggests a patient would start donanemab again once they had detectable amounts of amyloid again. Modeling projections suggested that it would take approximately four years for a patient treated with donanemab to the point of amyloid clearance to reach detectable amounts of amyloid again.<sup>39</sup> The second course of donanemab was modeled as a fixed duration of 6 months given the lower levels of amyloid at the restart period as compared to baseline.</p>
<p>Donanemab’s adverse-event related discontinuation was from the available Phase II evidence.</p>	<p>Early evidence for TRAILBLAZER 4 suggests much lower adverse-event related discontinuation than what was observed in the Phase II evidence; however, the early evidence for TRAILBLAZER 4 on adverse-event related discontinuation could not be used because there were no clinical outcomes presented and it was only for six months. A lower discontinuation rate for donanemab would result in less favorable cost-effectiveness estimates for donanemab because it would increase the treatment costs over the time horizon. Updated discontinuation evidence from the Phase III trial is needed for donanemab before a health benefit price benchmark can be calculated.</p>

All occurrences of ARIA and its associated consequences (on cost, quality of life, and treatment discontinuation) was modeled in the first year of treatment.	ARIA has been observed as an adverse event for many studied treatments that target aggregated beta-amyloid. Consistent findings across these studies suggest ARIA occurs early in the treatment course.
Caregiver impacts were incorporated in the societal perspective.	The health care system perspective included the patient's cost and outcomes.
Long-term care costs were incorporated in the health care system perspective.	The health care system perspective included the cost and outcomes of the patient.
Caregiver impacts were modeled as if each patient had one primary caregiver.	Evidence on caregiver impacts was collected from a single, primary caregiver.

AD: Alzheimer's disease, ARIA: amyloid-related imaging abnormality, CDR-SB: Clinical Dementia Rating-Sum of Boxes, MCI: mild cognitive impairment

## Model Inputs

Model inputs were identified from best-available evidence and stakeholder engagement. The primary clinical inputs included the transition probabilities among alive health states, mortality, progressions to long-term care, treatment efficacy, the occurrence of adverse events, and discontinuation. Utility estimates were retrieved for both the patient and caregiver. The primary cost inputs included intervention acquisition costs, administration costs, monitoring costs, adverse event costs, long-term care costs, and other patient medical and pharmacy costs. Costs to inform the societal perspective included patient productivity, caregiver productivity, and caregiver health care costs.

### *Clinical Inputs*

#### *Transition Probabilities Between Alive Health States*

Table E4 provides the annual transition probabilities between each of the alive health states. These estimates were from a recent analysis of AD progression using data from beta-amyloid positive individuals in the National Alzheimer's Coordinating Center database.<sup>114</sup> Due to differences in age and sex (two characteristics that influence mortality) between the sample from the National Alzheimer's Coordinating Center and our baseline population characteristics described above, we calculated probabilities of transitioning to each health state conditioned on if an individual was alive. The calculation of these conditional probabilities normalizes the annual transition probabilities to be applied to our modeled population. The annual transition probabilities reported in Table E4 are the conditional probabilities and will be applied given the individual does not die in the model cycle.

**Table E4. Transition Probabilities**

	MCI Due to AD	Mild AD	Moderate AD	Severe AD	Source
<b>MCI Due to AD</b>	77%	23%	0%	0%	Potashman et al., 2020 <sup>114</sup>
<b>Mild AD</b>	3%	58%	35%	4%	
<b>Moderate AD</b>	0%	3%	55%	42%	
<b>Severe AD</b>	0%	0%	2%	98%	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

### Mortality

For each cycle, a risk of death was assigned based on age, sex, and health state occupancy. Age and sex-adjusted mortality served as the foundation for transitions to the dead health state, with an increased risk of death associated with AD dependent on the severity of AD. Age- and sex-adjusted mortality was sourced from US-specific life tables. Table E5 provides the relative risk of death from each health state. These relative risks were multiplied by the age- and sex-adjusted mortality for each model cycle.

**Table E5. Relative Risk of Death Based on Severity of Dementia**

	Value	Source	Notes
<b>MCI Due to AD</b>	1.82	Andersen et al., 2010 <sup>115</sup>	Multiplied by age- and sex-adjusted all-cause mortality
<b>Mild AD</b>	2.92		
<b>Moderate AD</b>	3.85		
<b>Severe AD</b>	9.52		

AD: Alzheimer’s disease, MCI: mild cognitive impairment

### Progressions to Long-Term Care

Specific to each health state, the model tracked the setting of care (e.g., community or long-term care). Individuals with AD could progress from community to long-term care; however, once in long-term care, they remained there until death. Table E6 provides the annual probability of progressing to long-term care specific to each alive health state. These estimates are from an analysis that used Consortium to Establish a Registry for Alzheimer’s Disease data.<sup>51</sup>

**Table E6. Annual Transition Probabilities to Long-Term Care**

	Value	Source
<b>MCI Due to AD</b>	2.4%	Calculated based on the reported mild AD annual transition probability and the relationship between the relative risk of death for MCI due to AD and mild AD Neumann et al., 1999 <sup>51</sup>
<b>Mild AD</b>	3.8%	
<b>Moderate AD</b>	11.0%	
<b>Severe AD</b>	25.9%	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

## Treatment Effectiveness

We assumed that donanemab and lecanemab influenced disease progression from the MCI due to AD and mild AD health states. The evidence on clinical outcomes that exists for these treatments is in early AD. Based on trials of anti-amyloid therapies suggesting no benefit in moderate AD, clinical experts suggested there is likely no effect with these treatments at reducing disease progression once a patient has reached moderate AD. We used best available evidence to estimate the effect of donanemab and lecanemab on slowing disease progression from these health states.

The most relevant clinical evidence for the model include the rates of transitions among health states defined by AD severity. For lecanemab, Phase III evidence existed on the progression to the next stage of dementia. That evidence served as the best available evidence to estimate the effect of these treatments on slowing disease progression from MCI due to AD and mild AD. We assumed donanemab's effectiveness on slowing the progression of disease was equivalent to lecanemab's effectiveness on slowing the progression of disease because there was no evidence for donanemab on how donanemab influences the progression to the next stage of dementia. The hazard ratio for lecanemab for the progression to the next stage of dementia was similar to the relative change in the primary endpoint for donanemab; therefore, we made a very optimistic assumption that donanemab's effectiveness on slowing progression to the next stage of dementia was the same as lecanemab's effectiveness on slowing progression to the next stage of dementia.

Table E7 presents the estimates of treatment effectiveness we used in the model. These treatment effectiveness estimates were applied to the transition probabilities associated with disease progression reported in Table E4.

**Table E7. Treatment Effectiveness\* on Slowing Progression**

Health State	Donanemab	Lecanemab	Notes
MCI Due to AD	0.69	0.69	Equivalent to lecanemab's hazard ratio for slowing the progression of disease
Mild AD	0.69	0.69	
Moderate AD	1.00	1.00	Patient stopped treatment at moderate AD
Evidence Source	van Dyck et al., 2022 <sup>28</sup>		

AD: Alzheimer's disease, CDR-SB: Clinical Dementia Rating-Sum of Boxes, MCI: mild cognitive impairment

\*Only applied to health state progressions (i.e., transitions to more severe health states).

## Adverse Events

An important adverse event associated with beta-amyloid antibodies is the occurrence of amyloid-related imaging abnormalities (ARIA). ARIA typically occurs early in the treatment course and is often not associated with any symptoms. Table E8 presents the probability of ARIA events for each

treatment. We modeled that all ARIA occurred in the first model cycle. Later sections of this Supplement detail how the occurrence of these events influenced cost and quality of life. We did not model a risk of death from an ARIA event, but this is an important area for future research.

**Table E8. Adverse Events**

Parameter	Donanemab	Lecanemab
<b>Probability of Any ARIA</b>	36.4%*	21.5%
<b>Probability of Symptomatic ARIA</b>	5.2%*	3.5%
<b>Source</b>	Mintun et al., 2021 <sup>29</sup> & TRAILBLAZER 4 <sup>40</sup>	van Dyck et al., 2022 <sup>28</sup>

ARIA: amyloid-related imaging abnormalities

\*Calculated based on a weighted (by sample size) average from the two sources after adjusting the TRAILBLAZER-4 evidence beyond six months

### Discontinuation

Evidence on discontinuation due to adverse events from the pivotal trials was used to estimate discontinuation over the first 12 months on treatment. We assumed individuals discontinued donanemab and lecanemab due to adverse events halfway through the first model cycle (i.e., six months after starting treatment), in alignment with evidence that most serious adverse events occurred within the first six months of initiating the treatment. No discontinuation due to adverse events was assumed after the first year due to consistent findings that ARIA occurs at the beginning of the treatment course. Table E9 presents the treatment discontinuation rates due to adverse events reported in both pivotal trials. Importantly, the AE-related discontinuation of treatment for donanemab is from the Phase II trial. Early evidence for TRAILBLAZER 4 suggests much lower AE-related discontinuation. A lower discontinuation rate for donanemab would result in less favorable cost-effectiveness estimates for donanemab because it would increase the treatment costs over the time horizon. Updated discontinuation evidence from Phase III trials is needed for donanemab before a ceiling price can be determined.

**Table E9. Treatment Discontinuation**

Parameter	Donanemab	Lecanemab
<b>AE-related Discontinuation of Treatment</b>	30.5%	6.9%
<b>Source</b>	Mintun et al., 2021 <sup>29</sup>	van Dyck et al., 2022 <sup>28</sup>

AE: adverse event

Separate from discontinuation due to adverse events, treatment stopped once a patient reached moderate AD. Stakeholders suggested there is likely no effect with these treatments at reducing disease progression once a patient has reached moderate AD, and therefore, treatment could discontinue. Given the mechanism of action for donanemab, we modeled that people treated with donanemab could stop treatment prior to reaching moderate AD if they reached complete amyloid

clearance.<sup>29</sup> From currently available evidence on complete amyloid clearance following treatment with donanemab, we modeled 60% of people with AD treated with donanemab stopped treatment within the first model cycle and 68% had stopped treatment by the end of the second model cycle. The treatment benefit for donanemab was applied while a patient was either on treatment or while amyloid was not detected if a patient had stopped treatment due to achieving complete amyloid clearance and had not progressed to moderate AD. Discontinuation, either due to adverse event, disease severity or amyloid clearance, occurred halfway through the model cycle.

### Utility Inputs

Health state utilities were derived from publicly available literature. These utility estimates primarily came from a cross-sectional study of patients with AD and caregivers with stratifications for both disease severity and setting of care.<sup>116</sup> The utility weights were derived from the Health Utilities Index Mark II (HUI:2) with weights based on the standard-gamble approach.<sup>116</sup> The HUI:2 is a commonly used instrument to calculate utility weights in the AD population because cognition is a separate attribute. The caregivers served as proxy respondents for the patient’s quality of life, but also assessed their own quality of life.<sup>116</sup> Responses from the HUI:2 were converted to utility weights using the multi-attribute utility function developed for the HUI:2. We compared the utility estimates from this cross-sectional study to a recent systematic literature review published in 2020 and the estimates were comparable.<sup>117</sup> We elected not to select the recent systematic literature review estimates because the utility estimates were not stratified by care setting (e.g., community versus long-term care) and did not report quality-of-life estimates for the caregiver of the patient.

The model used the utility estimates and the age of the people with AD from the cross-sectional study<sup>116</sup> to calculate a disutility for each disease state and setting of care based off age-adjusted utility estimates. The calculated disutility was directly used in the model and was subtracted from age-adjusted utility estimates that varied based on age for each model cycle. Therefore, the model estimated quality of life was a function of age, disease severity, and setting of care. Table E10 presents the disutilities that were calculated from these estimates. Each disutility was applied for the duration of occupancy in the health state and setting of care.

**Table E10. Patient Disutility Estimates**

Parameter	Community Setting	Long-Term Care Setting	Source
MCI Due to AD	-0.17	-0.17	Calculated from utility estimates and patient demographics in Neumann et al., 1999 <sup>51,116</sup>
Mild AD	-0.22	-0.19	
Moderate AD	-0.36	-0.42	
Severe AD	-0.53	-0.59	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

In addition to the health state utilities reported in Table E10, a disutility of -0.14 was applied to people with AD experiencing symptomatic ARIA. This disutility was applied for the average duration of ARIA (12 weeks).<sup>29,86</sup> This disutility estimate represents the disutility estimate for headache,<sup>118</sup> which was the most reported symptom among those with symptomatic ARIA.<sup>29,86</sup>

Impacts on the quality of life of caregivers was incorporated in the societal perspective. Caregiver utility estimates were calculated from the same cross-sectional study as the patient utility estimates described above.<sup>116</sup> We used the age of the caregivers in the cross-sectional study<sup>116</sup> to calculate a disutility for each disease state and setting of care. The calculated disutility was directly used in the model. Importantly, the utility estimates reported in the cross-sectional study did not vary by AD disease severity (i.e., did not suggest a difference in caregiver utility for if the patient had mild, moderate, or severe AD). We adjusted these estimates to account for the difference in caregiver utility among AD disease severity reported in a study by Mesterton and colleagues.<sup>119</sup> The disutilities that were calculated from these estimates are presented in Table E11. The caregiver disutility was applied onto the patient’s utility estimate. No caregiver disutility was assigned upon or following the patient’s death.

**Table E11. Caregiver Utility Estimates**

Parameter	Caregiver Disutility	Source
MCI Due to AD	-0.03	Calculated from utility estimates and patient demographics in Neumann et al., 1999, <sup>51,116</sup> adjusted for AD severity using relationship from Mesterton et al., 2010 <sup>119</sup>
Mild AD	-0.05	
Moderate AD	-0.08	
Severe AD	-0.10	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

### ***Economic Inputs***

#### **Drug Utilization**

The following inputs were used to model drug utilization and associated costs:

- Route of administration
- Dosing
- Frequency of administration
- Duration of treatment

Table E12 reports these characteristics for donanemab and lecanemab.

**Table E12. Treatment Regimen Recommended Dosage**

<b>Generic Name</b>	Donanemab	Lecanemab
<b>Manufacturer</b>	Eli Lilly & Co.	Eisai Co., Ltd
<b>Route of Administration</b>	Intravenous	Intravenous
<b>Dosing</b>	700 mg for the first three doses and 1400 mg thereafter	10 mg/kg
<b>Frequency of Administration</b>	Every 4 weeks	Every 2 weeks
<b>Duration of Treatment</b>	Until moderate AD or at point of complete amyloid clearance	Until moderate AD
<b>Source</b>	Mintun et al., 2021 <sup>29</sup>	van Dyck et al., 2022 <sup>28</sup>

AD: Alzheimer’s disease, kg: kilogram, MCI: mild cognitive impairment, mg: milligram

### Intervention Costs

Given that neither a wholesale acquisition nor net cost are available yet for donanemab and lecanemab, we used a placeholder price based on the current price of aducanumab, the only approved beta-amyloid antibody for early AD. The annual cost in Table E13 does not include any provider-administered mark-up (assumed to be 6% in addition to the costs in Table E13), or any treatment-associated administration or monitoring costs.

**Table E13. Drug Acquisition Costs**

<b>Drug</b>	<b>Annual Acquisition Cost*</b>	<b>Source</b>
Donanemab	\$26,100	REDBOOK <sup>120</sup>
Lecanemab	\$26,100	REDBOOK <sup>120</sup>

\*Doesn’t include any provider-administered mark-up (assumed to be 6% in addition to the costs in table E12).

### Non-Intervention Costs

Costs outside of drug acquisition are stratified by perspective below.

### **Health Care System Costs**

#### Administration Costs

Donanemab and lecanemab are administered by way of intravenous administration. We assumed an average administration cost of \$78.35 per administration (HCPCS code 96365).<sup>121</sup>

### Monitoring Costs

For the first year while a patient used donanemab or lecanemab, we assumed they were monitored for ARIA using brain magnetic resonance imaging (MRI) every three months. Because evidence suggests the vast majority of ARIA occurs within the first year of treatment, no MRIs were modeled after the first year on treatment. We assumed an average brain MRI cost of \$261.10 per scan (HCPCS code 70553).<sup>121</sup> For donanemab, we modeled a PET scan given every six months while on the drug to test for complete amyloid clearance. If a patient stopped treatment with donanemab due to achieving complete amyloid clearance, they received a PET scan every year to test amyloid levels if they had not reached moderate AD. We assumed an average amyloid PET scan cost of \$4,467.<sup>122</sup>

### Adverse Event Costs

In addition to the brain MRIs described above for monitoring, if a patient experienced an ARIA event, the patient received a brain MRI every four weeks until the ARIA was either resolved or stabilized.<sup>56</sup> The average duration of an ARIA event was 12 weeks; therefore, a patient that experienced an ARIA event received three additional brain MRIs associated with managing the adverse event. We assumed an average brain MRI cost of \$261.10 per scan (HCPCS code 70553).<sup>121</sup>

### Non-Treatment Related Health Care Costs

Annual medical costs stratified by disease severity were sourced from a study conducted by Leibson and colleagues.<sup>123</sup> This study reported the average annual inpatient and outpatient medical costs for people who were cognitively normal, had MCI, were newly diagnosed with dementia, and had prevalent dementia. We assumed costs associated with the newly diagnosed dementia group corresponded to the mild AD health state, and costs associated with the prevalent dementia group corresponded to the moderate and severe AD health states. We assumed the annual medical costs were the same for people with AD in the community or in long-term care. Using these estimates, we calculated a cost multiplier for each health state in the model based on those that were cognitively normal. In the model, we multiplied this cost multiplier by the average age-adjusted health care costs for the US general population. These annual costs were included in the model to account for related and unrelated medical health care utilization, stratified by disease severity. Table E14 reports these cost multipliers that were applied to the health care costs of the general population.

**Table E14. Direct Medical Cost Multipliers**

Health State	Multiplier	Source
MCI Due to AD	1.12	Leibson et al., 2015 <sup>123</sup>
Mild AD	1.56	
Moderate AD	1.93	
Severe AD	1.93	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

To capture other pharmacy costs not related to donanemab and lecanemab, we assumed 33.3% of individuals with mild AD received generic donepezil 10 mg once daily (\$0.21 per day)<sup>120</sup> and 33.3% of individuals with moderate AD received generic memantine 10 mg twice daily (\$0.66 per day).<sup>120,124</sup>

### Long-Term Care Costs

For people with AD in the long-term care setting, additional costs associated with long-term care were included. Table E15 lists the monthly costs for long-term care that were assigned to those individuals who progressed to the long-term care setting.

**Table E15. Long-Term Care Costs**

Parameter	Value	Source	Notes
Long-Term Care	\$7,394 per month	Administration on Aging <sup>125</sup>	Skilled nursing facility cost

Costs have been inflated from 2016 US dollars to 2021 US dollars using the price index for health care services.<sup>126</sup>

### ***Societal Costs***

#### Patient Productivity Costs

A study published in 2020 by Robinson and colleagues reported that among people with amyloid-beta positive MCI, 20.4% reported still working, with 4.9% of those who worked reporting a reduction in work due to AD.<sup>127</sup> Similarly, among people with beta-amyloid positive mild AD, 11.2% reported still working, with 8.6% of those who worked reporting a reduction in work due to AD.<sup>127</sup> We assumed 0% of individuals with moderate and severe AD work with the reason for non-employment not attributed to AD. The average age of the population in the Robinson study was comparable to the average age of our modeled cohort. For those individuals who reduced work due to AD, we assigned lost productivity costs of 20 hours per week. The average hourly wage of \$32.46 was used to monetize the lost productivity.<sup>128</sup>

#### Caregiver Productivity Costs

The Robinson et al., 2020 study also reported caregiver time spent caregiving for individuals with MCI.<sup>127</sup> A separate source by Haro and colleagues reported caregiver time spent caregiving for

community-dwelling people with mild, moderate, and severe AD.<sup>129</sup> Table E16 reports the average caregiver time spent caregiving for community-dwelling people with AD in each health state that were used in the model for people with AD dwelling in the community. Time includes time spent providing supervision and activities of daily living (basic and instrumental).

**Table E16. Caregiver Time Spent Caregiving for Community-Dwelling Caregivers**

Health State	Value	Source
MCI Due to AD	69 hours/month	Robinson et al., 2020 <sup>127</sup>
Mild AD	113 hours/month	Haro et al., 2014 <sup>129</sup>
Moderate AD	169 hours/month	
Severe AD	298 hours/month	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

The What Matters Most study, sponsored by the Alzheimer’s Disease Patient and Caregiver Engagement consortium, suggested caregiver time spent with long-term-care-dwelling people with AD was 44% that of caregiver time spent with community-dwelling people with AD; and thus the estimates reported were multiplied by 44% to estimate the caregiver time spent for long-term-care-dwelling people with AD.<sup>130</sup> The average hourly wage of \$32.46 was used to monetize the time spent caregiving.<sup>128</sup>

#### Caregiver Direct Medical Costs

Table E17 presents the direct medical costs for the primary caregiver of a patient with AD. These are the same values we used in our prior AD review but have been inflated to 2021 US dollars.

**Table E17. Caregiver Direct Medical Costs**

Health State	Value	Source
MCI Due to AD	\$460 per month	Robinson et al, 2020 <sup>127</sup>
Mild AD	\$965 per month	Robinson et al, 2020 <sup>127</sup> & Mesterton et al., 2010 <sup>119</sup>
Moderate AD	\$1,544 per month	
Severe AD	\$1,930 per month	

AD: Alzheimer’s disease, MCI: mild cognitive impairment

## E3. Results

### Description of evLY Calculations


The evLY considers any extension of life at the same “weight” no matter what treatment is being evaluated. Below are the stepwise calculations used to derive the evLY.

1. First, we attribute a utility of 0.851, the age- and gender-adjusted utility of the general population in the US that are considered healthy.<sup>131</sup>
2. For each cycle (Cycle I) in the model where using the intervention results in additional years of life gained, we multiply this general population utility with the additional life years gained ( $\Delta$ LYG).
3. We sum the product of the life years and average utility (cumulative LYs/cumulative QALYs) for Cycle I in the comparator arm with the value derived in Step 2 to derive the equal value of life years (evLY) for that cycle.
4. If no life years were gained using the intervention versus the comparator, we use the conventional utility estimate for that Cycle I.
5. The total evLY is then calculated as the cumulative sum of QALYs gained using the above calculations for each arm.
6. We use the same calculations in the comparator arm to derive its evLY.

Finally, the evLYG is the incremental difference in evLY between the intervention and the comparator arms.

## E4. Sensitivity Analyses

**Figure E1. One-Way Sensitivity Analysis Results: Donanemab versus Supportive Care Alone, Health Care Sector Perspective**



**Table E18. Tornado Diagram Inputs: Donanemab versus Supportive Care Alone, Health Care Sector Perspective**

Model Input	Low Input ICER	Upper Input ICER	Lower Input	Upper Input
Hazard ratio on slowing progression of disease*	\$87,000	\$538,000	0.49	0.92
Percent achieving complete amyloid clearance by two years	\$157,000	\$123,000	54%	80%
Cost of PET scan	\$131,000	\$148,000	\$3,635	\$5,384
Adverse-event related discontinuation	\$147,000	\$131,000	25%	37%
Patient disutility Severe AD, long-term care setting	\$132,000	\$147,000	-0.71	-0.47
Percent of MCI alive people moving to Mild	\$148,000	\$133,000	19%	28%
Relative Risk of death from Severe	\$132,000	\$144,000	7.75	11.47
Percent of Mild alive people moving to Moderate	\$146,000	\$134,000	28%	42%
Annual medical cost multiplier for MCI	\$134,000	\$145,000	1.00	1.35
Annual medical cost multiplier for Mild	\$134,000	\$144,000	1.27	1.88

AD: Alzheimer's disease, MCI: mild cognitive impairment

\*Standard error assumed to be the same as the model input for lecanemab

**Table E19. Credible Intervals from Probabilistic Sensitivity Analysis for Lecanemab versus Supportive Care**

Model Outcome	Lecanemab	Supportive Care
Total Costs	\$463,000	\$339,000
Total QALYs	3.74 (3.30, 4.22)	3.25 (3.01, 3.50)
ICER (\$/QALY)	\$252,000	
Total evLYs	3.85 (3.37, 4.37)	3.25 (3.01, 3.50)
ICER (\$/evLY)	\$204,000	

evLY: equal-value life year, QALY: quality-adjusted life year

**Table E20. Probabilistic Sensitivity Analysis Results: Donanemab versus Supportive Care**

Health Care Sector Perspective	Cost Effective at \$50,000	Cost Effective at \$100,000	Cost Effective at \$150,000	Cost Effective at \$200,000
Per QALY Gained	0%	20%	66%	84%
Per evLY Gained	0%	46%	81%	91%
Modified Societal Perspective	Cost Effective at \$50,000	Cost Effective at \$100,000	Cost Effective at \$150,000	Cost Effective at \$200,000
Per QALY Gained	1%	35%	73%	86%
Per evLY Gained	5%	60%	85%	93%

evLY: equal-value life year, QALY: quality-adjusted life year

**Table E21. Credible Intervals from Probabilistic Sensitivity Analysis for Donanemab versus Supportive Care**

Model Outcome	Lecanemab	Supportive Care
Total Costs	\$402,000	\$339,000
Total QALYs	3.74 (3.30, 4.22)	3.25 (3.01, 3.50)
ICER (\$/QALY)	\$127,000	
Total evLYs	3.85 (3.37, 4.37)	3.25 (3.01, 3.50)
ICER (\$/evLY)	\$104,000	

evLY: equal-value life year, QALY: quality-adjusted life year

## E5. Scenario Analyses

We conducted numerous scenario analyses to test the structural assumptions that were made.

### Scenario Analysis 1: Treatment Stop at Severe AD

The incremental cost-effectiveness ratios are provided in the main report, but we include the model outcomes in Table E22 and Table E23.

**Table E22. Model Outcomes for the Health Care Sector Perspective, Treatment Stop at Severe AD**

Treatment	Intervention Cost*	Total Cost	Life Years	QALYs	evLYs	Years in the Community
<b>Lecanemab</b>	\$131,000	\$498,000	6.07	3.78	3.92	4.17
<b>Donanemab†</b>	\$47,000	\$425,000	6.07	3.78	3.92	4.17
<b>Supportive Care</b>	\$0	\$339,000	5.53	3.23	3.23	3.61

evLYs: equal-value life years, QALYs: quality-adjusted life years

\*Assuming a placeholder price of \$26,100; intervention cost doesn't include provider administered mark-up (modeled as 6%), monitoring costs, or administration costs.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through moderate AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

**Table E23. Model Outcomes for the Modified Societal Perspective, Treatment Stop at Severe AD**

Treatment	Intervention Cost*	Total Cost	Life Years	QALYs	evLYs	Years in the Community
<b>Lecanemab</b>	\$131,000	\$786,000	6.07	3.45	3.62	4.17
<b>Donanemab†</b>	\$47,000	\$713,000	6.07	3.45	3.62	4.17
<b>Supportive Care</b>	\$0	\$629,000	5.53	2.89	2.89	3.61

evLYs: equal-value life years, QALYs: quality-adjusted life years

\*Assuming a placeholder price of \$26,100; intervention cost doesn't include provider administered mark-up (modeled as 6%), monitoring costs, or administration costs.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through moderate AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

## Scenario Analysis 2: Continuous Treatment Strategy for Donanemab

In the main report, we provide cost-effectiveness estimates for donanemab based on a treatment stopping strategy of achieving complete amyloid clearance or stopping based on disease severity at moderate AD. In this scenario analyses, we provide cost-effectiveness estimates for donanemab based on a continuous treatment strategy until moderate AD. Table E24 reports the incremental cost-effectiveness ratios for donanemab assuming this continuous treatment strategy.

**Table E24. Incremental Cost-Effectiveness Ratios for Donanemab, Continuous Treatment Strategy**

<b>Donanemab*† vs. Supportive Care</b>			
Perspective	Cost per Life Year Gained	Cost per QALY Gained	Cost per evLY Gained
<b>Health Care Sector</b>	\$211,000	\$195,000	\$158,000
<b>Societal</b>	\$200,000	\$180,000	\$140,000

evLY: equal-value life year, QALY: quality-adjusted life year

\*Assuming a placeholder price of \$26,100.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through mild AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

## Scenario Analysis 3: Updated Caregiver Disutility Estimates

In this scenario analysis, we updated the source for the caregiver disutility estimates to estimates reported in a recent conference poster.<sup>132</sup> Table E24 reports the caregiver disutilities, stratified by patient health state and setting of care, that were applied in this scenario analysis. These disutilities were not used in our base-case analysis for multiple reasons including the general appropriateness of using time tradeoff for eliciting utilities for a caregiver, the challenge for a person from the general population to detangle the patient health states from the caregiver quality of life in this exercise, the uncertainty in how the domains in the study mapped to our health states and setting of care, the limited information available regarding the framing of the questions, and the small sample size.

**Table E24. Caregiver Disutilities for Scenario Analysis**

Health State	Community Setting	Long-term Care Setting
MCI due to AD	-0.04	-0.04
Mild AD	-0.06	-0.11
Moderate AD	-0.20	-0.14
Severe AD	-0.36	-0.21

AD: Alzheimer's disease, MCI: mild cognitive impairment

These disutilities are larger than the estimates used in our base-case, and thus generated lower incremental cost-effectiveness ratios for both treatments from the societal perspective. Table E25 reports the updated societal perspective cost-effectiveness estimates assuming these disutilities.

**Table E25. Incremental Cost-Effectiveness Ratios, Updated Caregiver Disutility Estimates**

Lecanemab* vs. Supportive Care			
Perspective	Cost per Life Year Gained	Cost per QALY Gained	Cost per evLY Gained
Societal	\$268,000	\$218,000	\$167,000
Donanemab*† vs. Supportive Care			
Perspective	Cost per Life Year Gained	Cost per QALY Gained	Cost per evLY Gained
Societal	\$139,000	\$113,000	\$87,000

evLY: equal-value life year, QALY: quality-adjusted life year

\*Assuming a placeholder price of \$26,100.

†Assuming the same treatment effectiveness as lecanemab, a treatment benefit that persists through mild AD after discontinuation due to amyloid clearance, and adverse-event related discontinuation from Phase II evidence.

## E6. Model Validation

Model validation followed standard practices in the field. We used several approaches to validate the model. First, we provided the preliminary model structure, methods and assumptions to manufacturers, patient groups, and clinical experts. Based on feedback from these groups, we refined data inputs used in the model, as needed. Second, we varied model input parameters to evaluate face validity of changes in results. We performed model verification for model calculations

using internal reviewers. As part of ICER's efforts in acknowledging modeling transparency, we will also share the model with the relevant manufacturers for external verification around the time of publishing this draft report. Finally, we compared results to other cost-effectiveness models in this clinical area.

## Prior Economic Models

We compared our findings for lecanemab to a peer-reviewed publication on the potential economic value of lecanemab.<sup>133</sup> The peer-reviewed publication used a patient level simulation model (AD ACE) with the assumption that the treatment effect was driven by reductions in amyloid PET levels using evidence from the Phase II trial.<sup>133</sup> In our model, we used a Markov model with the treatment effect modeled as the hazard ratio for observed progressions to the next stage of dementia using evidence from the Phase III trial. Despite the difference in structure (Markov model versus patient level simulation) and treatment effectiveness estimates (hazard ratio on progressions to next stage of dementia versus amyloid PET level), our findings are relatively similar. The peer-reviewed publication reported a threshold range (from \$50,000 to \$200,000 per QALY gained) of \$9,000 to \$38,000.<sup>133</sup> Our reported threshold range (from \$50,000 to \$200,000) was \$3,000 to \$28,000. Differences in the findings can largely be explained by the fact that our model used direct clinical outcome data from the Phase III trial whereas the peer-reviewed publication used amyloid PET level as a surrogate predictor of clinical outcomes.

There is also a peer-reviewed publication on the cost-effectiveness of a hypothetical disease-modifying treatment for AD that modeled various treatment strategies, including a continuous dosing strategy and a fixed duration strategy.<sup>122</sup> The peer-reviewed publication used model inputs for a hypothetical intervention and reported an incremental cost-effectiveness ratio of \$612,000 per QALY gained under a continuous treatment strategy and an incremental cost-effectiveness ratio of \$126,000 per QALY gained under a fixed duration strategy where 40% discontinued at 6 months and 100% discontinued at 18 months.<sup>122</sup> Our model nearly replicated those incremental cost-effectiveness ratios when we made similar model assumptions (e.g., treatment effect, treatment duration, discontinuation, treatment cost). When we updated our model to reflect the inputs used for the hypothetical treatment that was modeled in this peer-reviewed publication, our model generated an incremental cost-effectiveness ratio of \$625,000 per QALY gained under a continuous treatment strategy and an incremental cost-effectiveness ratio of \$143,000 per QALY gained under a fixed duration strategy.

In our prior AD review that included aducanumab, we calculated an optimistic treatment benefit scenario that closely reflects the assumptions we have made in our base-case analysis of this review.<sup>27</sup> In the optimistic treatment benefit scenario of our prior AD review, we assumed the hazard ratio for the trial that showed a benefit (i.e., we did not blend the hazard ratio with the trial that did not show a benefit), we assumed the same treatment effect for transitions out of MCI and

mild, and we stopped treatment at moderate AD. The threshold range, using thresholds of \$100,000 to \$150,000, for aducanumab based on the optimistic treatment benefit scenarios was \$11,000 to \$25,000. This is similar to the threshold range we report for lecanemab which, similar to aducanumab, was also modeled as a continuous treatment. The threshold range, using thresholds of \$100,000 to \$150,000, for lecanemab was \$9,00 to \$21,000. This is slightly lower than the range for aducanumab that assumed the optimistic treatment benefit due to lower discontinuation for lecanemab (which increases treatment costs for the cohort) and a higher baseline starting age for lecanemab.